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NER plays an important role in remediating DNA damage. Latimer et al., have
previously shown nucleotide excision repair (NER) to be intrinsically deficient in stage I
sporadic BC by function and gene expression. Previous work performed on 12
isogenically matched stage I tumors and non-tumor adjacent (NTA) samples identified 2
types of NTA tissue with regard to functional NER. One type that represented 75% of the
samples, had lower NER capacity, similar to the tumor (Low: Low pair). The other type
had high NER relative to the tumor (High: Low pair). Two isogenic NTA/tumor cell line
pairs representing these 2 types of NTA were identified by the UDS assay for
downstream molecular analyses. Expression of the 20 canonical NER genes using
microarray analysis was consistent with functional NER of the Low: Low and High: Low
cell lines. Findings from expression microarray were validated using RNA sequencing,
where 16/20 genes were significantly higher in the NTA line of the High: Low pair
compared to the tumor line, but none of the 20 genes were significantly different in
expression among the Low: Low pair. Protein expression was also evaluated for RPA3,
XPC and RAD23B, however only RAD23B showed promising trends. We believe the
mechanism of downregulation of NER genes was epigenetic based on downregulation in
multiple genes and multiple patients. DNA methylation was explored as the mechanism
of this phenomenon. Using MethylationEPIC array, analysis of promoter level, gene level
and CpG island level methylation no correlation between methylation and gene
expression in our cell line pairs. DDB1 showed differential methylation among the both
High: Low and Low: Low pairs but in a direction opposite to gene expression, indicating
possible inhibition of a repressor at its promoter region. RNA sequencing allowed us to
explore the presence of single nucleotide variants in the 20 NER genes along with other
BC genes. We discovered notable variants in ERCC2, ERCC5, ERCC6 as well as in
BRCA1, CHK1 and ATR, which warrant further investigation using The Cancer Genome
Atlas. Finally, we were able to construct person-specific maps or our own
“Vogelsteinograms” for breast carcinogenesis.
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Chapter 1
Introduction
1.1 Problem Background
1.1.1 Breast Cancer
Breast Cancer is the leading cause of mortality among women. In 2017, 40,610
deaths and an additional 252,000 new incidences of invasive breast cancer have been
estimated, although earlier detection by regular mammograms has helped lower the stage
at diagnosis (R. Siegel, Naishadham, & Jemal, 2013). The etiology of sporadic breast
cancer cases, i.e., non-germline breast cancer, is still unknown and can be attributed to
various lifestyle factors, environmental factors such as estrogenic chemicals in consumer
products (e.g., bis-phenol A), as well as DNA-damage-causing agents (Ayyanan et al.,
2011). These factors are still not causatively correlated to breast cancer. Previous studies
in our lab have shown intrinsic deficiency of nucleotide excision repair (NER) capacity in
19/19 Stage I tumors compared to non-diseased breast reduction epithelium, as measured
by the functional Unscheduled DNA Synthesis (UDS) assay (Latimer et al., 2010). This
study has established a solid foundation of the role of NER in the etiology of sporadic
breast cancer for the first time. Understanding the etiology of sporadic breast cancer is
the ultimate objective of research at Dr. Latimer’s laboratory, and calls for further
evidence on the etiology of mechanism of regulation of NER.
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1.1.2 Non-tumor Adjacent Breast
The pathologically normal tissue surrounding a solid tumor (which we call the
non-tumor adjacent or NTA) has been traditionally used as a ‘normal control’ for
studying cancer etiology. Though the theory of field carcinogenesis is gaining acceptance
among cancer researchers, some recent studies on breast cancer still used the seemingly
normal tissue adjacent to the breast as a normal control (Faraglia et al., 2003; Fu, Mao,
Wang, Ding, & Li, 2017). Therefore, solid evidence is needed to show the genetic nonnormalcy of the NTA breast, especially from an NER perspective which is unprecedented
in literature to date to our knowledge.
1.1.3 Model for breast carcinogenesis
Carcinogenesis is an incremental process that results from accumulation of
mutations or mutation-like events over decades (Vogelstein & Kinzler, 1993). This
explains why majority of cancers develop later in life (with the exception of childhood
cancers, which are more often than not, a result of an inherited germ line mutation).
Breast cancer researchers in the past have illustrated a model of the events that are
involved in the trajectory of transformation from normal breast to neoplastic (Bieche &
Lidereau, 1995). However, this model is complicated and does not pinpoint specific
driver events, unlike certain models like the one for colon cancer by Vogelstein et. al.
(1993). Therefore, further experimental evidence is necessary to link mutations and
epigenetic changes to histopathological changes in breast cancer.
1.1.4 Regulation of Nucleotide Excision Repair in breast cancer
In 2010, Latimer et al., shown a correlation between NER and sporadic breast
cancer. Stage I breast tumor explants were shown to be intrinsically deficient in their
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NER capacity compared to that of normal breast epithelium, as measured by the
functional UDS assay. This intrinsic loss of NER capacity in early stage breast cancer is
most likely epigenetic in nature, due to three major lines of observations - reduction in
the expression of multiple genes (19/20), this phenomenon being observed in multiple
patient samples and NER capacity being tissue specific (Latimer et al., 2003). The exact
mechanism behind this epigenetic regulation of NER is unknown.
Methylation of cytosine bases in the CpG-rich gene promoter regions has been
known to be major mechanism of transcriptional regulation. Methylation is often
associated with carcinogenesis by either inactivation of tumor suppressor genes or
activation of proto-oncogenes (Wajed, Laird, & DeMeester, 2001). Although there have
been studies showing the role of methylation in NER genes (Sabatino et al., 2010; A.
Zhang et al., 2017; M. Zheng et al., 2017) as well as in breast cancer (Gao,
Widschwendter, & Teschendorff, 2018; Nindrea, Harahap, Aryandono, & Lazuardi,
2018; S. Zhang et al., 2018), the role of methylation has not been studied from an NER
perspective in breast cancer etiology to date.
1.2 Study Objective, Hypotheses and Aims
Our long-term goal is to understand the etiology of sporadic breast cancer. We
hypothesize that reduction in NER capacity in early stage breast cancer occurs via
epigenetic regulation of multiple NER genes. The objective of this study was to develop a
scheme of the sequence of alterations (mutations as well as epimutations) leading to the
formation of the tumor by studying tumor/NTA pairs. To accomplish this, we explored
the existence of shared alterations between the NTA cell lines (NTALs) and their
matched breast tumor cell lines (BTLs). Preliminary data on the primary NTA samples
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and their matched stage I tumors showed 2 types of NTA. One type manifested low NER
capacity similar to the tumor in 9/12 of the pairs (defined as Low NTAL: Low BTL pair
or Low: Low). The second type showed a higher repair capacity than the tumor, which
was not significantly different from the non-diseased breast tissue (hence defined as High
NTAL: Low BTL pair or High: Low).
Specific Aim 1: Assess the NER capacity of the available NTALs and their matched
early-stage BTLs using a functional assay, the 3H-thymidine-based UDS assay, in order
to identify representative Low: Low pairs and High: Low pairs.

Hypothesis 2: The gene expression pattern of the 20 canonical NER genes will correlate
with the UDS functional assay data.
Specific Aim 2: Determine the expression pattern of the 20 canonical NER genes in the
selected early-stage Low: Low pairs and High: Low pairs using gene expression
microarray analyses and validate these results using RNA sequencing

Hypothesis 3: The differences in expression levels for some of the 20 canonical NER
genes between tumors and their matched NTA lines will be similar to the expression
levels of their respective protein.
Specific Aim 3: Examine expression of chosen NER proteins using Western Blotting

Hypothesis 4: The underlying mechanism for the differences in NER capacity and gene
expression patterns is epigenetic in nature.
Specific Aim 4a: Perform methylation arrays on DNA derived from the Low: Low and
High: Low pairs.
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Aim 4b: Use RNA sequencing data on the selected Low: Low and High: Low pairs to find
mutations, if they exist, in the 20 NER genes.
1.3 Study Significance
1.3.1 Studying early stage breast cancer for understanding etiology
Along with being the leading cause of mortality among women, breast cancer is
also an expensive problem, manifested not only in terms of cost to families due to lost
wages, but also in cost to treatment. These costs increase with each increase in stage of
breast cancer (Blumen, Fitch, & Polkus, 2016). Although advancement in diagnostic
technologies are now allowing for early detection of breast cancer and timely treatment
increasing survival, there are still 3 million women walking with breast cancer in the US
(Howlader et al., 2018). With screening mammography, we have been able to lower the
average stage at diagnosis to stage I in the US within the past decade. This emphasizes
the importance of studying early stage tumors, as it enables us to go a step closer to
finding the etiology of sporadic breast cancer occurrence and allows us to determine the
impact of treatment of early stage breast cancer.
1.3.2 Importance of adjuvant radiation after lumpectomy
Breast conserving surgery or lumpectomy with adjuvant radiation is usually the
treatment modality for early stage breast cancers (Gradishar et al., 2015). Clinical trials
have shown that lumpectomy followed by radiation has similar outcomes and survival
rates as compared to a total mastectomy upon treatment of early stage breast cancer (B.
Fisher et al., 2002; Overgaard et al., 1999). However, there is still a debate as to the dose,
area as well as duration of radiation therapy given to women undergoing tumor-removal
surgery, where often times whole breast irradiation has been deemed either unnecessary
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or as providing similar outcomes as partial irradiation (Livi et al., 2010; Vicini et al.,
2003; Whelan et al., 2002). Our study provides solid evidence regarding the pivotal role
of adjuvant whole breast irradiation after lumpectomy, as we show that the NTA breast
represents a pre-neoplastic stage in breast carcinogenesis. This indicates that patients with
low DNA repair in their NTA breast might have a higher rate of recurrence owing to the
genomic instability of the breast tissue that is left behind, if not taken care of by adjuvant
radiation therapy. Our study also contributes towards settling the debate on the width of
margins during tumor resection, as there is still a widespread practice of trying not to get
wider margins for cosmetic and aesthetic purposes, with the preference of margin width
depending on the hospital and/or surgeon chosen for surgery.
1.4 Strengths of the Study
1.4.1 Clinical relevance
One major strength of this study is that it is clinically relevant. This study could
provide the rationale for a test for recurrence in breast cancer patients treated with
lumpectomy. After validation with a large study, patients could be screened for the NER
capacity or NER gene expression of their NTA breast sample. Patients’ risk of recurrence
could be predicted based on the functional NER capacity detected in the NTA breast,
where lower NER capacity would indicate higher risk of recurrence. This study will
contribute towards treatment strategies for increasing overall survival in breast cancer
patients, where patients showing low NER capacity in their NTA tissue could be treated
with either longer radiation treatments or recommended a total mastectomy. The patients
with normal NER capacity in the NTA could be saved the longer and radical treatments,
thus making individualized treatment for breast cancer plausible.
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1.4.2 Unique model system
Studies on breast cancer have been traditionally performed on commercially
available cell lines that have been in use for years and have been established from pleural
effusion samples obtained from patients having stage IV metastatic breast cancer.
Moreover, these cell lines have been immortalized using viruses, SV40, hTERT and other
transforming agents to prevent them from reaching senescence. Hence, commercially
available cell lines are poor representatives of in-vivo early stage breast cancer and are
not ideal model systems for studying etiology of breast cancer. This study has been
performed using early stage sporadic breast cancer cell lines established by the patented
tissue engineering system developed by Dr. Latimer’s lab. We have a unique advantage
of having a repository of extended explants and cell lines housing about 150 cell lines
established from tissues representing various stages of breast cancer as well as
pathologically normal adjacent breast and non-diseased breast.
1.4.3 NER in NTA breast in breast cancer
We are the first group, to our knowledge, to show two different types of NTA
tissue in the breast based on NER. NER-related abnormal alterations like polymorphisms,
gene expression changes and changes in epigenetic regulators have been documented in
studies involving tumor and adjacent samples in breast cancer (Faraglia et al., 2003; X.
Fu et al., 2017), colorectal cancer (Z. Zhao, Zhang, & Li, 2017), bladder cancer (Zhi et
al., 2017) and gastric cancer (He et al., 2012). However, all of the above studies have
used adjacent tissues to the tumor as normal controls for their study. Nevertheless, a few
studies document abnormalities in the adjacent sample as well (Faraglia et al., 2003; Gao
et al., 2018; Kayser et al., 2005). Therefore, we are the first group reporting a pathway-
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wide alteration in the NTA breast that is shared with the tumor the majority of the time,
and that this might be a contributing factor in local recurrence, and at the same time may
serve as the basis to continue adjuvant radiation therapy after lumpectomy. Where the
NER capacity is normal in the NTA, these patients could be given the normal standard
treatment that is currently given to early stage breast cancer patients. A larger study could
then confirm the effect of individualized treatment given to early stage breast cancer
patients after screening them based on their NTA tissue’s NER capacity on 5- and 10year survival rate.
1.5 Limitations of this study
1.5.1 Sample Size
The major limitation of this study is the limited sample size. The study was
designed with the aim of using cell lines as model systems, as they are easily manipulable
and this was a requirement in order to study regulation of the NER pathway. Preliminary
studies (on which this study is based) were conducted on primary cultures of tissues from
isogenically matched tumor-NTA pairs. The fact that cell lines could be established from
these was something that was realized and tried at a later point of time by Dr. Latimer in
her lab. Establishment of cell lines from primary tissues without the use of immortalizing
agents is extremely challenging, and maintenance of these cell lines is taxing, timeconsuming and intensive in terms of reagents and resources. Initially, an ideal sample
size of at least 3 pairs per group of High: Low and Low: Low pairs was proposed for this
study. However, we had only one representative cell line pair available for each of our
groups. We therefore proceeded with in-depth molecular analysis of these 2 cell line pairs
(4 cell lines) for the purpose of this study. The advantage of this approach lies in the
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creation of person-specific maps of common and uncommon genetic changes between the
NTA and the tumor, with the NTA reflecting pre-existing changes before transformation.
In addition, the Lab is currently working on an IRB for obtaining fresh tissues from early
stage breast cancer surgeries to identify more putative representative pairs for the
aforementioned groups and establish cell lines from the same. The molecular analyses
conducted in this study will be applied to the new cell line pairs as well in near future to
gain power for the current study.
1.6 Summary
This study aims to address one of the most pressing problems in healthcare in the
current time. Breast cancer is still the leading cause of mortality among women in the
USA, and our study aims to contribute towards strategies in the reduction of the same, by
providing evidence that shows the NTA breast to be a pre-neoplastic stage in breast
carcinogenesis. We therefore will be able to establish a temporal scheme or a
“Vogelsteinogram” of the events that take place during breast carcinogenesis and show
that loss of NER is an important event in this scheme. This will help fulfill our long-term
goal of finding etiology of sporadic breast cancer.
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Chapter 2
Literature Review
2.1 DNA Repair
2.1.1 DNA Damage
Maintaining the integrity of the genome is essential for life. This is implemented
by ensuring the fidelity of deoxyribonucleic acid or DNA, the blueprint of life (Jeggo,
Pearl, & Carr, 2016). DNA in our cells is subject to damage from endogenous as well as
exogenous agents. A cell is estimated to incur about 70,000 damage lesions per day in its
DNA (Tubbs & Nussenzweig, 2017). Failure to ensure DNA fidelity can result in
accumulation of damage inflicted by such agents, leading to the damage becoming
permanent and therefore leading to formation of mutations.
2.1.1.1 Endogenous DNA damage
Endogenous processes that result in DNA damage primarily constitute replication
errors, spontaneous alterations to the chemical structure of the bases by chemicals and
reactive oxygen species. Sometimes, during the replication of DNA in the S-phase of the
cell cycle when a cell prepares for division, wrong bases are inserted thereby creating a
mismatch in the base paring of nucleotides. The rates of generation of mismatches during
DNA replication are in usually within the range of 1 x 10-8 to 1 x 10-6, in spite of the
proof-reading activity of DNA polymerases. These mismatches, if left un-repaired can
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become mutations and affect the stability of the genome (Loeb & Monnat Jr, 2008).
Another source of endogenous DNA damage is oxidation via reactive oxygen species,
that are generated during normal metabolic functions performed by the cell, including
those by the mitochondria. These reactions lead to the formation of superoxide, peroxide
and hydroxyl radicals, that are known to alter about 20,000 nucleotides each day in the
mammalian genome (Donigan & Sweasy, 2009). Depurination alters the purine
nucleotides thereby giving rise to abasic sites and ultimately resulting in strand breakage
(An et al., 2014). Endogenous DNA damage is also caused due to spontaneous chemical
reactions that alter bases to offer a more chemically stable structure for the base. These
reactions include deamination, depurination and oxidation. Deamination of cytosines
convert them to thymine, methyl-cytosines to uracil, adenine to xanthine and guanines to
hypoxanthine (Griffiths et al., 2005). These alterations are serious mutagenic events and
are the targets of DNA repair mechanisms in the body.
2.1.1.2 Chemical carcinogens
Naturally occurring chemicals in the environment as well as those artificially
made or produced as by-products of human activities can cause DNA adducts. Some
intercalate into the base pairs of the helix leading to DNA damage. These chemicals are
known carcinogens as their cancer-causing potential has been demonstrated by
experiments on in-vitro as well as murine model systems (Rodgers, Udesky, Rudel, &
Brody, 2018; Rudel, Ackerman, Attfield, & Brody, 2014). An example of these include
chemicals from smoke like benzo[a]pyrene diol epoxide (Alexandrov, Rojas, & Rolando,
2006). This is a polycyclic aromatic hydrocarbon that forms adducts with DNA after
activation by the cytochrome P450 system (Lodish et al., 2008).
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2.1.1.3 Ionizing radiation
Ionizing radiation is one of the major sources of external DNA damaging agents,
inflicted by cosmic radiation from outer space. The risk of exposure to ionizing radiation
increases with increases in altitude. People residing at high altitudes get exposed to
higher levels of cosmic radiation than those at sea level (Friedberg, Walker, Siede, &
Wood, 2005). Also, frequent air travelers, which includes pilots and flight crew are at a
high risk for exposure and thereby at an increased risk for cancer (Sanlorenzo et al.,
2015). Another major source of ionizing radiation is X-rays and g-rays used in diagnostic
technologies in clinics and hospitals. Numerous studies have reported the association of
exposure to radiation via such diagnostic procedures and risk of breast cancer (S. Bhatia
et al., 2003; Boice Jr, Preston, Davis, & Monson, 1991; Pijpe et al., 2012). Ionizing
radiation causes either direct DNA damage by catalyzing bond breakage leading to single
and double strand breaks, or cause DNA damage indirectly by generating reactive oxygen
species (Lomax, Folkes, & O'neill, 2013).
2.1.1.4 Ultraviolet radiation
Ultraviolet radiation or UV is another main source of exogenous DNA damage
causing agents, the exposure to which occurs via sunlight. The UV spectrum can be
divided into three segments, UV-A (315-400 nm), UV-B (290-315 nm) and UV-C (290100 nm). Among these, UV-C is the most destructive forms of UV light in terms of DNA
damage, although it is mostly filtered out by the ozone layer in the earth’s atmosphere
(S.-L. Yu & Lee, 2017).
DNA damage from UV light manifest in 6 forms which are now known products
of UV irradiation (Figure 2.1) (Yagura, Makita, Yamamoto, Menck, & Schuch, 2011).
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Two main types of by-products of UV radiation damage that are biologically significant
in eukaryotes are cyclobutane pyrimidine dimers (CPDs) and 6,4-photoproducts. CPDs
are two pyrimidine rings joined by two covalent bonds, whereas 6,4-photoproducts are
made by one bond between 6’ end of one pyrimidine ring and 4’ end of the other
pyrimidine ring. Both these UV products cause helix distortion and strand breaks, but
6,4-photoproducts are more helix distorting than CPDs, although the latter occur more
frequently. Damage to DNA by UV light has been extensively studied in the context of
DNA repair, and therefore most germicidal lamps used for experiments studying DNA
damage and repair use UV-C irradiation (Bykov, Hemminki, Sheehan, & Young, 1999;
Osakabe et al., 2015; Rauth, 1986).

Figure 0.1 Six types of lesions that are now known to be caused by UV damage to DNA.
Two main lesions are cyclobutene pyrimidine dimers and 6,4-photoproducts. Along with these,
there is evidence for the formation of Dewar photoproduct (an isoform of the 6,4-photoproduct),
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Spore photoproduct (observed in certain bacteria), 8-oxoguanine (product of reaction with
reactive oxygen species generated due to UV) and single strand breaks due to UV light. (Yagura
et al., 2011) (Link to License: https://creativecommons.org/licenses/by/3.0/)

2.1.2 Mammalian DNA repair mechanisms
Cells have evolved with specialized conserved mechanisms to prevent damage in
DNA, thereby ensuring fidelity and integrity of DNA and the stability of the genome. In
eukaryotes, there are 5 major DNA repair pathways, some of which are specific to the
type of lesion occurring in DNA following exposure to damage-causing agent. These are
base excision repair, mismatch repair, double strand break repair comprising of
homologous recombination and non-homologous end joining, and nucleotide excision
repair.
2.1.2.1 Base excision repair
The base excision repair or BER pathway repairs non-helix distorting DNA
damage, mostly resulting from endogenous damage of DNA, prior to DNA replication.
These damages mostly result from endogenous processes like methylation, deamination,
alkylation, oxidation and depurination (Krokan & Bjørås, 2013; Wallace, 2014). This
pathway excises single bases that have been damaged with the help of specific enzymes
that cleave the bond between deoxyribose sugar and the base. These enzymes are known
as DNA glycosylases and were discovered first in E. coli by Lindahl in 1974 (Lindahl,
1974). Eleven distinct types of lesion-specific glycosylases are known and about 28
genes are required for BER to function (Krokan & Bjørås, 2013)
2.1.2.2 Mismatch repair
Mismatch repair (MMR) is a conserved DNA repair pathway that repairs
mismatches occurring in DNA during DNA replication. This pathway corrects
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mismatches caused due to a wrong base insertion by a DNA polymerase that escape the
proof-reading mechanism of the polymerase (Kunkel & Erie, 2015). Mismatch repair also
corrects for insertion or deletion loops, also called IDLs, that occur when DNA strands
dislocate while replication due to slipping over each other. The steps involved in this
pathway are recognition of the mismatch, excision and degradation of the strand
containing the mismatch and re-synthesis of the strand (Jiricny, 2013). Mutations in
genes involved in mismatch repair have been associated with microsatellite instability
and lynch syndrome (hereditary non-polyposis colorectal cancer) (Richman, 2015).
2.1.2.3 Homologous recombination
Homologous recombination is among the two major pathways (along with nonhomologous end joining) that repairs double strand breaks, gaps in DNA as well as cross
links in DNA (Xuan Li & Heyer, 2008). This pathway uses the sister chromatid as a
template to repair double strand breaks and hence is considered a more robust pathway
which is free of errors compared to non-homologous end joining. Homologous
recombination operates by location of the damage through the 5’ end and creates a 3’
overhang. This fragment locates the complementary sequence on the sister chromatid
with the formation of a complex called the D-loop. After extension of the 3’ strand using
the sister chromatid as the template, the complex is dissolved, and the repair process is
completed by ligation of the newly synthesized strand with the parent (Jasin & Rothstein,
2013; Krejci, Altmannova, Spirek, & Zhao, 2012). Mutations in the genes involved in
homologous recombination have been implicated in ovarian and breast cancers,
especially the ones in BRCA1 and BRCA2 genes (Mehrgou & Akouchekian, 2016).
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Poly-ADP-ribose polymerase or PARP1 inhibitors are now being used to exploit this
specific vulnerability in DNA repair in these mutation carriers.
2.1.2.4 Non-homologous end joining
Non-homologous end joining is the other double strand break repairing pathway.
However, it is different from homologous recombination in the sense that it does not use
a template for repairing the damaged strand. The broken strand is simply ligated repairing
the break but not the flanking sequence, which makes this pathway prone to mutation
with errors likely to be perpetuated. Whereas homologous recombination dominates
during the S-phase of the cell cycle (involving DNA replication), non-homologous end
joining mainly occurs during G1 and G2 phases of the cell cycle and is the dominant
pathway for the repair of double strand breaks (Karanam, Kafri, Loewer, & Lahav, 2012).
Repair by non-homologous end joining mainly occurs by identification of the break and
subsequent binding of Ku proteins, which then leads to trimming of nucleotides around
the break. This is followed by gap synthesis and ligation. The structure of the ends in the
break determine the exact mechanism and proteins to be used for repair (Chang,
Pannunzio, Adachi, & Lieber, 2017). Mutations in factors involved in non-homologous
end joining have been implicated in certain lymphomas (Moshous et al., 2003) and also
other cancer types like cancers of the breast, ovaries and the colon/rectum (F.-M. Hsu,
Zhang, & Chen, 2012).
2.1.3 Nucleotide Excision Repair
Nucleotide Excision Repair (NER) is one of the major DNA repair mechanisms.
Also called ‘long-patch repair’, this pathway repairs inter and intra-strand crosslinks in
DNA which primarily include cyclopyrimidine dimers (CPDs) and 6-4-photoproducts (6-
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4-PPs). The functionality of NER is important primarily because the lesions repaired by
this mechanism distort the geometry of the DNA helix thereby destabilizing the genome.
The major steps involved in NER include recognition of the damage, opening of the
DNA helix by helicases, incision and excision of the fragment of DNA containing the
damage by endonucleases and finally re-synthesis of the excised strand and its ligation to
the parent strand. There are about 20 canonical genes involved in the NER pathway, the
protein products of which are crucial for NER to occur and they are outlined along with
their function in Table 2.1.
2.1.4 Types of NER
NER can be divided into two main types, Global Genomic Repair and
Transcription Coupled Repair. The site of damage is what dictates the type of NER
pathway used to repair it. The main difference between the two NER sub-pathways is the
damage recognition step. Damage that cause adducts which stall the transcription
machinery are repaired by the Transcription-Coupled Repair pathway of NER. In
contrast, adducts formed in the bulk of the genome that comprises of non-transcribed
DNA is repaired by the Global Genomic Repair pathway of NER (Costa, 2003). Lesions
detected in transcribed strands are removed faster than that in the rest of the genome
(Hanawalt, 2002). Apart from the differences in recognition of damage between the two
sub-pathways of NER, the subsequent steps are the same in both pathways.
2.1.5 Mechanism of NER
Repair by the NER pathway (Figure 2.2) commences with recognition of the
damage. The trigger for initiating NER comes from two scenarios. Transcription Coupled
Repair is initiated by a stalled replication fork when RNA polymerase II encounters a
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damage and recruits CSB. Recognition in Global Genomic Repair is performed by the
XPC-RAD23B or XPC-hHR23B complex (Sugasawa et al., 1998). This complex detects
helix distortions caused by 6-4-PPs readily. CPDs, however, are too subtle to be
recognized by the XPC-hHR23B complex and hence, the presence of DDB proteins
(especially p48 or DDB2) aid lesion recognition in Global Genomic Repair (Tang,
Hwang, Ford, Hanawalt, & Chu, 2000). CSB is the recognition protein in transcription
coupled repair and is a part of the RNA polymerase II complex (van Gool et al., 1997).
CSB causes a conformational change that results in the temporary dislocation of RNA
polymerase II from the fork, thus allowing access of the repair machinery to the site of
damage. The CSA complex is then recruited by CSB, which consists of two more
proteins, ring box protein 1(RBX1) and Cullin 4A (CUL4A). If RNA polymerase II fails
to recruit proteins to perform NER, it is then degraded by ubiquitylation and the damage
is left to be recognized by NER (Hanawalt & Spivak, 2008).
After lesion recognition by either of the two aforementioned ways, a change in
DNA configuration leads to open structure formation in DNA with the help of TFIIH,
XPA, XPG and XPC (Citterio et al., 2000; Evans, Fellows, Coffer, & Wood, 1997). XPA
is also recruited to the open complex where it is required for the formation of the preincision complex by interacting with CSA, CSB, RPA and RNA polymerase II. XPD and
XPB are the two helicases involved in unwinding of the double helical structure, where
XPD has a 5’ to 3’ helicase function and XPB unwinds the DNA in a 3’ to 5’ direction
(Fuss & Tainer, 2011; Schaeffer et al., 1994). Both helicases are assisted by a cyclin
dependent kinase protein CDK7 (also known as CAK or MO15) that is a part of the
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TFIIH machinery (Fuss & Tainer, 2011; Roy et al., 1994). XPA, along with RPA1,
ensures proper unwinding and bending of DNA to facilitate incision.
XPG and ERCC1-XPF complex are the two endonucleases that excise the
fragment containing the damage and are both required to carry out incision of DNA
around the site of damage. Where XPG incises the strand at about 2-8 nucleotides away
from the site of damage from the 3’ end, ERCC1-XPF nicks the DNA at about 15-24
nucleotides from the damaged base at the 5’ end of the strand containing the damage
(Hunting, Gowans, & Dresler, 1991; Shivji, Podust, Huebscher, & Wood, 1995; Sijbers
et al., 1996). The 3’ hydroxyl group left by the ERCC1-XPF complex after the strand is
excised is a perfect template on its own for DNA synthesis using Pol d and Pol e, which
are known to be the primary polymerases involved in DNA synthesis during NER
(Hunting et al., 1991; Shivji et al., 1995). Ultimately, DNA ligase I joins the resynthesized strand to the parent strand, thus completing NER (Figure 2.2) (Tomkinson &
Levin, 1997).
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Figure 0.2 Schematic of the NER pathway. This diagram describes the major steps in NER
which are 1) damage recognition by XPC-hHr23B in global genomic repair (GG-NER) or by
CBS in transcription coupled repair (TC-NER); 2) Unwinding of the DNA helix by helicases
XPB and XPD along with XPA and RPA; 3) Incision of strands by XPG and ERCC1-XPF
followed by excision of the damage-containing fragment; 4) Re-synthesis of the excised strand by
using the complementary strand as template and its ligation to the parent strand. The 5th step
shows a repaired double-stranded DNA. From Research and Development (R&D) Systems 2003
catalog. R&D Systems, Bio-Techne, Minneapolis, USA. © R&D System, Inc.
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Table 2.1 List of the 20 canonical NER genes in alphabetical order, their functional role in the pathway; their contribution
towards functional NER capacity and the phenotype of their human as well as mouse mutants (Andressoo et al., 2006;
Andressoo et al., 2009; Bogliolo et al., 2013; Costa, 2003; Coverley, Kenny, Lane, & Wood, 1992; de Boer & Hoeijmakers, 2000;
Friedberg et al., 2005; Fuss & Tainer, 2011; Jaspers et al., 2007; Niedernhofer, 2008; Schärer, 2013; M. Tian, Shinkura, Shinkura, &
Alt, 2004; Yoon et al., 2005)
Official
gene symbol

Alias

Function

CCNH

CAK

CDK7

CAK;
MO15

DDB1
DDB2

XPE

ERCC1

-

Residual
repair
capacity
(%FF)
-

Human mutant
phenotype

Mouse mutant
phenotype

Part of the cdk-activating kinase
(CAK) complex; Regulates the
function of CDK7; provides stability
to the TFIIH complex
Part of the cdk-activating kinase
(CAK) complex; aids the activity of
helicases in the pathway by providing
stability
Recognizes minor helix distorting
damage in global genomic repair
along with XPC
Recognizes minor helix distorting
40-50%
damage in global genomic repair
along with XPC

No known human
mutant

Unknown

No known human
mutant

Unknown

Xeroderma
pigmentosum

Embryonic lethal

Xeroderma
pigmentosum

Complexes with XPF to perform 5’
endonuclease activity

Cerebro-oculo-facioskeletal syndrome

Defective CPD removal
upon UV exposure;
Premature death;
increased predisposition
to cancer
Mostly inviable. If they
live, they are small in
size with NER
deficiency

-
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Official
gene symbol

Alias

Function

Residual
repair
capacity
(%FF)
25-50%

Human mutant
phenotype

Mouse mutant
phenotype

ERCC2

XPD

5’®3’ helicase; unwinds DNA to
facilitate formation of the preincision complex

Xeroderma
pigmentosum;
Cockayne syndrome
and
Trichothiodystrophy

3’®5’ helicase; unwinds DNA to
facilitate formation of the preincision complex

3-7%

5’ endonuclease that makes an
incision at the 5’ end of the damagecontaining strand by forming a
heterodimer with ERCC1
3’ endonuclease that makes an
incision at the 3’ end of the damagecontaining strand
Recognizes damage in the
transcription-coupled repair pathway
of NER

20%

Xeroderma
Pigmentosum;
Cockayne syndrome
and
Trichothiodystrophy
Xeroderma
Pigmentosum; Fanconi
Anemia

Severe photosensitivity;
skin and eye tumors due
to increased cancer
predisposition; defective
repair of oxidative DNA
damage
Homozygous mutants
are embryonic lethal; no
evident signs of
Cockayne syndrome
observed
Severe post-natal
growth defects and
premature death

ERCC3

XPB

ERCC4

XPF

ERCC5

XPG

100%

Xeroderma
Pigmentosum;
Cockayne Syndrome
Cockayne Syndrome

ERCC6

CSB

ERCC8

CSA

Recognizes damage in the
transcription-coupled repair pathway
of NER

100%

Cockayne Syndrome

2%

NER-deficient runted
mice
Skin cancer upon UV
exposure; no evident
Cockayne syndrome
phenotype
Skin cancer upon UV
exposure; no evident
Cockayne syndrome
phenotype
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Official
gene symbol

Alias

GTF2H2

TFIIHp44 Member of the TFIIH complex. Aids
in stabilizing the repair complex
TFIIHp34 Member of the TFIIH complex. Aids
in stabilizing the repair complex
TFIIHp52 Member of the TFIIH complex. Aids
in stabilizing the repair complex
hHR23B Involved in damage recognition in
global genomic repair by binding to
XPC
RPAp70; Member of the replication protein A
HSSB;
family that binds to the undamaged
REPA1
strand of DNA. Prevents the
formation of secondary structures
that could interfere with repair and
protects DNA strands from nucleases
RPAp32; Member of the replication protein A
REPA2
family that binds to the undamaged
strand of DNA. Prevents the
formation of secondary structures
that could interfere with repair and
protects DNA strands from nucleases
RPAp14; Member of the replication protein A
REPA3
family that binds to the single
stranded DNA. Prevents the
formation of secondary structures

GTF2H3
GTF2H4
RAD23B
RPA1

RPA2

RPA3

Function

Residual
repair
capacity
(%FF)
-

Human mutant
phenotype

Mouse mutant
phenotype

No known human
mutant
No known human
mutant
No known human
mutant
No known human
mutant

Unknown

-

No known human
mutant

Embryonic lethal

-

No known human
mutant

Unknown

-

No known human
mutant

Unknown

-

Unknown
Unknown
Intact NER; small size
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Official
gene symbol

Alias

Function

XPA

-

that could interfere with repair and
protects DNA strands from nucleases
Verifies damage and proper
unwinding; recruits ERCC1-XPF
complex

XPC

RAD4,
p125

Recognizes damage in global
genomic repair

Residual
repair
capacity
(%FF)

Human mutant
phenotype

Mouse mutant
phenotype

2-5%

Xeroderma
Pigmentosum

5-30%

Xeroderma
Pigmentosum

NER-deficient mice.
Skin cancer upon UV
exposure or to
benzo[a]pyrene
NER-deficient mice;
skin cancer after UV
exposure, lung and liver
tumors after chemical
carcinogen exposure.
Increased predisposition
to skin cancer in
heterozygous mutants

25

2.1.6 Measurement of NER capacity
2.1.6.1 Unscheduled DNA Synthesis
The Unscheduled DNA synthesis (UDS) assay is the gold standard assay used for
the measurement of NER capacity and was developed by Dr. James Cleaver (Cleaver &
Thomas, 1981). This assay is traditionally used as a diagnostic test for Xeroderma
pigmentosum and other repair syndromes and measures the incorporation of a
radiolabeled nucleotide into DNA during the process of DNA repair after an insult with a
fixed dose of a damage causing agent (UV-C light in this case). Incorporation of the
radiolabeled nucleotide is detected by autoradiography. Autoradiography results in the
formation of silver grains in photographic emulsion directly over the nuclei of cells
wherein DNA underwent repair. The number of silver grains is directly proportional to
the DNA repair capacity of that sample, when expressed relative to the traditional
control, which is a fibroblastic cell explants established from newborn foreskin. This
assay is known as ‘Unscheduled’ DNA synthesis, because repair is measured by
assessing repair over nuclei that are not in their S-phase (Scheduled DNA synthesis)
wherein DNA is replicated. In the UDS assay, silver grains are also incorporated in cells
undergoing cell division which show up in the assay as immensely populated by silver
grains (Figure 2.3) as opposed to the non-S phase cells. These S-phase nuclei are
excluded from grain-counting (Latimer & Kelly, 2014). However, the percentage of cells
undergoing S phase is an important piece of data in addition to the nucleotide excision
repair capacity.
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Figure 0.3 Bright field image of cells run on the UDS assay at 1000x magnification under oil
immersion. Panel A shows an unirradiated field while Panel B shows an irradiated field. The tiny
black dots are silver grains and those on top of non-S-phase nuclei are counted. The densely
populated grains over 3 nuclei represent S phase cells, indicating mass accumulation of 3Hthymidine during DNA replication. Re-printed with permission from Latimer and Kelly, 2014.

UV-C light is used mainly due to its ease of use and dose optimization, no side
effects and also because it produces two main lesions, namely cyclopyrimidine dimers
(CPDs) and 6,4-photoproducts (6,4PPs), both of which are repaired by the NER pathway.
Our lab uses a UV-irradiating machine (or the “cell tanning salon”) to irradiate plated
cells as described previously (Steier & Cleaver, 1969). This exposure chamber contains 3
UV bulbs at a distance of 3 feet from a turntable that facilitates uniform dose delivery.
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This machine also contains an electronic shutter of a diameter of 6 inches to ensure a
fixed dose delivery where the time of dose given is based on the intensity of the UV
bulbs measured by a dosimeter (Figure 2.4).

Figure 0.4 UV-irradiation chamber or the cell tanning salon. This machine is used to deliver a
fixed and uniform dose using a time-controlled shutter and UV bulbs on top along with the speedcontrolled rotating turntable at the bottom. (Latimer and Kelly, 2014)

The UDS assay possesses some strong advantages. First, it measures total
genomic repair capacity of the cells. Transcription Coupled Repair remediates damages
only in a tiny fraction of total genomic repair, hence is not a good measure of the total
functional NER being performed in cells. As UDS measures Global Genomic Repair
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(along with Transcription Coupled Repair), this makes it one of the most robust
laboratory techniques for measuring NER capacity. Second, this assay also allows for the
measurement of proliferation in the cells being assayed (Latimer & Kelly, 2014). Finally,
the UDS assay measures complete repair in cells, as opposed to using lesion-directed
antibodies in ELISA based methods that are not representative of all the lesions generated
and repaired by NER (Matsunaga, Hatakeyama, Ohta, Mori, & Nikaido, 1993; Mori et
al., 1991).
The drawbacks of using the UDS assay to measure NER capacity would be the
need to use a radiolabeled nucleotide. The use of radioactive chemicals requires training
personnel in specialized handling, use and disposal of the same, and their use also
endangers the experimentalist to radiation exposure hazard. Moreover, manual counting
of grains seems to be the best method for retrieving data from slides run on the UDS
assay. Although liquid scintillation counters have been used in literature for assays
measuring the incorporation of 3[H]thymidine (Sawada, Furihata, & Matsushima, 1989),
these have been used for DNA extracts and not feasible for fixed cells.
2.1.6.2 Host cell reactivation assay
Host cell reactivation assay measures DNA repair in the actively transcribed
genome in cells. This assay involves transfection of a plasmid, that is previously
damaged by irradiation, into cells whose repair capacity is to be assessed. The plasmid
contains a reporter gene, usually luciferase, that generates bioluminescence upon active
transcription/repair of the plasmid. The emitted light can be measured by a luminometer.
This assay uses the host cell’s repair machinery to repair the damage in the transfected
irradiated plasmid and thereby assesses the ability of the cell to repair damage in actively
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transcribed DNA (Latimer, 2014). There are newer and advanced modifications that have
been tested as alternatives for the traditional host cell reactivation assay. Eukaryotic
mammalian plasmids with a gene coding for a modified green fluorescent protein
maxGFP was irradiated with UV light and transfected into cells to measure their repair
capacity. The expression of the protein was measured by flow cytometry and the results
found were highly reproducible, with stable and efficient transfections observed along
with cellular viability (Mendez et al., 2011).
Although the host cell reactivation assay provides an alternative to the UDS assay
in terms of the lack of use of radioactive chemicals as well as efficiency in time required
for the assay, there are drawbacks to the use of this assay. First, host cell reactivation
only measures transcription-coupled repair and therefore is not indicative of total
functional NER capacity of cells. Moreover, transfecting a recombinant DNA assumes
repair kinetics and dynamics of both moieties happen the same way, which may not be
the case (Latimer, 2014).
2.1.7 Measurement of NER gene expression
2.1.7.1 Expression microarrays
Gene expression profiling with the help of chip-based arrays is one of the most
comprehensive and cost-effective technologies to study the transcriptome of the desired
organism or sample (human in our case). Affymetrix assays enable comprehensive
measurement of steady state RNA levels for about 38,000 human genes and are the most
commonly used assays in literature to look at the entire transcriptome in parallel (Auer,
Newsom, & Kornacker, 2009). Among the available human gene expression profiling
chip arrays, the Genechipâ HG U133 Plus 2.0 array features the profiling of genes
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complied from 4 different publicly available databases, namely UniGene, dbEST,
GenBank and RefSeq. This chip contains about 54,000 probe sets for detection of about
47,000 transcripts for the 38,500 known genes (Affymetrix, 2003).
In this technique, total RNA isolated from eukaryotic samples is first primed with
oligo-dT primers and converted to cDNA via reverse transcription. After the first and
second strand cDNA synthesis, the single stranded antisense RNA is biotin-labelled. This
biotinylated cRNA is fragmented and hybridized to the oligonucleotide probes on the
Genechipâ. These probes represent the genes and transcripts being evaluated for
expression by the array. Hybridization is detected by addition of a streptavidinphycoerythrin antibody and its detection by a second biotinylated anti-streptavidin
antibody attached to a chromophore using a Genechipâ Scanner. This scanner measures
color intensities of probes hybridized to the Genechipâ and expression values are
produced in the form of .cel files (Figure 2.5).
Expression microarrays come with certain advantages. First, they are an
affordable technique for quantification of the transcriptome. Also, as microarrays have
been around for a while and have been used extensively for gene expression profiling, the
various sources of errors and bias are well understood in the field. However, they have
several drawbacks of their own. First, they come with probe bias, that is the transcripts
and genes are quantified only if they exist (S. A. Martin, Dehler, & Król, 2016).
Therefore, this technique cannot be used to detect novel genes or transcripts or to detect
genes or transcripts for which probes are unavailable. Moreover, microarrays have a
lower resolution, accuracy and sensitivity for detecting differential expression than some
of the recent techniques like RNA sequencing (Sîrbu, Kerr, Crane, & Ruskin, 2012).
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Figure 0.5 Schematic of gene expression microarray profiling using the Affymetrix
Genechipâ HG U133 Plus 2.0 array. (Ryan et al., 2004)

2.1.7.2 RNA sequencing
RNA sequencing is a cutting-edge technique that has evolved in the last decade as
an extension of the second-generation DNA sequencing methods. Though sequencing
methods like Sanger sequencing and 454 sequencing (also called as pyrosequencing)
have been available and were among the earliest sequencing techniques (Heather &
Chain, 2016), RNA sequencing is one of the newest next generation sequencing
technologies that employs the sequencing by synthesis methodology. Sequencing by
synthesis uses the traditional chain termination method of sequencing employed in
Sanger sequencing in combination with the immobilization of the template on a glass
surface, thus allowing multiple cycles of addition of nucleotides tagged with labels for
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detection of incorporation and thus, the sequence of RNA (Sanger, Nicklen, & Coulson,
1977; Weber, 2015). Illumina is now the leader in RNA sequencing instrumentation and
preparatory kits where the company has developed a wide variety of sequencing
instruments from benchtop sequencers having a smaller output to high throughput
parallel sequencers for multi-sample deeper sequencing. The workflow of a sequencing
run on using the Illumina technology is shown in Figure 2.6 and described below.
Preparation of the steady state RNA sample for sequencing involves a few major
steps, all included in library preparation. First, RNA is fragmented such that it reaches a
desired fragment length and is enriched for the desired type of RNA. Fragmentation is
achieved by either physical (shearing or acoustic methods), enzymatic (nucleases or
transposases) or chemical (heat or divalent ions) methods (Head et al., 2014). The
fragment size (or insert size) is just a few tens of bases longer than the desired read
length. Enrichment of a specific RNA molecule type in the sample is done by specialized
methods. Exome sequencing targeting the messenger RNA alone uses poly-A selection to
deplete other forms of RNA. In the ribo-depletion method ribosomal RNA, being the
most abundant RNA species, is depleted to enrich for messenger RNA, small non-coding
RNA and transfer RNA molecules (Hrdlickova, Toloue, & Tian, 2017).
Following fragmentation and target RNA selection, library preparation method
usually involves conversion of RNA to cDNA by either the addition of adapters (8bp
fragments for Illumina-compatible library preparation methods that help differentiate
samples from one another), random priming or priming with the help of oligo-dTs. This
is usually followed by amplification to allow for complexity of library preparation.
Maintenance of strand specificity is recommended for RNA sequencing which is carried
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out by sequentially amplifying each of the strand after degrading the other (Hrdlickova et
al., 2017). Finally, the created library can also be size selected to enrich for certain
populations of amplicons, like small RNAs, in case that is the desired application (Röther
& Meister, 2011).
In Illumina sequencers, the prepared library of fragments of sample RNA is then
loaded onto glass slides containing lanes called flow cells. Each flow cell is coated with
oligonucleotides, the sequences of which are complementary to the adapter molecules.
When the samples are allowed to hybridize to the oligonucleotides on the flow cells, they
undergo a process called ‘bridge amplification’ by which clusters of forward and reverse
strands are generated (Dündar, Skrabanek, & Zumbo, 2015). The cluster generation
ensures that the light signal emitted after insertion of a base during sequencing is within
the detection range for the camera used. Sequencing at a single base resolution is carried
out using ‘Sequencing by Synthesis’ technology which uses a modification of Sanger’s
Chain Termination method to sequence cDNA fragments. Reversible chain termination
allows repeated cyclic addition of bases and their subsequent fluorescence-based
detection (Figure 2.6) (Buermans & Den Dunnen, 2014).
Analysis of RNA sequencing data is a complex process for which the standards in
the field are still being established. However, there are some commonly used and
recommended practices for RNA sequencing data handling and analysis (Figure 2.7).
Raw sequence data from the sequencing runs is usually in the form of FASTA or FASTQ
files and performing quality control on the raw unaligned reads is recommended to
ensure optimum read quality based on Phred scores. Phred scores range from 10-60 and
indicate the average base calling score at a position in the read. A score of 10 indicates
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the probability of 1 erroneous base call in 10 base calls. The higher the score, the more
accurate is the base calling at that position, for example a score of 60 indicates an
accuracy of 99.9999% (Ewing, Hillier, Wendl, & Green, 1998). After ensuring the
optimum quality of raw reads, alignment of raw reads is performed to the reference
genome of interest, in this case the human genome. A vast variety of aligners are
available for the user to choose from. A major sub-classification of aligners is whether
they are spliced or non-spliced. Spliced aligners (also known as splice aware aligners)
can recognize intron gaps while non-spliced aligners (splice unaware aligners) are usually
used for alignment of output from DNA sequencing runs and will not recognize and
relate to large gaps in alignment as introns (Engström et al., 2013). The most common
aligners used for RNA sequencing data are STAR (Dobin et al., 2013), Tophat (Kim et
al., 2013), MapSlice (K. Wang et al., 2010)and GSNAP (T. D. Wu & Nacu, 2010). Hisat
is another new aligner by the designers of Tophat and its usage is increasing in the
literature (Kim, Langmead, & Salzberg, 2015).
Verification of optimum alignment is made by post-alignment quality control and
read filtering and adapter trimming is performed as necessary. Illumina’s output of raw
reads is trimmed for adapter removal. This is followed by expression quantification and
measurement of differential expression among sample groups under investigation (Figure
2.7). A plethora of algorithms and software solutions, either freeware or proprietary
solutions are available for the analysis of RNA sequencing data. An important
consideration while designing RNA sequencing experiments is the read depth. Typically,
a read depth of 10-25 million reads per sample is sufficient for differential expression
studies whereas studies involving alternative splicing require about 50 million reads per
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sample depth. De-novo assembly of the genome (in the absence of a reference genome
for a particular sample) requires a read depth up to 100 million reads per sample
(Consortium, 2011) (Yichuan Liu et al., 2013).
RNA sequencing has some great advantages over microarray technologies which
are outlined in Table 2.2, it but also has its own drawbacks. Nevertheless, RNA
sequencing has served as a validation technique for microarray due to higher resolution
(single base) and sensitivity. This is particularly important for the purposes of this study
for two reasons. Firstly, RNAse protection assay was used previously in our work as a
validation strategy for microarray analysis (Latimer et al., 2010), but this assay is
complex and time consuming, and is also limited by its multiplexing ability and lack of
probe flexibility. Secondly, RNA sequencing not only helped with gene expression
validation, but also with the investigation of single nucleotide variants in the coding
regions of the NER genes and other important breast cancer-related genes (Chapter 4 and
5).
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Figure 0.6 Steps involved in RNA sequencing. Modified from (Malone & Oliver, 2011) (Link to
license: https://creativecommons.org/licenses/by/2.0/)
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Figure 2.7 Flowchart illustrating the commonly used steps for RNA sequencing data
analysis. Input of raw FASTA or FASTQ reads is followed by quality control and alignment to a
reference genome. Post-alignment QA/QC is then performed to check for optimum alignment>
reads are annotated if the reference genome for the organism being studied is available. If not, the
genome is constructed using specialized algorithms and this requires a high coverage of the
genome. Quantification of expression is the performed, which is followed by measurement of
differential expression among the defined sample groups (I. S. Yang & Kim, 2015) (Link to
license: https://creativecommons.org/licenses/by-nc/4.0/)
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Table 2.2 Major differences between Microarray and RNA sequencing (G. Russo,
Zegar, & Giordano, 2003; Y. Wang, 2014)
Parameter

Microarray

RNA sequencing

Cost

Low

High

Resolution

Low

High (Single Base)

Applications

Gene expression
Quantification

Gene expression
Quantification,
Variant Calling,
Alternative Splicing,
Novel transcript discovery

Sensitivity

Low

High

Probe Bias

Yes

No

Amount of RNA required

1 ug

100 ng

Multiplexing of samples in
a run
Sequence of RNA along
with expression
quantification
Easy data portability and
storage
Data reproducibility

No

Yes

No

Yes

Yes

No

Yes

Yes

2.1.8 Diseases caused due to defects in the NER pathway
The genes involved in NER pathway are different in terms of their contribution to
functional NER capacity. This was demonstrated by early work on mutant mouse models
of these genes that were assayed for their NER capacity, as well as human mutants that
showed severe phenotypes due to mutations in NER genes and therefore, loss of the
ability to perform NER (Table 2.1). Three diseases are associated with NER deficiency,
namely Xeroderma pigmentosum, Cockayne syndrome and Trichothiodystrophy.
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2.1.8.1 Xeroderma pigmentosum
Xeroderma pigmentosum is primarily autosomal recessive disorder and its name
implies dry and pigmented skin (von Hebra & Kaposi, 1866). Individuals with xeroderma
pigmentosum are characterized by extreme sensitivity to sunlight resulting in severe skin
pigmentation and an unusually high predisposition to cancer (Bradford et al., 2010; de
Boer & Hoeijmakers, 2000). Patients with xeroderma pigmentosum have a 2000-fold
higher risk of getting skin cancers as well as cancers of internal organs, and usually die
prematurely than a normal human at 8 years of age from cancer (Kraemer, 1997).
Although the incidence of this disease is very rare in the US (1 in 250,000), xeroderma
pigmentosum has an unusually high incidence in the Japanese population (Imoto et al.,
2013; Lehmann, McGibbon, & Stefanini, 2011).
James Cleaver discovered that xeroderma pigmentosum patients are intrinsically
deficient in their ability to perform NER (Cleaver, 1968). This discovery was made
independently by Richard Setlow as well (Setlow, Regan, German, & Carrier, 1969). The
severity of the loss of NER function depends on the gene that harbors the mutation. Eight
complementation groups were discovered in xeroderma pigmentation using fusion
experiments on cells obtained from patients suffering from this disease. These groups
were XP-A to XP-G and XPV, and the residual repair capacity after a mutation in each of
these complementation groups can be found in Table 2.1(for XPV, the residual NER
capacity is still 100%). Restoration of NER capacity after fusing two cells from two
different patients (and thereby forming a heterokaryon) indicated that the mutations are in
two different genes in each of the patients and they complemented each other. However,
persistence of a deficient NER capacity after cell fusion indicated a mutation in the same
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gene which was the deemed non-complementary. The link of NER deficiency to cancer is
shown unequivocally by the susceptibility of xeroderma pigmentosum patients to skin
and other cancers.
2.1.8.2 Cockayne syndrome
Named after Edward Cockayne who discovered this disease phenotype in 1936,
Cockayne syndrome is characterized by sensitivity to sunlight, mental retardation, stunted
growth and development as well as progeroid symptoms (Cockayne, 1936). However,
Cockayne syndrome patients do not have a susceptibility to cancer like xeroderma
pigmentosum patients, the reason for which is not known to date (de Boer &
Hoeijmakers, 2000; Kraemer et al., 2007). CSA and CSB are the two complementation
groups that have been identified, and germline mutations in these two genes are the cause
for Cockayne syndrome’s phenotype. These two proteins are localized to the
mitochondria, and they play an important role in the repair of mitochondrial DNA
(Aamann et al., 2010; Kamenisch et al., 2010). As the impairment in the function of
mitochondria has been implicated in neurodegenerative disorders, this might be a
possible explanation for the phenotype for this disease. As these genes are involved in
damage recognition in the transcription-coupled repair pathway, UV-induced
mutagenesis mechanism does not result into a cancer predisposition in these patients as it
does in xeroderma pigmentosum. A possible explanation is that the global genomic repair
pathway, being intact, compensates for the lack of transcription coupled-repair(ReidBayliss, Arron, Loeb, Bezrookove, & Cleaver, 2016).
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2.1.8.3 Trichothiodystrophy
Trichothiodystrophy is an autosomal recessive disorder characterized by 5 major
phenotypic traits, namely photosensitivity, ichthyosis (meaning dry, scaly and thickened
skin), decreased fertility, brittle hair due to deficiency in sulfur, short stature and
impaired growth (Stefanini, Botta, Lanzafame, & Orioli, 2010). This disease was
discovered from a mutation in the XPD gene by Stefanini and colleagues and manifests
as a deficiency in the NER pathway (Stefanini et al., 1986). Three complementation
groups have been identified – XPB, XPD and TTD-A. Patients suffering from
trichothiodystrophy, although showing a mix of phenotype between xeroderma
pigmentosum and Cockayne syndrome, do not have an increased susceptibility to cancer
(Stefanini et al., 2010)
2.1.9 NER and Breast Cancer
There have been a few studies that have studied NER in the context of breast
cancer. The earliest accounts come from studies by Kovacs et al. who studied NER in the
lymphocytes of breast cancer patients (Table 2.3). Their studies involved using the UDS
assay to measure the NER capacity of lymphocytes obtained from patients with breast
cancer and comparing them to those from healthy controls. This group also studied NER
capacity in the blood of healthy women who had a familial history of breast cancer
(women whose mothers, or sisters, or mothers and sisters had breast cancer) and
compared them to that of controls that did not have a family history of breast cancer.
They found that the NER capacity as measured by the UDS assay was low for both these
test groups of women compared to controls (Table 2.3). Another group, Shi et. al. (2004)
found similar results by measuring NER capacity in lymphocytes from breast cancer
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patients and comparing them with those from non-diseased controls. Matta et. al. (2012)
again showed significantly lower NER capacity in lymphocytes from Puerto Rican
women with breast cancer compared to those from controls.
A major drawback of all the studies mentioned above used lymphocytes from
blood of patients as surrogates of breast or breast function to correlate NER capacity with
the incidence and risk of breast cancer. Latimer et. al. (2003) have shown previously that
peripheral blood lymphocytes have low baseline NER capacity than normal breast,
ovaries and the skin. Therefore, NER is tissue specific and lymphocytes are not a good
representative of the NER capacity in the breast (Latimer et al., 2003). Correlation of
breast cancer risk with the NER capacity of lymphocytes, therefore, would not be
accurate.
Another drawback of most of these studies is that they have used the host cell
reactivation assay to measure the DNA repair capacity. As discussed previously, this
assay measures transcription-coupled repair and hence is not an indicator of total
functional NER capacity of the samples. We have been the first group in literature to
study NER capacity using the functional UDS assay to measure total NER capacity in
early stage sporadic breast tumor samples and compare them with that of non-diseased
breast control samples. We showed that NER capacity in stage I breast tumors is
intrinsically low in sporadic Stage I tumors compared to the NER capacity of 23 nondiseased breast reduction explants, thereby establishing the foundation of the link of NER
with sporadic early stage breast cancer.
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Table 2.3 Overview of studies measuring NER capacity in breast cancer

Title

Model system
and study
subjects

Assay
used to
measure
NER

Major
Finding

Reference

Reduced DNA
repair synthesis in
healthy women
having first
degree relatives
with breast
cancer.

Lymphocytes from
64 healthy women
having a familial
history of breast
cancer and 48
control women
without a family
history of breast
cancer
Peripheral blood
lymphocytes from
69 untreated
women with breast
cancer compared
with 79 controls

UDS

45 out of 64
women had low
DNA repair as
measured by the
UDS assay.
Only 8 out of 48
controls had low
DNA repair.

(Kovacs &
Almendral, 1987)

Host cell
reactivation

Low DNA
repair capacity
in breast cancer
samples
compared to
controls

(Q. Shi et al.,
2004)

Lymphocytes from
285 Hispanic
women diagnosed
with breast cancer
compared to 539
controls

Host cell
reactivation

(Matta et al.,
2012)

Lymphoblastoid
cell lines
established from
158 breast cancer
patients and 154
sister controls

UDS

DNA repair
capacity of
women with
breast cancer
was lower by
60% compared
to controls
Lower NER
capacity in
breast cancer
patients
compared to
controls

Lymphocytes from
465 breast cancer
cases and 661
controls

Host cell
reactivation

Low DNA
repair capacity
was associated
with increased
breast cancer
risk

(Morales et al.,
2013)

Reduced DNA
repair of
benzo[a]pyrene
diol epoxideinduced adducts
and common
XPD
polymorphisms in
breast cancer
patients
The association of
DNA repair with
breast cancer risk
in women. A
comparative
observational
study
DNA
repair capacity of
lymphoblastoid
cell lines from
sisters discordant
for breast cancer.
Factors associated
with breast cancer
in Puerto Rican
women

(Kennedy et al.,
2005)
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2.2 Breast Cancer
2.2.1 Anatomy of the breast
The breast is a lactiferous gland that produces milk in the human body. The breast
consists of lobes, which are in turn made up of multiple lobules. Lobules are the milkproducing structures in the breast. These lobules located at the back of the breast anterior
to the sternum are connected to the nipple via a network of branching ducts that converge
at the nipple. These lobules are known as terminal ductal lobular units or TDLUs and
about 20-40 TDLUs constitute each lobe in the breast (Hoda, Rosen, Koerner, & Brogi,
2014).
The microenvironment of the breast consists of epithelial and stromal
components. The luminal epithelial cells lining the lobules and ducts form the epithelial
component, where this epithelium in the lobules is what produces milk. Epithelial cells
are situated on a myoepithelial cell lining that contracts to release the milk from the
apical surface of the luminal epithelial cells in the lumen of the duct, upon stimulation by
oxytocin. Therefore, each TDLU consists of epithelial cells lining the lumen, an outer
myoepithelial lining which is finally covered by an outer basement membrane (Hoda et
al., 2014). The stroma of the breast constitutes collagen, fibroblasts, macrophages,
plasma cells, peripheral blood lymphocytes and blood vessels. The majority of the breast
consists of fat made up of adipocytes, and these are necessary for the formation of
secondary structures during embryogenesis (Figure 2.8). It is usually the epithelial cells
that line the ducts and lobules which undergo uncontrolled proliferation and show
morphological changes in the cancer of the breast. (Hoda et al., 2014).
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Figure 2.8 Anatomy of the breast. Panel A shows gross anatomy of the breast. Panel B shows a
cross section of a TDLU stained with hematoxylin and eosin. A magnified image of a single
lobule is shown in the top right corner of Panel B that shows a single lobule lined with epithelial
cells around a hollow lumen. Panel C shows a scanning electron micrograph of a lobule. Adapted
from Vidi et. al., 2013 and cancergov.org.

2.2.2 Breast cancer incidence, mortality and survival rates
Breast cancer still remains a debilitating disease for women in spite of
advancement in diagnostic technologies and treatment modalities. Breast cancer
comprises of about 15% new cases of cancer diagnosed in the US, and about 252,000
cases were expected to be diagnosed in 2017 (Howlader et. al., 2017). Breast cancer is
not only prevalent in the US but is also the most common cancer worldwide among
women and second most common among all cancers. Breast cancer has a worldwide
incidence of about 1.6 million cases and an age adjusted rate of 43.3 per 10,000 personyears. It was also shown to have the highest cumulative risk of either incidence or
mortality compared to all cancer types (Ferlay et al., 2015).
In the US, 40,610 deaths were estimated from breast cancer alone for the year
2017, and breast cancer is second on the causes of death from cancer, after lung cancer
for men and women (Howlader et. al., 2017). However, breast cancer still remains the
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cause of mortality among women worldwide, followed by cervical/uterine and lung
cancer (Ferlay et al., 2015).
Although the 10-year relative survival rate for women diagnosed with breast
cancer is 89.7% with this survival percentage having increased by 16.1% since 1975, this
number dramatically decreases with increase in stage. About 3 million women are
presently living with breast cancer in the US, thereby making breast cancer one of the
major sources of cancer burden (Howlader et.al., 2017).
2.2.3 Risk factors for breast cancer
Certain factors increase the risk of getting breast cancer, and they can be
classified into either modifiable or non-modifiable risk factors. Non-modifiable risk
factors are the ones that are inherited and cannot be changed, such as age, race, ethnicity
as well as germline mutations that predispose an individual towards breast cancer.
Modifiable risk factors are environmental and lifestyle conditions which expose the
individual to certain factors that can cause carcinogenesis, such as smoking, diet,
pregnancy, breastfeeding, alcohol and the use of hormone replacement therapy or
contraceptives (Gierach & Vogel, 2004).
Genetic susceptibility is a key risk factor for breast cancer involving two genes,
BRCA1 and BRCA2. Inherited germline mutations in either of these genes increases the
risk of developing breast cancer by approximately 70% by the time a woman reaches 80
years of age (Kuchenbaecker et al., 2017). Age is another major risk factor for breast
cancer, where women older than 65 years of age are about 6 times more likely to get
breast cancer than women younger than 65 (S. E. Singletary, 2003) (Howlader et al.,
2014). Pregnancy has been shown to decrease the risk for getting breast cancer with
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white women who are pregnant before the age of 20 have a 50% less risk of getting
breast cancer over their period of life (Britt, Ashworth, & Smalley, 2007). This has been
attributed mainly to a more differentiated and therefore a more stable state of the
epithelial cells of the breast, as the mammary gland undergoes differentiation during
pregnancy to prepare for lactation (J. Russo, Tay, & Russo, 1982).
Smoking, both in the active or passive form, has been correlated with a higher
breast cancer risk by multiple studies compared to non-smokers (Bjerkaas et al., 2014;
Catsburg, Miller, & Rohan, 2015; B. Li et al., 2015). About 5300 chemicals are found in
the smoke from a cigarette, most of which are known chemical carcinogens (Perfetti &
Rodgman, 2014). Chemicals found in tobacco smoke such as benzo[a]pyrene cause
adducts in DNA which are remediated by DNA repair pathways, especially NER. Hence,
impaired DNA repair may be a major risk factor in breast cancer (Schärer, 2013). Studies
have also linked alcohol consumption with breast cancer risk, mostly due to increased
estrogen levels associated with alcohol consumption (K. W. Singletary & Gapstur, 2001).
The risk increases with every glass of alcohol consumed, reaching up to 40% for 3
glasses of alcohol per day (Ellison, Zhang, McLennan, & Rothman, 2001; S. M. Zhang et
al., 2007).
2.2.4 Breast Cancer Classification
Malhotra et. al., have laid out breast cancer classification based on 3 broad
classes, namely histological, molecular and functional. Histological classification
categorizes breast cancer based on the location of origin within the breast (Malhotra,
Zhao, Band, & Band, 2010)
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2.2.4.1 In-situ breast carcinomas
In-situ breast carcinomas are comprised of breast cancers that are localized (also
known as Stage 0) can be limited either to the lumen of the duct (ductal carcinoma in-situ
or DCIS) or the lobules (lobular carcinoma in-situ or LCIS). In-situ carcinomas can
become invasive, with 10-year rate being 5.4/1000 person-years for DCIS and 7.3/1000
person-years for LCIS (C. I. Li, Malone, Saltzman, & Daling, 2006).
2.2.4.2 Invasive breast carcinomas
Invasive breast carcinomas are comprised of breast cancers that have spread from
their site of origin but may still be contained within the breast. Invasive carcinomas are
further classified into subtypes based on histology, and are laid out in a well
characterized diagram by Malhotra et al. (Figure 2.9)
2.2.5 Molecular subtypes of breast cancer
Gene expression profiling techniques have allowed to analyze breast cancer cases
on a molecular basis and hence have given rise to molecular subtypes of breast cancer.
Sørlie et al., and Perou et al., performed pioneering work which enabled the subtyping of
breast cancer cases into 5 major classes based on gene expression profiling, namely
Luminal A, Luminal B, Her2 overexpressed, Basal and Normal-like (Perou et al., 2000;
Sørlie et al., 2001). A newer sub-class called Claudin-Low has also been established in
the basal type (Prat et al., 2010). Molecular subtype classification is either based on
immunohistochemistry (IHC) markers or on gene-based assays. Gao and Swain (2018)
give a comprehensive overview on the various molecular subtype determination methods
and assays.
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2.2.5.1 Luminal A type BC
This class of breast cancer comprises tumors that overexpress Estrogen receptor
(ER) but not the Progesterone receptor (PR) or the HER2 receptor. Luminal A breast
tumors are defined as ER-positive, PR < or = 20%, HER2-negative and Ki67 (a cellular
proliferation marker) <14% (Goldhirsch et al., 2013). Luminal A is the most common
type of BC diagnosed (about 55%), has the best prognosis among all breast cancer sub
types and also has the lowest grade (X. Dai et al., 2015; O'Brien et al., 2010; Sørlie et al.,
2003). Because these tumors are characterized by overexpression of estrogen receptors,
they respond well to hormone therapy like tamoxifen (Brenton, Carey, Ahmed, & Caldas,
2005).

Fig. 2.9. Histological classification of breast cancer. Each of DCIS, LCIS and Invasive
Carcinomas are categorized into further histological subtypes. Histological grade is defined
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based on the degree of differentiation of the tumor cells (discussed later on). Adapted and
reprinted with permission (Malhotra et al., 2010)

2.2.5.2 Luminal B type BC
Nearly 40% of diagnosed BC types are Luminal B and are ER+ along with being
either HER2-positive or HER2-negative. HER2-positive Luminal B BCs can have any
PR or Ki-67 levels, whereas HER2-negative Luminal B type can have either Ki-67³20%
and PR-, or alternatively Ki-67 <20% and have a high recurrence score based on gene
expression panels (X. Dai et al., 2015; Goldhirsch et al., 2013). Luminal B BCs usually
have high histological grades and poorer prognosis than Luminal A type, similar to nonLuminal BCs. The lack of PR expression in some of these tumors, which is a predictor
for hormone therapy response, makes these tumors less responsive to endocrine
treatments for BC (Tran & Bedard, 2011).
2.2.5.3 HER2 enriched BC
Breast tumors overexpressing HER2 receptors can be either hormone receptor
(ER and PR) positive or negative, i.e., HR+ or HR-. These tumors show overexpression
and/or amplification of the ERBB2 gene and other cell proliferation related genes.
Patients with HER2-enriched disease are treated with targeted HER2 antagonists like
trastuzumab or HerceptinÒ, although HER2-enriched tumors that are HR+ have a better
prognosis than HR- ones, and this observation was made even independent of
trastuzumab treatment in clinical trials (Piccart-Gebhart et al., 2014; Tolaney et al.,
2015). However, HR status does not affect response of these tumors to trastuzumab
(Gianni et al., 2012; Perez et al., 2014; Pogue-Geile et al., 2015).
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2.2.5.4 Triple negative breast cancers or TNBC
Triple negative BCs are the cases where there is no significant overexpression of
either the hormonal receptors (ER-negative, PR-negative) or the HER2 receptors (HER2negative). These characteristic makes their treatment challenging, and they are generally
the most aggressive tumors due to the lack of molecular targets (Malorni et al., 2012).
TNBC are the most lethal form of breast cancer at every stage. Being devoid of
expression of hormonal receptors or HER2 receptors, these cases are usually treated with
non-targeted conventional chemotherapeutic agents (Gradishar et al., 2016). Triple
negative breast cancers are more frequently observed among and correlated with
premenopausal women, women below the age of 40 (Bauer, Brown, Cress, Parise, &
Caggiano, 2007), carriers of BRCA1 or BRCA2 mutation (Peshkin, Alabek, & Isaacs,
2011), women belonging to the African American ancestry (Dietze, Sistrunk, MirandaCarboni, O'regan, & Seewaldt, 2015).
2.2.5.5 Basal type BC
Basal type of breast cancer are characterized by homogeneity in their tumors and
high expression of genes peculiar to the normal myoepithelial layer surrounding the ducts
in the breast, such as smooth muscle markers, b4 integrin, and high molecular weight
cytokeratins (Bertucci, Finetti, & Birnbaum, 2012). Basal type and triple negative breast
cancers show a lot of similarity, however basal BC cases are classified with gene
expression arrays (Perou et al., 2000), as opposed to triple negative breast cancers, that
are solely classified based on the lack of expression of hormone receptors and HER2
receptors.
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2.2.5.6 Claudin Low BC
Claudin Low breast cancer is a relatively newer discovery among molecular BC
sub types and is quite similar in characteristics to the triple negative type, as in it lacks
the expression of hormone receptors as well as HER2 enrichment. In addition, Claudin
Low BCs show a low expression of tight junction proteins like claudin 3,4 and 7 as well
as E-cadherin (Dias et al., 2017). This class of BC has an intermediate prognosis between
Luminal A type and the ones that have a poor prognosis like Luminal B and triple
negative BC types.
2.2.5.7 Normal-like BC
Normal-like breast cancer is characterized by over expression of progesterone
receptors (PR-positive) but a lack of expression of estrogen receptor, HER2 receptor and
Ki-67 (X. Dai et al., 2015). This subtype, defined by gene expression microarray
analyses, shows the over expression of genes specific to the adipose tissue and other nonepithelial cell types (Sørlie et al., 2001).
2.2.6 Functional classification of breast cancer
Functional classification of breast cancer is based on tumor stage and tumor
grade. Tumor stage is defined by the TNM staging guide by the American Joint Cancer
Commission, which comprises of a combination of clinical examinations, surgical
interventions and imaging techniques (Amin et al., 2018). T in the TNM staging guide
refers to tumor size, N to lymph node status and M to metastasis. Taken all together, a
final cancer stage is defined which forms the basis of the course of treatment along with
immunohistochemical marker analyses and now molecular subtyping. TNM staging
guide is described in Table 2.4a and 2.4b.
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TNM class
T1

T2
T3
T4

Subclass
T1mi
T1a
T1b
T1c
T4a
T4b

Definition
Tumor size £ 1mm
Tumor size >1mm but £ 5 mm
Tumor size > 5 mm but £ 10 mm
Tumor size >10 mm but £ 20 mm
Tumor size >20mm but £ 50 mm
Tumor size > 50mm
Extension to the chest wall
Ulceration and/or ipsilateral satellite nodules and/or edema
of the skin
Both T4a and T4b
Inflammatory carcinoma
Lymph node status could not be determined
No regional lymph nodes metastasis
Metastases to movable ipsilateral level I, II axillary lymph
nodes
Metastases in ipsilateral level I, II axillary lymph nodes
that are clinically fixed or matted; or in clinically detected
ipsilateral internal mammary nodes in the absence of
clinically evident axillary lymph node metastasis
Metastases in ipsilateral infraclavicular (level III axillary)
lymph node(s) with or without level I, II axillary lymph
node involvement; or in clinically detected ipsilateral
internal mammary lymph node(s) with clinically evident
level I, II axillary lymph node metastases; or metastases in
ipsilateral supraclavicular lymph node(s) with or without
axillary or internal mammary lymph node involvement

NX
N0
N1

T4c
T4d
-

N2

N2a, N2b, N2c

N3

N3a, N3b, N3c

M

M0

No evidence of distant metastasis

M1

Distant detectable metastasis by clinical, radiological and
histological interventions (>0.2mm)

Table 2.4a. Definitions of the TNM classes for clinical classification of stage for breast
cancer. Further discussion on the N subtypes is out of scope of this dissertation Adapted from
AJCC’s staging poster (seventh edition) based on (Edge & Compton, 2010)
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Stage

T (Tumor Size)

IA
IB

T1
T0
T1
T0
T1
T2
T2
T3
T0
T1
T2
T3
T3
T4
T4
T4
Any T
Any T

IIA
IIB
IIIA

IIIB
IIIC
IV

N (Lymph Node
Status)
N0
N1mi
N1mi
N1
N1
N0
N1
N0
N2
N2
N2
N1
N2
N0
N1
N2
N3
Any N

M (Metastases)
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1

Table 2.4b. TNM staging guide for breast cancer. Adapted from the AJCC’s staging poster
based on Edge & Compton, 2010.

Tumor grade is defined based on the cell differentiation status and the
morphological characteristic of the tumor cells and is an indication of the prognosis of the
disease in that patient. A tumor is classified into one of 4 grades, where grade 1 has the
best prognosis and signifies normal-looking cells similar to that of the tissue of origin that
are well differentiated. tumor grade 2 has worse prognosis that grade 1, but better than
tumor grade 3 and 4, and is characterized by abnormal looking cells that are somewhat
like the cells from the tissue of origin. Tumor grade 3 consists of poorly differentiated
cells and is considered a high grade with poor disease prognosis. Tumor grade 4 has the
worst prognosis and is characterized by undifferentiated cells that are completely
different than breast epithelial cells and abnormal-looking (Figure 2.10) (Rakha et al.,
2010).

55

Fig 2.10 Histological images depicting grade of tumor cells of the breast. a) Welldifferentiated normal looking tumor cells with well-defined lumen lined by a monolayer of
cells in ducts; b) Abnormal cells with intermediate differentiation leading to multiple layers of
cells causing narrowing of ducts; c) poorly differentiated abnormal tumor cells with hardly
visible ductal lumens. (Rakha et al., 2010)

2.2.7 Treatment for Breast Cancer
2.2.7.1 Surgery
Error! Bookmark not defined. Surgery for tumor removal is considered as
preferred route of treatment for Stages I, IIA, IIB and sometimes stage III. Up until the
1970s, radical mastectomy, which involves removal of both breasts along with axillary
lymph nodes and chest wall muscles, was considered the standard of care. However,
mastectomy posed a severe disadvantage from a patient’s psychological and social
perspective and also posed challenges for breast reconstruction (Arroyo & López, 2011;
Gerber, 2017; Guthrie & Cucin, 1980)Early accounts of modified radical mastectomy
were given by Madden, Kandalaft and Bourque in 1972.
Surgical resection of the tumor is the most preferred way of treating early stage
BC and is referred to as lumpectomy. Lumpectomy is now the chosen as well as preferred
standard of care for early stage BC, followed by adjuvant radiation therapy, unless certain
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factors prevent this course of treatment in certain patients, such as the inability to receive
radiation treatment (Gradishar et al., 2016). This standard of care has followed six
clinical trials that showed lumpectomy with adjuvant radiation has the same outcome as
mastectomy (B. Fisher et al., 2002; Veronesi et al., 2002). There has also been a
reduction in local recurrence rates after breast conserving surgeries, with the rate being
less than 10% in 10-year follow-up studies (Anderson et al., 2009; Wapnir et al., 2006).
Margin width during resection of the tumor has been a subject of debate to date.
There has been considerable variation found in determination of how much of the
surrounding histopathologically normal tissue to excise along with the tumor, and the
decision is usually surgeon-specific (Barrio & Morrow, 2016). The usual process
involves the surgeon resecting the tumor along with at least a 2 mm pathologically
normal margin surrounding the tumor and this excised specimen is then sent to be
analyzed by a pathologist. The pathologist then evaluates the specimen after staining the
margin to determine if the margin is “positive” or “close”, meaning the tumor either
extends to the full length of the margin or is very close to the margin. In such a case, reexcision is carried out, until the margin of the resected specimen is “negative”, meaning
no tumor is seen infiltrating the margin (Figure 2.11) (Brown et al., 2010). The most
recent NCCN guidelines on breast tumor resection recommend “no ink on tumor” to be
sufficient, which means the absence of tumor on the inked margin is sufficient for
surgical resection of stage I and II breast cancers with adjuvant radiation therapy
(Morrow et al., 2016).
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Figure 2.11 Histopathological sections of inked margins after tumor resection from breast
conserving surgery. The pink stain indicates epithelium, where the white sections mostly
indicate adipose tissue. Black solid arrows point towards the edge of the malignant tissue. Panel
A indicates a positive margin, where the tumor is invading the margin. Panel B is considered
close to the margin as the tumor is within 1 mm of the inked margin. Panel C is considered a
negative margin, where at least 2 mm or more of the margin is seen outside of the tumor.
Reprinted with permission (Brown et al., 2010)

2.2.7.2 Radiation therapy
Because of the high recurrence rates of breast cancer with lumpectomy alone,
radiation therapy is given to patients along with breast conserving surgery, known as
adjuvant radiation therapy. According to the NCCN guidelines, patients undergoing
lumpectomy for Stage I, IIA and IIB are recommended whole breast irradiation. A dose
of 45-50 Gy is recommended to be administered at a frequency of 1.8 to 2 Gy per
fraction, or a dose of 42.5 Gy at 2.66 Gy per fraction (Gradishar et al., 2016). An
additional boost of radiation therapy is recommended for patients that have a higher
tumor grade or are above the age of 50 years. A further strong recommendation of
mammary node irradiation is also given by these guidelines for patients that are positive
for the spread of cancer to their axillary lymph nodes (Gradishar et al., 2016).
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Accelerated partial breast irradiation can be considered for certain patients if they
meet the required criteria. Patients with early stage breast cancers that are ER-positive
and did not have lymph node positivity can be considered for partial breast irradiation,
according to the consensus guidelines by the American Society for Radiation Oncology
(ASTRO) (Smith et al., 2009). While studies have shown benefit by using accelerated
partial breast irradiation (Formenti et al., 2004; Polgár et al., 2007), studies have also
shown conflicting results and an inferior cosmetic outcome(Jagsi et al., 2010).
Clinical trials have shown adjuvant radiation therapy given along with
lumpectomy reduced local recurrence of breast cancer (Anderson et al., 2009) (Wapnir et
al., 2006). Important clinical trials have also shown radiation therapy along with
lumpectomy has similar outcomes as that of mastectomy, which is why adjuvant
radiation therapy is imperative for early stage breast cancer treatment (B. Fisher et al.,
2002; Veronesi et al., 2002). Finally, patients that have advanced stage breast cancer
receive neo-adjuvant radiation therapy along with chemotherapy to de-bulk the tumor
prior to surgery to make it operable (Lerouge et al., 2004).
Radiation therapy uses ionizing radiation to destroy cells by either directly
damaging the genome or by causing the production of free radicals that damage DNA
(Baskar, Dai, Wenlong, Yeo, & Yeoh, 2014). The inability of breast cancer cells to
efficiently repair their DNA due to defective DNA repair mechanisms is taken advantage
of by using radiation therapy which selectively destroys cancer cells faster than normal
cells that have intact DNA repair capacity (Shahidi, Mozdarani, & Bryant, 2007).
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2.2.7.3 Chemotherapy
Treatment of chemotherapeutic agents is recommended for advanced breast
cancer patients with stage III or IV breast cancer or with patients having triple negative
breast cancer. Chemotherapeutic agents target cancer cells by a variety of mechanisms as
outlined in Figure 2.12

Figure 2.12 Mechanisms of action of chemotherapeutic agents used in breast cancer. Most
drugs targeting cancer cells work by targeting the cell division stages, like DNA replication,
mitotic phase, promoting DNA supercoiling by inhibiting topoisomerases. Other agents act via
mechanisms independent of the cell cycle. Reprinted from mycancergenome.org

Chemotherapy is usually given as a combination of drugs acting via two different
mechanisms, mainly to prevent chemotherapy resistance which is a debilitating problem
in cancer treatment for late stage cancers (Housman et al., 2014). Two main
chemotherapeutic agents used in breast cancer are Cyclophosphamide and Adriamycin.
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These agents might be substituted for anthracyclines due to cardiac toxicity by these
agents. Gemcitabine is also often used as a single chemotherapy agent.
For breast cancers that are ER positive, i.e., luminal type, hormone therapy is
administered. The drugs primarily block the activity of estrogen, which is required for
cellular growth and proliferation in the breast. Two main categories of drugs under
hormone therapy are selective estrogen receptor modulators (SERMs) (examples are
tamoxifen, raloxifene and toremifene) or aromatase inhibitors. Aromatase inhibitors are
the drugs of choice for post-menopausal women as they do not block the production of
estrogen by the ovaries but block the conversion of androgens to estrogen mediated by
the enzyme aromatase. This is the main mechanism of estrogen production in postmenopausal women (Abdulkareem & Zurmi, 2012). Resistance to hormone therapy is
quite commonly observed and it occurs mainly due to loss of expression of hormone
receptors or an alteration in the signaling pathway responsible for the proliferation and
growth of cancer cells (W. Fan, Chang, & Fu, 2015).
Treatment of breast cancer has improved significantly with the advent of targeted
therapies, like HER2 receptor antagonists. Trastuzumab (Herceptinâ) is the drug of
choice for HER2 overexpressing cancers. This is a monoclonal antibody acts by the
inhibition of HER2 receptors, thereby disrupting the MAPK and PI3K/Akt signaling
pathways responsible for cellular growth and proliferation. In addition, Trastuzumab also
activates the PTEN tumor suppressor gene which leads to cell cycle arrest by the
recruitment of immune cells to the tumor that eradicate cancer cells via antibodymediated cellular toxicity (Claret & Vu, 2012). Other targeted therapies include
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monoclonal antibodies targeting VEGF, IL5 and PDL-1 (Shepard, Phillips, Thanos, &
Feldmann, 2017).
2.3 Non-tumor adjacent (NTA)
2.3.1 Step-wise progression of cancer
Carcinogenesis is a complex process that has been known to proceed in a stepwise manner. Early studies on development of tumors were performed on rodent models,
which elucidated a two-step model of carcinogenesis (Berenblum & Shubik, 1947; Fujiki,
Sueoka, & Suganuma, 2013; Mottram, 1944). However, more recent accounts show
evidence regarding the fact that development of cancer has been thought to follow three
main steps, i.e., initiation, promotion and progression (Barrett, 1993; Pitot, Goldsworthy,
& Moran, 1981).
2.3.1.1 Tumor initiation
Tumor initiation has been attributed to an irreversible alteration in a cell in the
form of mutation or a mutation-like event, more recently termed as an ‘epimutation’.
Evidence in literature regarding initiation of mammary tumors points to factors including,
but not limited to, inactivation of tumor suppressors (Simin et al., 2004) or activation of
oncogenes (Morrison & Leder, 1994) along with dysregulation in matrix
metalloproteinases (Sternlicht, Bissell, & Werb, 2000), collagen density (Provenzano et
al., 2008), genes of the notch pathway (Robbins, Blondel, Gallahan, & Callahan, 1992)
and dietary fat (Welsch, 1987). However, involvement of nucleotide excision repair in
mammary tumor initiation has not been studied yet, to our knowledge.
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2.3.1.2 Tumor promotion
Tumor promotion allows the cell harboring the genetic alteration to bypass
cellular checkpoints and thrive, which ultimately manifests as a tumor mass in the case of
solid tumors (Diamond, O'Brien, & Baird, 1980). A multitude of factors can contribute to
tumor promotion, including endogenous promoters like prostaglandins as well as
exogenous chemical promoters (Pitot, 1991). Therefore, tumor promotion has been
thought of as a target for anti-cancer interventions, as they are reversible up until the
formation of a benign tumor (Marks, Fürstenberger, & Müller-Decker, 2007).
2.3.1.3 Tumor progression
Tumor progression is where a formed cell harbors irreversible changes that leads
to the creation of a subpopulation of cells that go on to become increasingly invasive.
Such changes involve mutations or mutation-like events in oncogenes (e.g., Ras and src)
as well as tumor suppressor genes (e.g. p53 and APC) and studies involving early versus
late stage cancers have shown step-wise accumulation of such changes (Yokota, 2000).
The number of somatic non-synonymous mutations, which means mutations that cause a
downstream change in the functional protein coded by the gene harboring the mutation,
has not been found correlated to stage, suggesting some mutations are lost during tumor
progression while others are gained (Xia Li, 2016). An ovarian cancer study found losses
in chromosomal bands to be common in earlier stages, whereas amplifications were seen
in greater numbers in late stage, making the later a characteristic of tumor progression
(Shridhar et al., 2001). A major hallmark of cancer, which is increased genomic
instability, is the biggest contributor to harboring changes during tumor progression, and
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the loss or reduction in the NER capacity has been mostly implicated to contribute to
genomic instability (Hanahan & Weinberg, 2000).
Cancer, therefore is a manifestation of a step-wise accumulation of driver as well
as passenger alterations where the former are responsible for tumor initiation and
promotion, while the latter mainly are a characteristic of tumor progression.
2.3.2 Somatic evolution in carcinogenesis
2.3.2.1 Driver events
Development of cancer is a complex process involving the interplay of a number
of interconnected events. It is now an established theory, that a solid tumor is the ultimate
fate of clonal expansion of specific cells that harbor molecular alterations that the cell
acquires on its way to neoplasia. The initiation of these mutations or alterations could be
due to a variety of reasons which include, but are not limited to, external insults from
chemicals as well as internal processes like oxidative damage, in sporadic cases of
cancer. Now it is important to note that not all the abnormalities seen in a tumor cell are
present from the start. These changes are acquired during expansion of the cells harboring
the initial molecular alteration (which is more commonly referred to as the ‘driver’ event
or events). This driver event provides selective advantage to the cell that helps it to
bypass cellular checkpoints and proliferate, generating a clone of such cells, by evading
certain checkpoints that regulate normal cellular growth, proliferation and function.
These include cessation of replication upon damage detection and cell-to-cell contact,
apoptosis etc. (Hanahan & Weinberg, 2000). This driver event makes the cell prone to
further abnormal alterations (known as ‘passenger’ events) until a final change that gives
this mass of cells harboring all the characteristics of the tumor, an abnormal phenotype
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and histology (Vogelstein et al., 2013). Computational approaches can help determine the
driver events that are involved in the development of cancers. Rajendran and Deng have
reviewed 12 such approaches to find driver mutations in breast cancer and found 63
driver genes. An interesting aspect of their results was that none of these genes included
genes from the NER pathway (Rajendran & Deng, 2017). This point further emphasizes
the importance of our study in early stage disease with a known phenotype as the
correlative element.
2.3.2.2 Passenger events
The passenger events offer no selective advantage to the cells, but accumulate in
the pre-neoplastic cells, increasing their mutation burden. This expansion often goes
unnoticed by clinicians and researchers trying to focus on the disease itself and the
treatment for its eradication. The harboring of these changes takes time, as a mutation (or
a mutation-like molecular alteration) is usually a one in a millionth event. This explains
why the majority of the cancer cases occur later in life (Hahn & Weinberg, 2002;
Vogelstein et al., 2013). The exception to this rule is pediatric cancers, which more often
than not, result from genetic predisposition to the disease. Sporadic cancers, i.e., the ones
that are not attributed to a genetically inherited germline predisposition are mostly seen in
older individuals.
Evidence regarding the theory of clonal selection or ‘stemness’ of a cancer cell
came from initial studies. The idea that tumors develop from a cell that is preferentially
selected originated, and this was also called a tumor ‘stemline’ (Nowell, 1976). Rodent
models of cancer have also shown that cancer that is induced chemically is clonal in
nature, and that its progression occurs in a step-wise fashion (Iannaccone, Weinberg, &
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Deamant, 1987). Rodents have a much more limited lifespan than humans and may
reflect a narrower range of possibilities simply due to the lack of decades and time for the
original clone to further evolve(Y. Ma et al., 2015). Now, molecular studies of tumor
heterogeneity in humans show that multiple cell types may be present in a neoplastic
lesion that were initiated by an important event or events that decreased genomic stability
early and allowed for the explosion and expansion of several alternative successful paths
forward. The fact still remains that the earlier initiating and promoting events somehow
led to a tumor mass which is a result of preferential selection of altered cells and their
clonal expansion.
Tumor heterogeneity can be explained with an alternative model, which is the
cancer stem cell (CSC) theory of development of cancer. This theory states that a single
mutated cancer stem cell leads to sequential development of generations of differentiated
as well as more stem cells, thus adding variety into the pool of clonal cancer cells
(Marjanovic, Weinberg, & Chaffer, 2013). The CSC theory also stresses the fact that
tumor evolution is in fact clonal.
2.3.3 Models of Carcinogenesis
2.3.3.1 Knudson’s two hit model for carcinogenesis
This model served as the earliest account for a multi-step tumorigenesis theory
which was proposed by Nordling in 1953 (Nordling, 1953) and supported by evidence
from Knudson in 1971. Knudson used a cohort of 48 patients with retinoblastoma to test
his mutation models in cases of bilateral versus unilateral retinoblastoma patients and
their age of onset of the disease. He found a correlation with bilateral retinoblastoma (in
both eyes) and his one-mutation model, hypothesizing that inheritance of a germline
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mutation in the retinoblastoma gene requires only one sporadic mutation event in the
gene for phenotypic manifestation of the disease. Knudson also found a correlation
between unilateral retinoblastoma and a two-mutation model, where both mutations in the
retinoblastoma gene are sporadic events (Knudson, 1971). Thus, this model gave the
perfect working theory for the identification of tumor-suppressor genes and their
mechanism of loss of function in cancer.
Current multi-step models for carcinogenesis are built upon Knudson’s model
which, although suffices for explaining the occurrence of retinoblastoma, might be
simplistic in the case of other cancers. Models following this took into account other
scenarios in tumor suppressor genes that this model does not explain, like
haploinsufficiency, multiple gene interactions or loss/gain of function isoforms (Paige,
2003).
2.3.3.2 Multistep model for colorectal carcinogenesis
Mathematical and theoretical models had in the past been proposed to enumerate
the multi-step process of neoplasia (Armitage, 1985). One of the most ground-breaking
studies that provides clinical evidence for these models was provided by Bert Vogelstein
and his colleagues. Vogelstein proposed a model for colon carcinogenesis and was able to
determine the changes that occurred during each step of progression of colon cancer
from a familial lineage of colon cancer called HNPCC (Hereditary nonpolyposis
colorectal cancer) (Fearon & Vogelstein, 1990). In this model, pathological and
molecular changes happening at each step of carcinogenesis from a normal colon tissue
to a tumor have been delineated. This has been possible as colorectal cancer passes
through well- characterized morphologically-distinguishable stages especially in a
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germline mutation carrying family (Vogelstein & Kinzler, 1993). The main steps
involved in the carcinogenesis of the colon are sequential mutations first in the APC
tumor suppressor gene causing loss of its function and then the Ras oncogene causing its
activation, and methylation is involved in between these as well. Finally, DDC and p53
genes are mutated causing loss of both DDC and p53 activity leading to a tumor (Figure
2.13).

Figure 2.13 Genetic model of colorectal tumorigenesis. Reprinted with permission
(Vogelstein & Kinzler, 1993)

2.3.3.3 Model for Esophageal Adenocarcinoma: Barrett’s Esophagus
A landmark study in 1999 showed a strong association of gastroesophageal reflux
and the development of esophageal carcinoma. This constant acid reflux leads to a benign
condition known as Barrett’s esophagus, a precancerous precursor to esophageal
adenocarcinoma (Lagergren, Bergström, Lindgren, & Nyrén, 1999). Barrett’s esophagus
is histologically characterized by the replacement of the normal squamous epithelial
mucosa to a columnar epithelium which is confirmed by an endoscopy (Fitzgerald et al.,
2013). The current guidelines available for the diagnosis of Barrett’s requires the
presence of intestinal metaplasia, as it has been known to lead to progression and
therefore neoplastic lesions. Genetic models of carcinogenesis from Barrett’s esophagus
to esophageal adenocarcinoma show how this can be a false negative, as there is
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considerable sampling bias. This model is described in Figure 2.14 and gives further
evidence for the multi-step carcinogenesis model and field cancerization theory
(Gregson, Bornschein, & Fitzgerald, 2016).
Although the risk of progression of Barrett’s esophagus becoming cancerous is
low, occurrence of epithelial dysplasia increases the risk of progression significantly
(Kastelein et al., 2015). Therefore, the model shown by Gregson et. al. mapped the
overlapping of possible driver mutations and dysplastic phenotype. Barrett’s is riddled
with a mutation burden of about 10 variants per million bases, a frequency much higher
than even some malignancies like breast cancer, myeloma, hepatocellular carcinoma and
colorectal adenocarcinoma(Ross-Innes et al., 2015). Among the early events in dysplastic
transformation of Barrett’s are mutations in p16, p53 as well as SMAD1 and CDKN2A
(Figure 2.14)
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Figure 2.14 Genetic model of transformation of Barrett’s esophagus to esophageal
adenocarcinoma. Barrett’s esophagus provides an example for the importance of
histopathologically normal tissue harboring genetic alterations and being a few steps away
from becoming neoplastic. An interesting aspect of this model is the creation of “fields” and
not all patches have all the changes shared between them. Reprinted with permission (Gregson
et al., 2016) (Link to license: https://creativecommons.org/licenses/by-nc-sa/4.0/).

2.3.3.4 Model for breast carcinogenesis
Bièche and Lidereau gave one of the first comprehensive models for the
alterations seen in the development of mammary tumorigenesis. This model shows well
delineated stages involved in mammary carcinogenesis, where in an ideal scenario,
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normal breast undergoes hyperplastic growth that first manifests as in-situ carcinoma
(ductal or lobular) and then proceeds to invasive breast cancer followed by metastatic
breast cancer. The major alterations that lead to the transformation included activating
mutations in MYC and ERBB2 leading to their overexpression. Mutations or loss of
heterozygosity in tumor suppressor genes TP53 and NME1 is also involved. Loss of
heterozygosity at a number of locations is seen in the transformation of invasive
carcinoma to metastatic (Figure 2.15) (Bieche & Lidereau, 1995).

Figure 2.15 Model of genetic alterations in mammary carcinogenesis. Reprinted with
permission (Bieche & Lidereau, 1995)

A caveat to the breast carcinogenesis model is that although conceptually correct,
the stages in breast cancer do not always necessarily follow this order and have been
known to skip steps. For example, hyperplasia in the breast may lead to invasive
carcinoma does not always go through the in-situ carcinoma stage (Page et al., 2003).
Also, the heterogeneity of breast cancer makes the elucidation of specific alterations
related to tumorigeneses extremely difficult, as certain mutations tend arise preferentially
in specific cell types than the other, an example of which is preferential p53 mutations in
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the ductal and medullary tumors than other histotypes (Marchetti et al., 1993).
Moreover, distinct molecular profiles and biologies of the subtypes of breast cancer are
evidence that breast cancer is a complex disease (Guedj et al., 2012).
Further evidence is needed for a conclusive mammary tumorigenesis model. Most
of the molecular changes listed at the end of this schematic are from studies performed on
late stage breast cancers. They are therefore not likely to be drivers but could reflect a
combination of many generations of genetic changes, some of which occurred rather
recently in a long progression of changes. To determine the early changes requires a
study of early stage breast cancer, with isogenically matching tissues.
2.3.4 Field cancerization
The harboring of abnormal genetic alterations predisposing a cell towards
neoplasia and offering selective growth and proliferative advantage raises an important
point. If the clonal expansion of cells at each step after acquiring these abnormal
alterations is factored in, there are patches or “fields” of these abnormal cells generated in
a 2 and 3-dimensional plane in a tissue. This field of cells harboring the abnormal
alterations, some of which will be shared with the tumor, have been found to be clonal.
The cells forming these fields may be otherwise histopathologically normal and lack the
invasion and metastatic markers found in cancer (Braakhuis, Tabor, Kummer, Leemans,
& Brakenhoff, 2003).
The idea of field carcinogenesis was introduced by Slaughter and colleagues in
1944 and the term was subsequently coined in 1953. Slaughter studied the non-tumor
adjacent tissue along with tumors in 783 patients with squamous cell carcinoma of the
oral cavity. The resected benign epithelium around the tumor was found to be
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microscopically abnormal in all patients studied and the presence of independent multifocal tumors was seen in 88 patients, indicating ‘pre-conditioning’ of the surrounding
benign tissue to ultimately transform to cancerous lesions (Slaughter, Southwick, &
Smejkal, 1953).
An interesting aspect of the field cancerization theory is that it explains the
development of new tumors from a genetic standpoint during recurrence of a cancer type.
This phenomenon was originally shown in 1957 by Qualheim and Gall with respect to
breast cancer, where they analyzed histological sections of 157 resected breasts from
patients with breast cancer. Out of these, 54% had multi-focal tumors and 29% had
different histological patterns from one another, suggesting the convergence of two or
more tumors (Qualheim & Gall, 1957). Another study showed that local recurrences of
tumors of the head and neck were genetically more closely related to the surrounding
mucosa than the original primary tumor (Tabor et al., 2001).
Evidence for field cancerization has also been shown in the carcinogenesis of the
skin (Stern, Bolshakov, Nataraj, & Ananthaswamy, 2002), lung (Franklin et al., 1997),
cervix (T. Y. Chu, Shen, Lee, & Liu, 1999), vulva (Rosenthal, Ryan, Hopster, & Jacobs,
2002), prostate (Nonn, Ananthanarayanan, & Gann, 2009), colon (Jothy et al., 1996),
esophagus (DeWard & Critchley-Thorne, 2017) and bladder (Försti, Louhelainen,
Söderberg, Wijkström, & Hemminki, 2001; Takahashi et al., 1998).
All in all, the theory of field cancerization emphasizes the importance of studying
the histopathologically normal tissue surrounding the tumor and this makes the nontumor adjacent tissue a great model system for the evaluation of genetic changes
occurring en route to the tumor. This is particularly important when a phenotype is
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associated with the non-tumor adjacent tissue that distinguishes it as being cancer prone
in spite of its normal histological appearance. Our study utilizes such a system.
2.3.5 In-vitro model systems for normal mammary cells
2.3.5.1 Human mammary epithelial cultures (HMECs)
Evidence for the ability to be able to culture human mammary cells in vitro came
from the studies of several groups. Among these was Martha Stampfer and colleagues in
the 1980s. This group cultured human mammary tissue obtained from non-diseased
breast reduction mammoplasty surgeries. This procedure is usually performed for
aesthetic or medical purposes as women with large breasts suffer from poor posture,
backaches and breast pain (Kerrigan et al., 2001). Stampfer and colleagues established
HMECs by gentle laceration of breast reduction tissue and culturing it in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum.
Collagenase and hyaluronidase enzymes were used to break down the stroma and the
basement membrane. Finally, they showed that used of an enriched medium
supplemented with supernatant medium of the early HMECs, which they called
conditioned medium (CM) led to stimulation of growth of mammary cells in culture up to
a couple sub-cultures, after which the cells start to show senescence and decrease in their
proliferation. While the enriched medium supported the outgrowth of epithelial cell
types, a non-enriched medium was shown to favor the growth of myoepithelial cells that
have a more fibroblastic phenotype (Stampfer, Hallowes, & Hackett, 1980).
A modified culture protocol showed that the use of a pituitary extract without the
use of serum extended the number of subcultures to 20 passages for these human
mammary cultures (Hammond, Ham, & Stampfer, 1984). The HMEC cell line 184 was
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later shown by expression microarray analysis to be myoepithelial in origin (Ince et al.,
2007).
The culture of HMECs have now evolved to include the use of basement
membrane extracts or extra-cellular matrices (ECMs), to support the growth of nontransformed mammary cells in-vitro. This extract was first isolated from a tumor in mice
and had properties of a liquid at 4°C. but forms a gel-like consistency at 370 C (Kleinman
& Martin, 2005). A commonly known brand for this is Matrigel (Bissell & Hall, 1987;
Kleinman & Martin, 2005). These basement membrane extracts contain growth factors,
collagen, lamelin and other components, that mimic the basement membrane in-vivo
(Benton, Kleinman, George, & Arnaoutova, 2011). Use of the ECM to culture HMECs
have shown acini formation along with production of milk proteins with breast epithelial
cells and this has been extensively studied by Bissell and colleagues (Ghajar & Bissell,
2008) primarily from mouse mammary glands. The formation of tubular capillaries is
observed with endothelial cell culture on ECM (Arnaoutova, George, Kleinman, &
Benton, 2009) . Where normal cells appear to grow as aggregates on ECM, culture of
cancer cells show an independent and invasive morphology and therefore ECM is used in
an assay to study the invasiveness of cancer cells (Albini et al., 1987).
2.3.5.2 MCF-10A as a normal breast line
MCF-10 is a cell line derived from a woman who had a fibrocystic disease and
underwent subcutaneous mastectomy by the Michigan Cancer Foundation. This line had
the characteristics of a normal cell line, wherein it had a diploid karyotype for earlier
cultures and some rearrangements and a near-diploid karyotype in further subcultures.
MCF-10 also formed organoid structures in collagen, showed growth regulation by
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hormones and growth factors and did not form tumors upon transplantation in mice.
Interestingly, the continuation of growth of this cell line in vitro was observed to be
dependent on the concentration of Ca+. When MCF-10 was cultured in regular DMEM
with 5% equine serum containing Ca+, the cells still reached senescence and were mortal.
However, upon transferring to a medium containing lower calcium chloride
concentrations and maintaining the cells in culture for a period of 849 days, MCF-10
cells acquired resistance to calcium-induced senescence and showed an immortal growth
pattern in DMEM with regular calcium concentrations (Soule et al., 1990; Soule &
McGrath, 1986). This immortal sub-line of MCF-10 was termed as MCF-10A which was
widely used thereafter and is still used as a model for normal human mammary cells in
literature (Qu et al., 2015).
2.3.6 In-vitro model systems for breast tumors
Commercially available cell lines are commonly used as model systems to study
the cancers of the breast as well as other organs. These cell lines provide advantages of
having unlimited growth potential and high turnover rate. They also lack the
disadvantage of cellular heterogeneity that comes with using tissue samples and therefore
produce reliable and reproducible results. These commercially available cell lines are
used extensively in literature and have broadened the horizons of our knowledge
regarding metastasis and hormonal therapy in cancer (Burdall, Hanby, Lansdown, &
Speirs, 2003).
A major drawback with these cell lines is that they are established from pleural
effusions from patients having stage IV breast cancer (e.g., MCF-7, MDA-MB231 and
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others) (Riaz et al., 2013). These therefore are not representative of early stage breast
cancer and would not be proper model systems to study the etiology of breast cancer.
Subsequent cell lines from earlier stage breast cancers are becoming more
common (J. W. Shay, Wright, & Werbin, 1991; Van Der Haegen & Shay, 1993).
However, immortalization of these cell lines has been achieved using immortalizing
agents like viruses (SV40), Papilloma virus components and telomerase (hTERT) which
have been known to affect multiple DNA damage signaling and repair (Boichuk, Hu,
Hein, & Gjoerup, 2010; J. Shay, Wright, Brasiskyte, & Van der Haegen, 1993; Van Der
Haegen & Shay, 1993).
2.3.7 Tissue engineering system of the Latimer Lab
Due to the drawbacks mentioned above, we have established a novel tissue
engineering system to overcome the drawbacks with the available model systems
mentioned above. Using this tissue engineering system, the Latimer Lab has established
over 150 extended explants (< 13 passages) and cell lines (> 13 passages) from the
following: breast tumors representing all stages and molecular types of breast cancers
(85% success), matched histopathologically normal tissues adjacent to the tumors (75%
success), ductal carcinoma in-situ and normal non-diseased breast tissue obtained from
women undergoing reduction mammoplasty surgeries (100%) for aesthetic or medical
purposes.
Using this system, tissue samples are minced and plated onto a basement
membrane extract to support the growth of cells in these cultures. A specialized nutrient
medium is used which was originally established from a growth medium used for
maintaining embryonic stem cells at the Magee Women’s Research Institute (MWRI)
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(Latimer, 2000). These primary cultures are then allowed to grow by maintaining them at
37°C. and 10% CO2 after which they are passaged into extended explants. These
extended explants are then deemed as cell lines after passage number 13, as this is when
they establish a stable, albeit slow, growth pattern (Figure 2.16). There are no
immortalizing agents used in this culture system in order to keep them pristine and true to
their origin. Validation of representative cell lines in this collection has been performed
using karyotype analysis, expression microarray analysis, RNA-seq analysis and
validation of ER status using RT-PCR.
The advantage of this culture system is that it has allowed us to perform extensive
molecular studies on matched cell line pairs of tumor and non-tumor adjacent samples
from the same patient, which would otherwise not be possible on tissue samples or
primary cultures of the same. At the same time, the slower rate of growth of our breast
cultures is a drawback as it leads to longer experimental turn over times. Also, these
cultures, just like 2-dimensional culture systems, tend to select for a more fibroblastic
morphology among mixed cultures. However, we have previously compared differences
between NER capacities between fibroblastic and epithelial cell types in our breast
cultures and found no significant difference between the two cell types (Latimer et al.,
2003). The presence of basement membrane extract in these dishes maintains epithelial
cells which in the primary and early passaged state form 3D structures that can
differentiate all the way to ductal systems in non-diseased breast and some non-tumor
adjacent cultures (Figure 2.16B).
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Figure 2.16A Tissue engineering system at the Latimer Lab. Tissue samples obtained from
patients undergoing breast surgery are minced and placed into dishes or slides coated with
basement membrane extract at 37°C and 10% CO2. These primary cultures are further passaged
to generate extended explants up until a passage number of 13, after which they are deemed
cell lines.
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Figure 2.16B Latimer tissue engineering system. This timeline shows the progressive
differentiation manifested by non-diseased breast reduction mammoplasties placed into
primary culture

2.3.8 NTA in breast cancer
Blood is commonly used as a normal control for studies involving cancer,
especially for the discovery of biomarkers (H. Dai et al., 2017; Mudenda et al., 1994).
This is mainly to eliminate invasive procedures to aid in diagnosis as blood is easy to
obtain. However, tissue specific differences make blood a poor representative for
comparison of cancer cell types. We have previously shown that the NER capacity in
peripheral blood lymphocytes is lower than that of normal breast tissue samples (Latimer
et al., 2003). Therefore, the importance of using non-diseased tissue of similar origin as
the tumor has been recognized in the scientific community, which is hard to obtain in
majority of the cases.
The tissue adjacent to the tumor from the same lineage, which we call the nontumor adjacent or NTA, has been used traditionally in literature as a normal control to
establish cancer biomarkers and tumor-specific abnormalities. Certain important studies
showed karyotypic changes in the adjacent normal tissue and therefore, laid the
groundwork for the NTA tissue being genetically altered (E. R. Fisher & Paulson, 1978;
Teixeira, Pandis, Bardi, Andersen, & Heim, 1996; Teixeira et al., 1995). However,
although the concept of NTA tissues harboring genetic abnormalities is becoming more
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prevalent in the literature after factoring in field cancerization, studies to date still
generally use NTA as a normal control or at least as a measure of “pre-existing” variants.
Table 2.5 delineates the use of NTA in breast cancer and shows the need for further
evidence of the possible genetic abnormality of the NTA tissue, seeing that it is still being
used for comparing tumor tissues.
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Table 2.5 Studies using NTA in breast cancer and their context of use

NTA Status

Study description and major finding

Reference

NTA used as normal
control

Low Caspase-I expression in breast cancer compared to tumor adjacent,
promoting proliferation and invasion
Reduction of isocitrate dehydrogenase-I expression and high Snail
expression correlates with poor prognosis of breast cancer
PD-L1 overexpression in breast cancer, correlated with lymph node status,
grade and clinical stage
Effects of 4-hydroxyltamoxifen on human breast cancer cells and
confirmation of gene expression patterns in breast cancer tissues and tumor
adjacent tissues
Increased 5-formylcytosine and 5-caboxymethylcytosine in tumors
compared to adjacent normal; distinct DNA methylation profiles in different
molecular subtypes of breast tumors compared to tumor-adjacent tissues
Higher expression of matrix metalloproteinases MMP-2 and MMP-9 in
breast cancer as compared to tumor adjacent tissues; potential use as
biomarkers to predict prognosis
Increased PRKDC expression (DNA-dependent kinase catalytic subunitinvolved in DNA repair) in breast tumors compared to non-tumor adjacent
breast samples
Expression quantitative loci analysis of 71 SNPs in 376 invasive breast
FFPE samples compared with 264 tumor-adjacent normal tissues; found 21
loci associated with expression variation in 271 genes compared to tumoradjacent normal
Differential gene expression using breast tissues and non-tumor adjacent
samples in Lebanese women using the Affymetrix HG U133 Plus 2.0 array
Premature polyadenylation of MAGI3 leading to the activation of an
oncogene observed in 160 breast tumors but not in matched normal adjacent
tissues

(Y. Sun & Guo, 2018)
(W.-S. Liu et al., 2018)
(F. Li, Ren, & Wang,
2018; Raji et al., 2013)
(Fang, Yao, Luo, &
Zhang, 2018)
(Guo et al., 2017)
(Hai Li, Qiu, Li, &
Wang, 2017)
(G. Sun et al., 2017)
(Quiroz-Zárate et al.,
2017)
(Makoukji et al., 2016)
(Ni & Kuperwasser,
2016)
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NTA Status

Study description and major finding

Reference

Overexpression of TPX2 in breast cancer compared to adjacent breast
leading to cell migration and invasion
HAX1 and Ki-67 overexpression in breast cancer than adjacent normal
tissues, leading to promotion of tumor invasion and metastasis
Global hypomethylation of 5-methylcytosines as a biomarker in breast
cancer, compared with 309 normal adjacent tissues
R-Ras activation seen in normal adjacent tissues but not in breast cancer
tissues, suggesting a protective role of R-Ras in breast cancer
Field emission electron microscopy used to identify benign adjacent tissue
from cancerous tissues
STAT3 activation leads to malignancy and metastasis in breast cancer
tissues compared to normal tumor-adjacent breast tissues
Mitochondrial DNA as a biomarker for breast cancer, significantly lower in
buffy coat and tumor tissue but not in serum as compared to non-tumor
adjacent breast tissue
Melanoma-associated antigen MAGE-A9 overexpression indicative of poor
prognosis in breast cancer as compared to normal adjacent tissues
Upregulated expression of TACSTD2 and Cyclin D1 in breast cancer
compared to non-malignant tumor-adjacent tissues
High expression of ALCAM (activated leukocyte cell adhesion molecule) in
tumors compared to adjacent breast tissue; associated with metastasis and
invasion
DNA adducts due to PhIP ( a chemical in charred meat and tobacco smoke)
are not present in non-tumor adjacent breast samples acquired from 70
breast cancer patients
Differential gene expression in breast cancer tissues compared to tumoradjacent normal breast tissue in Saudi women

(Y. Yang et al., 2015)
(Sheng & Ni, 2015)
(Tsai et al., 2015)
(J. Song, Zheng, Bu, Fei,
& Shi, 2014)
(Pandya, Chen, Goodell,
Foran, & Desai, 2014)
(X. Liu et al., 2014)
(Zhou & Chen, 2014)
(Xu et al., 2014)
(Lin et al., 2013)
(Piao et al., 2012)
(Gu et al., 2011)
(Amer et al., 2008)
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NTA Status

NTA abnormal

Study description and major finding

Reference

Formation of 4-ABP-DNA adducts due to smoking associated with breast
cancer; compared with 55 normal adjacent breast tissues
Fibroblasts from tumor-adjacent tissue promote cell growth in the presence
of breast cancer cells, but otherwise suppress progenitor cells in a normal
breast environment
Hypermethylation of CDKN2A in tumor-adjacent tissues and tumor-distant
tissues compared to normal non-diseased breast tissues; supports field
cancerization theory
Heterogenous patterns of enhancement in quantitative imaging
characteristics of tumor-adjacent parenchyma showed an enrichment in the
tumor necrotic factor pathway and a poor survival in breast cancer
Tumor-induced STAT1 expression was shown to affect surrounding tissue
causing dysregulation of tissue homeostasis. Field effect of cancer was
shown in the tumor microenvironment
HIN-1 methylation was found to be a putative biomarker for detecting field
cancerization in breast cancer

(Faraglia et al., 2003)

NF-kB as an inflammatory marker and a potential inhibitory target in
adjacent stroma of the breast
IGF-2 expression in invasive breast tumors was higher than in the tumoradjacent tissue. However, expression of IGF-2 in the tumor-adjacent tissue
was in turn higher than that in non-diseased breast tissue
Differential as well as shared miRNA expression profiles among 3 breast
tumors, their adjacent normal tissues and non-diseased breast tissues
Hypermethylation of 8 tumor suppressor genes detected in all of the tumor
tissues from invasive carcinoma of the breast as well as tumor-adjacent
tissues. However, this was not detected in WBC samples of same patients

(Chatterjee et al., 2018)
(Spitzwieser et al., 2017)
(J. Wu et al., 2017)
(Zellmer et al., 2017)
(Spitzwieser, Holzweber,
Pfeiler, Hacker, &
Cichna-Markl, 2015)
(Katanov et al., 2015)
(Jun Qiu, Yang, Rao, Du,
& Kalembo, 2012)
(Persson et al., 2011)
(Y. H. Cho et al., 2010)
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NTA Status

NTA used in
comparison with
tumor; abnormalities
found

Study description and major finding

Reference

Gln allele due to an XRCC1 polymorphism is detected frequently in tumoradjacent breast than in non-diseased breast samples from reduction
mammoplasty
Structural polymorphism on chromosome 11 detected in both tumor DNA
and tumor-adjacent breast DNA, which is also a hotspot for DNA
methylation
Differential expression of insulin-like growth factor 1 (IGF1) in tumor and
tumor-adjacent tissues from invasive breast cancer; no difference in IGF
between tumor and tumor-adjacent breast in benign disease
Study provides evidence of field cancerization. Aneusomy of chromosome
1 and 17 detected shared in 66% of tumor-adjacent samples, similar to that
of the tumors
Residual tumor found in 60% tumor adjacent samples on which mastectomy
was performed, and residual tumor also found in distant sites
Lower lipid metabolism by alcohol intake in ER+ breast tumors and their
tumor adjacent tissues; gene set enrichment was similar in ER- tumors and
their tumor adjacent tissues

(Ali, Meza, Rogan, &
Chakravarti, 2008)

Detected 4 somatic variants in cell-free DNA from frozen breast tumor
samples; found high number of variants in the tumor-adjacent FFPE
samples, most of which were C>T transitions
Promoter methylation of ABCB1, ABCC1 and ABCG1 analyzed in breast
tumors, tumor adjacent and tumor distant tissues based on previous studies
showing the phenomenon in tumor adjacent tissues; did not find significant
methylation in tumor adjacent
Adjacent adipose tissue from invasive breast cancers were compared to
those from non-malignant samples; found increased inflammatory markers
in the adjacent adipose tissue of invasive breast cancers

(Weerts et al., 2017)

(Clark & Smith, 2008)
(Shin et al., 2007)
(Botti et al., 2000)
(Singer, 1993)
(J. Wang et al., 2017)

(Spitzwieser et al., 2016)

(Sturtz et al., 2014)
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NTA Status

Study description and major finding

Reference

Differences in the proteomics of tumor adjacent stroma and tumor-distant
stroma of invasive ductal carcinomas
Tumor-adjacent breast did not show gene expression profile that
differentiate breast tumors from non-diseased breast reduction samples, but
tumor-adjacent breast samples from ER-/PR-/HER2- tumors clustered with
those from basal type
Smoking caused pattern of adducts called diagonal zone of radioactivity in
30% of tumor and tumor-adjacent breast tissues

(Reddy et al., 2014)
(Finak et al., 2006)

(Perera et al., 1995)
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2.4 Epigenetic regulation of gene expression
The age old adage for mechanism of carcinogenesis states that specific genetic
alterations in the sequence of nucleotides, known as mutations, in certain genes either
results in a loss of tumor-suppressing functions of these genes or a gain of oncogenic
function (Grandér, 1998). Cancer research has now progressed to include alterations in
the genome that are heritable and do not involve a direct change in the DNA sequence.
These are epigenetic alteration and they are known as an ‘epimutations’ (Handy, Castro,
& Loscalzo, 2011). Epigenetic mechanisms of regulation include DNA methylation,
histone and chromatin modifications and regulation via small and long non-coding RNA
molecules. These mechanisms can affect transcriptional regulation of genes.
2.4.1 Non-coding RNA molecules as regulators of gene expression
In Chapter 4 of this thesis, we did not find methylation to be the putative pathway
of regulation of NER in our cell line pairs studied. Therefore, we will be exploring the
role of small non-coding RNA molecules, especially microRNA, in the regulation of this
pathway. This has been previously studied in the lab with respect to late stage breast
cancer (As Sobeai, 2017).
Non-coding RNA (ncRNA) molecules are important regulatory moieties that alter
gene expression by specific mechanisms particular to the type of ncRNA. These include
transfer RNA (tRNA), ribosomal RNA (rRNA), micro RNA (miRNA), small interfering
RNA (siRNA). small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and long
non-coding RNA (lncRNA).
Small non-coding RNA molecules, especially miRNAs, are involved in post
transcriptional regulation, as they have direct binding capability to mRNA and thereby
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regulate translation. miRNAs are approximately 19-21 nucleotide-long single-stranded
fragments of RNA that most often bind to the 3’ UTR of mRNA (Bartel, 2004).
Depending on the specificity and site of binding, mRNA and lead either to mRNA
degradation or its inhibition towards translation (Doench, Petersen, & Sharp, 2003;
Hutvágner & Zamore, 2002; Yan Zeng, Wagner, & Cullen, 2002). Small interfering RNA
on the other hand, have perfect complementarity to their mRNA binding sites, induce
mRNA degradation upon binding and are about 20-25 nucleotide-long (Agrawal et al.,
2003). Small nuclear RNA is involved in mRNA splicing and snoRNA plays a role as a
guide in rRNA modifications. Long non-coding RNAs are more than 200 nucleotides in
length and are involved in regulation of the aforementioned small ncRNA molecules
(Kung, Colognori, & Lee, 2013).
2.4.2 Chromatin modifications
Histones are proteins that give structure to chromatin, as DNA coils onto the
histone proteins, thus forming nucleosomes. Transcribed DNA, which is about 2-3% of
the genome, is in an open configuration called Euchromatin, which readily allows access
to DNA for transcription factors to bind and initiate gene expression. Heterochromatin,
on the other hand, is tightly coiled chromatin, usually found with heavy methylation and
deacetylation of histones. Out of the many modifications, those that may alter
transcription and thereby gene expression include acetylation, methylation, ubiquitination
and phosphorylation (Handy et al., 2011).
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2.4.3 DNA methylation
DNA methylation is the most studied epigenetic mechanism, with the earliest
account of the mechanism as a hereditary epigenetic mark and its direct role in gene
silencing came in 1975 (Holliday & Pugh, 1975; Riggs, 1975). Methylation is more
associated with heterochromatin, which is the highly condensed, tightly-coiled chromatin
configuration. Euchromatin, which is the less condensed and open chromatin
configuration, is transcriptionally active and therefore devoid of a heavily methylated
DNA signature (Handy et al., 2011; Keshet, Lieman-Hurwitz, & Cedar, 1986; Richards
& Elgin, 2002).
2.4.4 Sites of DNA methylation
2.4.4.1 CpG islands
DNA methylation occurs at the C5 position of cytosine bases at cytosine-guanine
dinucleotides in DNA, also known as CpG sites. CpG refers to 5’ – cytosine – phosphate
– guanine – 3’ on one strand of DNA, and this would form a palindromic dinucleotide
sequence along with the complementary strand. The genomes of vertebrates are usually
depleted in CpG sites, due to the spontaneous deamination of cytosine to thymine (Bird,
1980). CpG dinucleotides are known to be present in clusters on the promoter regions of
genes and are generally unmethylated. These clusters are known as CpG islands. CpG
islands are defined as a 200 kb DNA fragment with a GC percentage of greater than 50%
and an observed to expected ratio of C to G greater than 0.6 (Gardiner-Garden &
Frommer, 1987; Larsen, Gundersen, Lopez, & Prydz, 1992). Researchers have used CpG
islands as a way to discover novel genes and their promoter regions, as the promoter
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regions of a majority of Eukaryotic genes are overlapping one or more CpG islands
(Antequera & Bird, 1993; Lee, Salido, & Yen, 1994; Tribioli et al., 1994)..
Not all CpG islands lie on promoter regions of genes and promoter-associated
CpG islands constitute a fraction of the total number of known CpG islands in the
mammalian genome. Larsen et. al. have stated that all housekeeping genes are CpG
island-rich whereas only a fraction of tissue specific and coding genes have CpG islands
5’ of their promoters (Larsen et al., 1992).
2.4.4.2 Structure of a CpG island
While CpG island was discovered as clustered CpG sites, mostly overlapping
promoter regions of genes, important CpG sites have been discovered a couple thousand
bases upstream and downstream of a CpG island. This region, known as the CpG island
“shore”, is 2kb upstream and downstream of the CpG island, known as the north shore
and the south shore of a CpG island respectively (Irizarry et al., 2009). Moreover,
genomic regions 2kb upstream and downstream of the shore regions, known as CpG
island “shelves” have also been implicated to be important in gene expression regulation
and are queried in methylation array technologies. Apart from the CpG dinucleotides that
are a part of CpG islands and their flanking shore and shelf regions, orphan CpG sites
that are present in gene body regions or other regions of the genome not enriched by GCs
are known as “Open-sea” regions (Figure 2.17) (Sandoval et al., 2011).

Figure 2.17 Diagrammatic representation of a CpG island, shore and shelf regions. (Huang
et al., 2014)
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2.4.5 Mechanism of DNA methylation
DNA methyltransferases are the class of enzymes that methylate the cytosines of
DNA, and three major methyltransferase enzymes have been identified, namely DNMT1,
DNMT3a and DNMT3b. DNMT3a and DNMT3b are involved in de-novo methylation
(Okano, Bell, Haber, & Li, 1999) whereas DNMT1 is responsible for maintaining
methylation patters after DNA replication (Leonhardt, Page, Weier, & Bestor, 1992).
During gametogenesis, the DNA undergoes a wave of demethylation and a complete
reprogramming of DNA methylation occurs after implantation via the de-novo
methyltransferases (Razin & Cedar, 1993). All three methyltransferase enzymes are
therefore involved in embryonic development and viability (E. Li, Bestor, & Jaenisch,
1992).
Demethylation of 5-methylcytosines occurs by spontaneous deamination to uracil
or oxidation. This then is a target for the base excision repair pathway, as this change
from cytosine to uracil is a major mutagenic event if not remediated (Kow, 2002).
Chemical demethylation in cells can be induced in-vitro by 5-aza-2’-deoxycytidine,
which is a DNA methyltransferase inhibitor and will inhibit the maintenance methylation
that occurs after replication of DNA(Creusot, Acs, & Christman, 1982).
2.4.6 Role of DNA methylation in eukaryotes
DNA methylation plays a major role in X-chromosome inactivation, imprinting of
genes and gene silencing. Imprinting of genes refers to inheritance of expression patterns
from parental genes, meaning that the copy for a gene obtained from each parent may
have a different expression pattern. Therefore, monoallelic expression of imprinted genes
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requires specialized methylation patterns specific to the individual that are established
and maintained from embryonic development into adulthood (Surani, 1998).
Methylation is also responsible for X chromosome inactivation. In females,
though there are two copies of the X-chromosome, only one is active while the other is
randomly inactivated to ensure both males and females have the same X-linked dosage of
genes (Monk & Grant, 1990).
DNA methylation has also been known to regulate tissue specific gene
expression. This phenomenon is particularly observed in rabbit globin genes where
undermethylation allowed expression of these genes in erythroid cells, but this was
absent in non-erythroid cells (Shen & Maniatis, 1980). Expression of placental lactogen 1
is found only in the placenta and not in any other tissues in rodents, and it was shown to
be regulated by DNA methylation as well (J.-H. Cho et al., 2001). The regulation of
tissue-specific gene expression by methylation is described in Figure 2.18. This
phenomenon is particularly observed during embryonic stem cell differentiation. CpG
sites in embryonic stem cells are largely unmethylated at CpG-rich regions (Fouse et al.,
2008). During differentiation, this pattern changes as cell-type specific methylation
patterns are established onto the CpG sites (Meissner et al., 2008). CpG poor regions
(that are otherwise globally hypermethylated) undergo demethylation during cellular
differentiation (Nagae et al., 2011)

92

Figure 2.18 Mechanisms of cell-type specific regulation of transcription by CpG
methylation. CpG-rich regions like the CpG islands are, under normal conditions, found to be
less methylated, where CpG poor promoters are found highly methylated. Transposons and
repeats in DNA are always heavily methylated to ensure their silencing and hence, stability of
the genome. Methylation prevents the binding of transcriptional factors (TFs) that activate
transcription, whereas it favors the binding of methyl-CpG-binding domain (MBD) proteins
thereby repressing expression. Reprinted with permission. (Carrió & Suelves, 2015) (Link to
license: https://creativecommons.org/licenses/by/4.0/).

2.4.7 DNA methylation and cancer
2.4.7.1 Hypomethylation of DNA in cancer
The earliest evidence of involvement of DNA methylation in cancer came in 1983
where Feinberg and Vogelstein showed reduced methylation of specific genes in colon
cancer and Gama-Sosa et.al., showed global hypomethylation in human neoplasms
compared to normal human tissues (Feinberg & Vogelstein, 1983; Gama-Sosa et al.,
1983). Overall, a trend of DNA hypomethylation is seen in cancer, and this
hypomethylation is mostly observed in non-genic (non-protein coding) areas of DNA.
One explanation that has been proposed is that cancer-related mutations in the
methyltransferase enzyme DNMT3b leads to the formation of inactive catalytic units of
the enzyme. This abnormal alteration in the enzyme either makes it non-functional or
competes for the binding of the functional DNMT3b (Ostler et al., 2007).
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Another possible mechanism of DNA demethylation leading to the
hypomethylated state in cancer is the activity of MBD2 (methyl-CpG-binding-protein-2),
which preferentially binds to methylated CpG sites and catalyzes the breaking of the
bond cleaving the methyl group from the cytosine (Bhattacharya, Ramchandani, Cervoni,
& Szyf, 1999).
DNA hypomethylation in cancer activates regions that are otherwise repressed
transcriptionally in normal tissues. For example, viral genes are usually silenced with the
help of DNA methylation, and hypomethylation of such integrated viral DNA (Badal et
al., 2003). Moreover, DNA hypomethylation of repetitive DNA elements known as
satellite DNA has also been observed in some ovarian tumors (Widschwendter et al.,
2004). Specific proto-oncogenes like MYC, RAS and HOX11 are known to be
hypomethylated in cancer, leading to their activation and expression (Borrello et al.,
1992; Van Tongelen, Loriot, & De Smet, 2017; Watt, Kumar, & Kees, 2000). Overall,
hypomethylation of DNA in cancer increases genomic instability due to the activation of
these repetitive elements, transposons and specific onco-genes as well eventually paving
the way towards a tumor phenotype(Kulis & Esteller, 2010).
2.4.7.2 Hypermethylation of DNA in cancer
DNA methylation causes gene silencing for certain genes which is observed in all
types of cancers. Since the discovery of the function of methylation, a number of studies
have found associations with promoter hyper methylation and gene silencing in cancer.
Most of these hypermethylated genes in cancer are tumor suppressor genes, which upon
silencing by methylation lose function and lead to oncogenesis. Examples of these genes
are the ones that code for cell cycle dependent kinases like CDKN2A and CDKN2B
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(Drexler, 1998), proteins involved in cell cycle adhesion thereby preventing abnormal
proliferation of cells (Seuk Kim, Han, Shim, Park, & Kim, 2005) and transcription factors
that regulate gene expression (Akiyama et al., 2003). Moreover, CpG island methylation
of certain small non-coding RNA molecules like microRNAs have been known to silence
their expression. These microRNAs have tumor suppressor functions and their silencing
is observed to be implicated to contribute towards a tumor phenotype (Davalos &
Esteller, 2010). Although the exact mechanism and reason for why only specific genes
are methylated remain unclear, numerous studies show that methyltransferase enzymes
preferentially target certain genes for methylation that eventually aid in the survival of
cancer cells (Gopalakrishnan, Van Emburgh, & Robertson, 2008).
2.4.8 DNA methylation in breast cancer
DNA methylation has been extensively studied in breast cancer. Evidence for
methylation-mediated silencing of tumor suppressor genes has been shown, such as the
inactivation of the retinoblastoma protein interacting zing finger gene RIZ1 by its
promoter methylation in breast cancer cases (Du et al., 2001). Cyclin D2, an important
cell cycle regulator gene has also been found to be silenced via hypermethylation of its
promoter region in 50% of studied breast cancer cases by Evron and colleagues (Evron et
al., 2001). Hypermethylation of CpG sites in the promoter region of the p53 gene has
been found in breast tumors, which is has been proposed to be an alternative mechanism
of inactivation of this tumor suppressor gene in the absence of a deleterious p53 mutation
(Kang et al., 2001).
One of the most interesting findings in breast cancer related to methylation is the
absence of expression of the stratifin gene, 14-3.3-s, which belongs to a family of

95
regulatory proteins analogous to the epithelial marker HME1. The expression of this gene
was observed to be reduced in breast cancer cell lines (but not in other types of cancer
lines) by serial analysis of gene expression as well as by northern blotting. The
mechanism of reduced expression of 14-3.3-s was found to be hypermethylation of the
promoter region of this gene and revival of its expression after treatment with 5-aza-2’deoxycytidine provided evidence for methylation being its inactivating mechanism
(Ferguson et al., 2000). An interesting aspect is that downregulation of this gene was also
observed in the tissue adjacent to the breast, suggesting hypermethylation of 14-3.3-s is
an early event in mammary tumorigenesis (Umbricht et al., 2001).
The 20 canonical NER genes are rich in CpG islands in their promoter regions
and previous work in Dr. Latimer’s laboratory showed the restoration of gene expression
of 3 NER genes, CDK7, TFIIHp34 and TFIIHp52 after treatment of two early stage
breast cancer lines (JL BTL-8 and JL BTL-29) with 5-aza-2’-deoxycytidine (Johnson,
2006). Methylation in breast cancer with regards to NER is understudied in literature, as
there is a gaping void of the lack of evidence for the role of methylation in regulation of
the NER pathway in breast cancer. Interestingly the 14-3.3-s gene was used as a positive
control in these experiments.
Involvement of methylation with respect to DNA repair has been shown for
BRCA1 (double strand break repair), MGMT (repairs DNA damage created by alkylating
agents and hMLH1 (mismatch repair) (Asiaf et al., 2015; Esteller, 2000; Jacot et al.,
2013). Jaime Matta and colleagues have shown that promoter hypermethylation of a gene
belonging to the kinesin family, KIF1A, is associated with the incidence of breast cancer
and is inversely related to DNA repair capacity (Guerrero-Preston et al., 2014). Another
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study showed that 17-beta estradiol (E2) causes the hypermethylation and therefore
reduced expression of ERCC1 and XPC in the MCF7 cell line, which is restored upon
treatment with 5-aza-2’-deoxycytidine treatment (Singh, Treas, Tyagi, & Gao, 2012).
2.4.9 Measurement of DNA methylation status
Genome wide methylation profiling per CpG locus can be performed via the
Methylation EPIC array by IlluminaÒ, which is also known as Illumina’s 850K
methylation array, employs about 850K probes targeting important CpG sites curated by
methylation experts. This chip includes more than 90% of the content of Illumina’s 450K
array (Sandoval et al., 2011) and additional CpG sites that lie outside of CpG islands,
FANTOM enhancers, DNase hypersensitivity areas as well as gene promoter regions
(Illumina, 2017). MethylationEPIC arrays involve detection of the methylation status of a
CpG site by employing single base extension of bisulfite-converted DNA fragments at
CpG site after the fragment hybridizes to a BeadChip. Bisulfite conversion results in the
conversion of unmethylated cytosines to uracil, while the methylated cytosines remain
intact. Depending on the assay design, either the occurrence or absence of base extension
determines the methylation status of the site (Balog et al., 2002).
This assay employs two types of assay designs employing two different types of
probes, namely Infinium I and Infinium II. Where Infinium I assay design has two beads
each for an unmethylated and methylated locus, the Infinium II type has only one bead
for both, methylated and unmethylated loci (Figure 4.2). Single base extension was
carried out using the bisulfite-converted fragment of DNA hybridized to the probe, and
laser excitation was used to detect the inserted base and therefore to determine the
methylation status. Methylation status was reported as a beta value for each CpG locus,

97
which ranges from 0 to 1, where 0 denotes an unmethylated site, 1 denotes a completely
methylated site and 0.5 denotes a hemi-methylated site. The values are never exactly 0,1
or 0.5, and are continuous between 0 and 1, as the methylation status for each locus is an
average of methylated and unmethylated bread types across about 30 bead replicates
(Kuan, Wang, Zhou, & Chu, 2010).
Analysis of data from methylome profiling can be performed with a variety of
software solutions, both freeware and proprietary. Free software is provided by Illumina
called Genome Studio that has a Methylation module enabling the analysis of both the
450K and 850K arrays. The most commonly used programs are R-based packages.
RnBeads (Müller, Assenov, & Lutsik, 2015) is the most popular one along with ChAMP
(Y. Tian et al., 2017), both of which have recently developed user-friendly interfaces for
inexperienced R users. All these software solutions enable differential methylation
analyses, principle component analyses as well as hierarchical clustering. However,
RnBeads was chosen as it provides, apart from individual CpG site level methylation,
region-level differential methylation analysis where differential methylation data is
generated at promoter level, gene level, CpG island level and tiling level.
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Figure 2.19 Infinium type I and II assay designs for probes in Illumina MethylationEPIC
array. Infinium I design employs two types of beads, one each for methylated and
unmethylated loci respectively. Detection of methylation is based on primer extension for the
correct bead type. Infinium II employs only one type of bead for both methylated and
unmethylated loci and primer extension happens for both loci, however insertion of the correct
base determines methylation status. The two types of assay designs ensure a broad coverage of
a large number of CpG sites.

While methylation profiling using array technologies has advantages, like
profiling of the entire methylome at low cost compared to some of the newer sequencingbased methylation assays like bisulfite sequencing. However, it has the drawbacks
commonly seen with array technologies. Probe bias is a major limitation, as only those
CpG sites are queried for which probes have been designed based on evidence in
literature (G. Russo et al., 2003). Methylation arrays are generally used first, to
determine where differential methylation is occurring, and then can be followed by more
specific and targeted analysis of that region using bisulfite sequencing.
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Chapter 3
Two varieties of non-tumor adjacent breast found outside early stage
sporadic breast cancer
3.1 Introduction
Breast Cancer remains a debilitating problem, the leading cause of mortality
among women and the second most common cancer after skin cancer (R. L. Siegel,
Miller, & Jemal, 2016). About 262000 cases were estimated to be diagnosed for the year
2017 and 42600 women were expected to die from breast cancer in the US alone
(Howlader et al., 2018). Breast cancer is also an expensive problem, with costs towards
treatment increasing by an increase in the stage of breast cancer (Blumen et al., 2016).
Although, breast cancer mortality has reduced by 38% from 1989 to 2014 and the stage
of diagnosis has now been lowered owing to more frequent mammographic screening
mandated for pre-menopausal women between the age of 45-54, there are about 3 million
women walking with breast cancer to date in the US (Howlader et al., 2018).
Familial cases of breast cancer caused due to the inheritance of germline
mutation in genes like BRCA1 and BRCA2 are relatively well studied in literature but
constitute only 15% of cases of the total breast cancer incidences (Ashford, 2014). The
etiology of sporadic breast cancer is largely unknown. As Stage I breast cancer is the
most commonly diagnosed stage of breast cancer in the US (R. L. Siegel et al., 2016),
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there is a pressing need for determining the etiology and the molecular natural history for
early stage breast cancer, ultimately aiming towards breast cancer eradication.
Genomic instability is a hallmark of all cancers, and is mainly caused due to the
impairment of conserved mechanisms of repair of DNA in the human body that allows
for accumulation of DNA damage and ultimately resulting in accumulation of mutations
or epimutations leading to cancer (Hanahan & Weinberg, 2000). Out of the 5 major DNA
repair mechanisms, Nucleotide Excision Repair (NER) is a particularly important one, as
it remediates bulky adducts and inter as well as intra-strand crosslinks in DNA that distort
the double helical DNA structure. These damages are caused due to exogenous agents
like UV light, adducts from carcinogens in tobacco smoke like benzo[a]pyrene, as well
as via endogenous cellular processes like oxidative stress and replication errors.
(Friedberg et al., 2005). The link between NER and cancer has been shown by the disease
Xeroderma Pigmentosum, which renders the individual extremely sensitive to sunlight
(as NER repairs UV damage). Xeroderma-pigmentosum-casing mutations, which lead to
a deficiency in the ability to perform NER, raises their risk for getting skin cancers by
2000-fold, along with a high risk for internal cancers as well (Bradford et al., 2010;
Kraemer, 1997)h. Therefore, NER plays an important role in cancer.
We have shown previously that NER capacity is intrinsically deficient in Stage I
sporadic breast tumors compared to that of non-diseased breast reduction epithelium
(BRE) using the traditional gold-standard Unscheduled DNA Synthesis (UDS) assay
(Latimer et al., 2010). Gene expression also followed the trend of functional NER
capacity, where DNA microarray results (that were validated by RNAse protection assay)
showed 19/20 canonical NER genes down regulated in these tumors compared to BRE.
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Figure 3.1 NER capacity of Stage I primary breast tumors (n = 19) relative to that of nondiseased BRE (n = 23). Solid lines through the two groups indicate their respective averages
and each dot represents an individual. Reprinted with permission (Latimer et al., 2010)
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Figure 3.2 Gene and protein expression of NER genes followed the trend of functional
NER capacity in the sporadic Stage I primary breast tumors. A) Gene expression
microarray showed a low expression signature in all NER genes in Stage I tumors (solid bars, n
= 3) relative to BRE (open bars, n = 3), with 9 genes significantly downregulated at p<0.05,
which were TFIIHp44 (P = 0.024), RPAp32 (P = 0.031), XPD (P = 0.013), CSA (P = 0.046),
CDK7 (P = 0.026), XPE (P = 0.035), DDB1 (P = 0.0002), hHRAD23B (P = 0.032), and
RPAp70 (P = 0.036) B) RPA showed 19 out of 20 genes significantly downregulated in Stage I
breast tumors relative to BRE except for ERCC1. C) Western blotting revealed expression of
XPA, DDB2, and CSB proteins to be significantly downregulated in Stage I tumors relative to
BRE. Figure reprinted with permission (Latimer et al., 2010).

Cancer is known to be a multistep process, with step wise changes occurring and
accumulating in cells and ultimately leading to transformation into a tumor phenotype.
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Bert Vogelstein derived and established a breakthrough model of colorectal
carcinogenesis that delineated the steps that a normal colorectal tissue would undergo at
the genetic and epigenetic level towards neoplasia (Vogelstein & Kinzler, 1993). Such a
multistep model exists for breast cancer as well that delineates the genetic alterations that
take place during mammary carcinogenesis (Bièche & Lidereau, 1995) (Figure 2.15). It
has been known that certain changes happening earlier in the trajectory of tumor
formation, like acquiring genomic instability, accelerate additional deleterious changes
and lead to a full-blown tumor (Rivenbark & Coleman, 2012; Vogelstein & Kinzler,
1993; Willenbucher et al., 1999).
The theory of field cancerization states that the pathologically normal tissue
adjacent to the tumor harbors some of the genetic and epigenetic anomalies that are
ultimately found accumulated in the tumor (Heaphy, Griffith, & Bisoffi, 2009; Rivenbark
& Coleman, 2012; Trujillo et al., 2011). The pathologically normal non-tumor adjacent or
NTA tissue therefore is a great model system to study shared changes that the normal
tissue acquires on its way to becoming neoplastic. NTA has been used extensively in the
literature and while some research groups detected karyotypic and other abnormalities in
the NTA (Aran et al., 2017; Spitzwieser et al., 2017; Teixeira et al., 1995), others are
either using the NTA as a normal control (Guo et al., 2017; Ni & Kuperwasser, 2016) or
have deemed the finding of abnormalities in the NTA a result of contamination with the
tumor. No study to date exists that has studied NTA with regards to sporadic breast
cancer and NER, and our study fills this major void in the literature.
We hypothesized that genetic alterations, including a loss of NER capacity, will
be detectable in the histologically normal NTA obtained from the same patient as the
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early stage tumor, and proposed to study this hypothesis on the functional as well as
transcriptional level of the NER pathway. We were able to identify two varieties of NTA
samples with regards to their NER capacity. One group was named as Low: Low group
of NTA/tumor pairs as they showed lower NER capacity in the NTA as well as tumor
than the average of non-diseased breast samples. The other group identified was the
High: Low group of NTA/tumor pairs having higher NER capacity in the NTA but lower
in the tumor as compared to the average of non-diseased breast samples.
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3.2 Methods
3.2.1 Procurement of samples and establishment of cell lines
We established primary NTA cultures from isogenically matched NTA tissue
samples procured along with the tumor samples as described previously (Latimer et al.,
2003). Upon resection of the tumor and the 2cm margin of histologically normal tissue
around the tumor to ensure complete removal of the tumor, the tumor was sampled from
a non-necrotic region and the NTA tissue was sampled about 1.5cm away from the
margin of the tumor (Figure 3.3). All surgeries were performed at Magee Women’s
Hospital (Institutional review board approval 0609002).

Normal Margin
Tumor

Figure 3.3 Procurement of the NTA sample and its matched tumor sample. The black
outline indicates resected tumor along with a 2cm margin. White portion indicates the
histologically normal margin around the light blue tumor. Red circle indicates portion of the
tumor cut out and handed to the lab, and the navy-blue circle indicates portion of the
histologically normal NTA sample cut out and handed to us, approximately 1.5cm away from
the tumor margin. The NTA sample was verified by a pathologist.

Primary cultures for some of these matched pairs were expanded into cell lines as
described in Chapter 2 (Figure 2.16). These cell line pairs were used for molecular
analyses in this study.
3.2.2 Unscheduled DNA Synthesis (UDS) Assay
The Unscheduled DNA synthesis (UDS) assay is the gold standard assay used for
the measurement of NER capacity and was developed by Dr. James Cleaver. This assay
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is traditionally used as a diagnostic test for XP and measures the incorporation of a
radiolabeled nucleotide into DNA while DNA is allowed to be repaired after an insult
with a fixed dose of a damage causing agent (UV-C light in this case). Incorporation of
the radiolabeled nucleotide is detected by autoradiography after fixation of cells.
Autoradiography generates silver grains above the nuclei of cells whose DNA underwent
repair, and the amount of silver grains is directly proportional to the repair capacity of
that sample, when expressed relative to the traditional control, which is a fibroblastic cell
lines established from newborn foreskin.
ID of the High: Low and Low: Low pairs was conducted on the NER capacity
data on available early stage breast cancer cell line pairs of the tumor and its matched
NTA based on UDS assays run in the past. The goal was to identify at least one
representative of each of the High: Low and Low: Low cell line pair groups. One Low:
Low cell line pair was already available, but there was no cell line available from the
High: Low pair to be able to go ahead with further molecular analyses. Therefore, the
UDS assay was used mainly to be able to identify at least one representative of the HighLow pair group in order to proceed with downstream aims of the study.
3.2.3 Identification of High: Low pairs
Available cell line pairs were run on the UDS assay with the aim of identifying a
High: Low representative pair. Each cell line among the pairs was plated in duplicate (2
slides) on 2-well chamber slides in MWRI medium with a dilution of 1:20 from a
confluent 12.5cm2 flask to ensure optimum confluence for the experiment. The well
closer to the cover glass was used as an irradiated control and covered during irradiation.
The positive control cell line (FF-F) was also plated with a dilution of 1:40 in MEM with
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10% fetal bovine serum (FBS) and 1% of 100x penicillin/streptomycin antibiotic
solution. Plated cells were irradiated with UV-C light at a dose of 14J/m2 using the UVirradiation machine (Latimer & Kelly, 2014). Cells were then allowed to incubate for 2
hours in a DMEM medium containing 3H-methyl thymidine at a concentration of 10 µCi/
mL (PerkinElmer Life Sciences®) (#Part NET027W001MC) in a Forma Series II Water
Jacketed CO2 incubator that is dedicated to radioactive treated cultures at 37oC in 5%
CO2. This was followed by a 2-hr chase with 10 mM non-radioactive thymidine (SigmaAldrich®) (Cat# T1895) to avoid non-specific binding of the radionucleotide. Following
the chase, cells were washed with 1X sodium citrate (Sigma-Aldrich®) (Cat# 1613859) in
PBS and fixed using 33% acetic acid (Fisher Scientific®) (Cat# A38-500) in ethanol
(Sigma-Aldrich®) (Cat# E7023) and 70% ethanol in distal water for 15 minutes each. The
chambers were snapped off and gaskets peeled off of the slides, after which the slides
were immersed in 4% perchloric acid solution (Fisher Scientific®) (Cat# A228) overnight
at 4oC.
The next day, slides were rinsed in distilled water and taken to the dark room,
where they were dipped in photographic emulsion (Caresteam®) (Cat# 8895666), placed
in slide boxes followed by wrapping them with 3 layers of foil to ensure light-tightness,
and allowed to expose for a total of 11 days at 4oC. Two of the control slides were kept in
a separate slide box as a tester, to be developed first in order to ensure optimum exposure.
On day 12, the tester slides were developed in D-19 developer (Kodak®) (Cat# 1464593),
fixed using a Kodak fixer (Kodak®) (Cat# 1971746), dried and then Giemsa stained
(Sigma-Aldrich®) (Cat# G9641). Grain counting was performed for 50 foreskin fibroblast
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nuclei to ensure optimum exposure. Upon confirmation, the rest of the slides were fixed,
developed and stained, after which they were allowed to dry overnight and were ready for
grain counting.
3.2.4 Data analysis for the UDS assay
Silver grains over 100 non-S phase nucleus on both chambers (irradiated and
unirradiated control) were counted by 3 independent counters. Local background was
also counted for each field and subtracted from the counts on the non-S phase nuclei.
Unirradiated counts for 100 non-S-phase nuclei were subtracted from irradiated counts
for 100 non-S-phase nuclei to remove a second layer of background. Descriptive statistics
were performed using the Data Analysis Tool Pack in Microsoft Excel and mean counts
per nucleus on each slide and counter were averaged. Final NER capacity was expressed
as percent relative to foreskin fibroblast (normal skin) controls.
S-phase indices were calculated for each cell line, which gives a measure of the
proliferation of the cell line. This was calculated by counting the total number of cells in
the S-phase on the unirradiated side of each slide for each cell line. This number of Sphases was expressed as a percentage of the total number of cells counted for that side for
the particular slide. Percentages were averaged for each counter and slide for a particular
cell line.
3.2.5 Isolation of total RNA
Total RNA was isolated using the miRNeasy mini kit for total RNA isolation
(QiagenÒ) (Cat#217004) according to manufacturer’s protocol. Briefly, Qiazol lysis
reagent was added onto cells plated on 4 flasks (125cm2), such that each flask received a
total of 350 µL. Cells were then scraped using a cell scraper (Fisher ScientificÒ) (Cat#

109
309635) and the lysate out of 2 flasks was moved into one 1.5 mL tube, homogenized
using a syringe with a 22-gauge needle by aspirating it up and down through the needle,
and allowed to stand for 5 mins at room temperature. 140 µL of chloroform was added to
the lysate, the tube was manually shaken vigorously for 15 seconds and allowed to stand
on the benchtop for 3 minutes. The mixture was then centrifuged at 12,000 rpm and 4°C
for 15 minutes to separate the aqueous layer containing RNA. This top aqueous layer was
then separated out by pipetting it off carefully, making sure not to disturb the other layers
to avoid contamination. 1.5 volumes of 200 proof ethanol were added to this separated
layer at room temperature, mixed well and the solution was added to a column in
volumes of 700 µL successively followed by centrifugation at a speed >10,000 rpm for
15 seconds, until all of the solution is passed through the column and centrifuged.
DNA digestion was performed with RNAse-free DNase kit (QiagenÒ)
(Cat#79254) by incubating the column with 80 µL solution of DNase in buffer RDD for
15 minutes at room temperature. DNase digestion was followed by washes with buffers
RWD and RPE (twice) to prevent carry over of ethanol into the final sample. A final dry
centrifugation for 1 minute at maximum speed (14,000 rpm) ensured complete drying of
column and finally the sample was eluted in 50µL of RNAse-free distilled water. Each
sample was run on Agilent’s TapeStation 4200 system (Cat# G2991AA) to assess quality
and concentration according to manufacturer’s instructions and protocol. 1 µL of sample
was mixed with 5µL of sample buffer (Agilent, Inc.) (Cat #5067-5577), and this solution,
along with RNA ScreenTapes (Agilent, Inc.) (Cat #5067-5576), was loaded onto the
TapeStation 4200 machine in 8-tube strips, with the first tube containing a sizing RNA
ladder (Agilent, Inc.) (Cat #5067-5581).
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3.2.6 Expression microarray using the Affymetrix HG U133 Plus 2.0 chip
Total RNA sample for each cell line of the Low: Low and High: Low cell lines
along with controls, FF-F and JL BRL-6 were isolated in triplicate and a total of 1µg of
total RNA at a concentration of 100 ng/µL for each sample was sent for gene expression
microarray to the Genomics core at the Hussman Institute of Human Genomics,
University of Miami. These samples were run on the Affymetrix HG U133 Plus 2.0 chip
according to manufacturer’s instructions. The core sent back raw data comprising probe
intensities for those hybridized to the respective RNA sample from the microarray run as
.cel files (one .cel file per sample) which were further analyzed to obtain gene expression
results.
3.2.7 Analysis of expression microarray data
Gene expression values were obtained from the raw .cel files using Genespring
software (Agilent, Inc.). The Probe Logarithmic Intensity Error Algorithm (PLIER) was
used to normalize probe intensities across all samples and normalized data was
downloaded as text files. All probe intensities corresponding to a single gene were
averaged and values were expressed relative to the average of tumor line for that gene ad
for each pair of cell line. Hypothesis-driven pairwise Student's t-tests were performed. 2tailed t-tests were performed for Low: Low pair as no difference in the expression was
hypothesized, and 1-tailed for High: Low pair as the NTA line was hypothesized to have
higher expression of NER genes than that of the tumor line. Data was plotted as column
graphs with standard error whiskers.
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3.2.8 RNA Sequencing
RNA sequencing was used as a cross platform validation tool for the results
obtained from gene expression microarrays, and also because this technology will enable
not only quantification of gene expression, but also obtaining sequence information for
genes and transcripts of interest, and the latter will serve a future mechanistic aim of this
study, i.e., to study mutations in the exonic regions – if any- that might be indicative of a
change in downstream functional expression of this gene and its products (Chapter 4 and
5). Data obtained from RNA sequencing can be used in future to look at other important
applications of RNA-seq, like finding products of gene fusions (fusion transcripts)-a
common phenomenon observed in cancer, as well as looking at pathways and genes other
than NER to uncover mechanisms underlying breast cancer etiology.
Total RNA was isolated from representative NTAL/BTL pairs (BTL/NTAL37
and BTL/NTAL47) as well as from controls (foreskin fibroblast lines and normal nondiseased breast cell line JL BRL-6) in triplicate as described above. 1ug of total RNA per
sample (bearing a concentration of 100ng/µL per sample) was sent for sequencing to the
Genomics Core at the Hussman Institute for Human Genomics at the University of
Miami, where the samples were subjected to the following steps to yield raw sequence
data, comprising RNA sequence information (one in the form of FASTA or FASTQ files.
After confirming integrity and sample concentration using Agilent’s Bioanalyzer at the
core, ribosomal RNA was removed to enrich RNA of interest (mRNA, tRNA and other
small and long non-coding RNA molecules), followed by library preparation on the sent
samples using Illumina’s TruSeq Stranded Total RNA Sample Preparation kit for human
samples according to manufacturer’s protocol (15031048E). Briefly, ribosomal RNA was
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depleted from total RNA with the use of RNA Clean XP beads and fragmentation
followed by priming with hexamers to prepare for reverse transcription. Fragmented
RNA is then primed with random primers to convert the first strand to cDNA the second
strand. This was followed by adenylation of the blunt end fragments of RNA to prepare
them for attachment of adapter oligonucleotides. These adapters allow for multiplexing of
samples to distinguish samples from one another. Special adapters are also added that are
complementary to the oligonucleotide probes on the flow cell for hybridization. Adapterligated fragments are then PCR amplified, followed by validation of library,
normalization and pooling of libraries for multiple samples. The pooled library was then
allowed to hybridize onto flow cells and sequenced in parallel on Illumina’s Hiseq 3000
that employs Illumina’s proprietary Sequencing by Synthesis technology to sequence
every fragment generating a ‘read’, the length of which is usually pre-defined and is
equal to the number of cycles of base addition and detection. Each cycle involves
addition of a complementary base tagged with a detection-enabling label that produces a
base-specific color upon incorporation, followed by cleavage of the label to reduce noise,
washing off the excess labelled bases and repeat of this process until desired read length
is reached.
Each of our samples were sequenced with a coverage of approximately 40 million
reads. The sequencing was paired-ended, i.e., each fragment was sequenced from both 5’
and 3’ ends to achieve a read length of 150 base pairs. The raw data was delivered to us
as FASTA files, with two FASTA files per sample (one for each forward and reverse end
sequenced during paired-end sequencing) and data analysis was performed on these raw
files as outlined below.
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3.2.9 Analysis of data from RNA sequencing
We analyzed data from RNA sequencing on samples for this study using Partek
FlowÒ software (Partek Inc., MO). FASTA files for all samples were uploaded onto
Partek’s server using FileZilla software’s file transfer protocol (FTP). This protocol is
convenient for transfer of large files, and each FASTA file was approximately 20GB in
size (making the total file size for all samples to up to 720 GB). Pre-alignment quality
check was performed to confirm accuracy and of sequence data, which is reported in the
form of Phred scores along with sequence data in the FASTA files. This was followed by
alignment of raw reads to human genome reference build 38 (hg38) using GSNAP (T. D.
Wu, Reeder, Lawrence, Becker, & Brauer, 2016). Post-alignment quality control check
was performed to confirm optimum alignment. Quantification was performed to the
annotation model Ensembl Transcripts (Release 88) using Partek’s expectation
maximization (E/M) algorithm that uses RPKM scaling method (Mortazavi, Williams,
McCue, Schaeffer, & Wold, 2008; Xing et al., 2006). Strict paired-end compatibility was
ensured and Partek was made to auto detect strand specificity. Moreover, a read had to be
100% within a feature (exon/gene in this case) to be mapped to that particular region. The
output of this quantification task was two nodes of gene counts and transcript counts. The
gene counts were filtered to remove extremely low or zero values, normalized using log
transformation, and downloaded as Partek Genomics Suite project format as well as text
files with features on columns. Finally, normalized gene counts were imported into
Partek Genomics SuiteÒ where read counts for the 20 canonical NER genes were sorted
out, downloaded as a text file and opened in Microsoft Excel, where pairwise t-tests were
performed to compare expression of each gene in the NTA line to its matched tumor line.
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One-tailed Student's t-test was used to compare the expression of the 20 NER genes
between the High: Low pair as NER gene expression was expected to be higher in the
NTA line compared to the tumor line, while two-tailed t-test was employed for the Low:
Low pair as no difference in NER gene expression was hypothesized. Comparison of
quantification of NER genes was also done for the tumor lines compared to the nondiseased normal breast line JL BRL-6 to ensure both tumors express the low gene
expression signature for the 20 canonical NER genes based on their functional NER
capacities.
Supervised hierarchical clustering was used to construct a tree-like image called
as a dendrogram in Partek FlowÒ. Clustering creates a hanging mobile-like figure where
the arms of the mobile represent samples, and the horizontal distance between those arms
indicate how closely related sample or sample groups are to each other. The Y-axis of the
figure represents genes, and gene expression intensity per gene for a sample or sample
group are represented by a color scheme which denotes over and under expressed genes.
Clustering was performed on the sample groups containing replicates for each of the cell
lines analyzed, namely FF-F, JL BRL6, JL BTL37, JL NTAL-37, JL BTL47 and JL
NTAL-47. These dendrograms represent a visualization of how closely related sample
groups and replicates are to each other based on the expression profiles of the 20
canonical NER genes. Hierarchical clustering was performed on the normalized read
counts on the 20 NER genes using Euclidean algorithm and average linkage metrics.
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3.2.10 Isolation of total protein
Total protein was isolated in triplicate from all cell lines used in this study, i.e. the
cell lines of the High: Low and Low: Low pairs, JL BRL-6 and FF-F. Cultured
monolayer of cells were lifted off of the T12.5 flasks using trypsin and centrifuged at
800rpm for 5 min. Pellets from 4 T12.5 flasks were combined and were resuspended in
ice-cold PBS and re-centrifuged. This combined pellet was then mixed in a 1.5 mL tube
with the lysis cocktail containing 100 µL of radioimmunoprecipitation assay (RIPA)
buffer (Life technologies®) (Cat# 89900) mixed with Halt® protease inhibitor cocktail
(Life technologies®) (Cat# 78438). This was mixed very well by pipetting up and down
several times to ensure the pellet was well mixed and cells lysed. This lysate was
maintained under constant shaking for 30 minutes at 4°C. This mixture was then
sonicated for 1 min at 4°C in an Ultrasonic cleaner (JSP®) (Model # US-20) and
centrifuged for 20 minutes at 12,000 rpm at 4°C. The clear supernatant was pipetted off
carefully to avoid contamination into another tube, and this consisted of total protein,
which was snap frozen and stored at -80°C.
PierceÒ bicinchoninic acid (BCA) assay kit (Life technologies®) (Cat# 89900)
was used to quantify total protein, which is a colorimetric assay. First, serial dilutions of
the protein standard (bovine serum albumin provided with the assay kit) were made
ranging from a concentration ranging from 25-2000 µg/mL. Protein sample was diluted
10-fold in DNase, RNAse and protease-free water. Detection solution mixture was mixed
beforehand by mixing reagents A and B in a 1:8 ratio. Three replicates of 25 µL of the
diluted protein sample as well as the BCA standards were mixed along with 200 µL of
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the detection mixture beforehand in 1.5 mL tubes and added into the wells of a 96-well
plate by adding one replicate per well. The plate was incubated at 37°C for 30 mins and
absorbance was measured at 562 nm wavelength on a Synergy H1 plate reader
(BioTekÒ).
A standard curve was plotted using 562nm absorbance values of the BCA
standards. Unknown protein sample concentrations were obtained using this standard
curve after correcting for background by subtracting the average of the blank readings
from the absorbance reading of each sample and standard.
3.2.11 Western blotting
Western blotting was performed to determine expression of NER proteins based
on gene expression data. This was done to see whether differences in gene expression are
consistent with the protein expression. RPA3, XPC, RAD23B were selected because they
showed the highest differences between tumor and NTA lines of the High: Low pair and
showed no difference in the Low: Low pair. All protein samples were run on sodium
dodecyl sulfate poly acrylamide (SDS-PAGE) stacked gels. While the stacking gel was
always 4% acrylamide, the resolving gel percentage was adjusted based on the molecular
weight of the protein of interest. The percentage of SDS-PAGE for resolving gels used
were 12.5% for RPA3 (14 kDa), 10% for RAD23B (58 kDa) and 8% for XPC (125
kDA). A dilution series of foreskin fibroblast protein isolate (5µ, 10µ and 20 µg) was
used as a control on each gel to determine the sensitivity and linearity and to establish a
consistent 20 µg band intensity across all western blots.

117
Running and transfer buffers were prepared in advance and allowed to cool at
4°C. Running buffer consisted of 25 mM Tris, 192 mM glycine, 3.5 mM SDS at pH 8.3
and transfer buffer was 25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3. Gels were
cast by mixing required amounts of 30% stock acrylamide-bis (prepared in advance),
10% SDS, pH-adjusted Tris HCl buffer, TEMED, 10% APS and making up the required
volume by distilled water. The Tris HCl buffer used was specific to the gel, where
resolving gel buffer (Bio-RadÒ ) (Cat #1610798) was used for resolving gel and stacking
gel buffer (Bio-RadÒ ) (Cat #1610799) for stacking gels. This solution was poured into
the casting chamber in between glass plates and allowed to polymerize for 45 mins.
Sample preparation involved mixing the required volume for 20 µg of protein
sample with RIPA lysis buffer to make up a total volume of 7 µL, to which 2.33 µL of
dye solution was added (10 % b-mercapto ethanol in 4X Laemmli loading dye) (BioRadÒ) (Cat# 1610747). Protein sample mixtures were denatured at 72°C for 10 mins,
were loaded onto the stacking gels along with dual color molecular weight standards
(Bio-RadÒ) (Cat# 1610374). 5 µL of the protein standard was mixed with 4.33 µL of
RIPA lysis buffer to be run as a molecular weight standard or ladder in order to ensure
the band of interest was the right size for the respective protein detected. Electrophoresis
of these gels was allowed to run for optimal times (1 hr for XPC, 1 hr 20 mins for
RAD23B and 1hr 45 for RPA3) at a constant voltage of 150V in the prepared and cooled
running buffer.
The protein bands from SDS-PAGE gels were then transferred onto nitrocellulose
membranes that had a pore size of 0.2 microns (BioTraceÒ) (Cat# 66489) at 4°C.
Transfer was carried out for optimum time and voltage depending on protein of interest

118
(run overnight for XPC and RAD23B at 20V; run for 1 h for RPA3 at 50V) by placing
the fiber pad – filter paper – gel – membrane – filter paper – fiber pad sandwich into the
casket in transfer buffer previously prepared and cooled. Each membrane upon which
protein bands were transferred was washed once with 1X tris buffered saline or TBS
buffer (Bio-RadÒ) (Cat #1706435) with vigorous shaking and blocked with 5% nonfat
dry milk (Bio-RadÒ) (Cat# 1706404XTU) in TBST wash buffer. TBST was comprised of
1X TBS with 10% Tween 20 (Bio-RadÒ) (Cat #1610781), to reduce background signal
due to non-specific binding of antibodies. Blocking with 5% milk solution in TBST was
performed for 1 hour for RPA3 and XPC, whereas membranes were blocked for 2 hours
for RAD23B. Following blocking, membranes were washed with 1X TBST twice with
vigorous shaking (120 rpm) for 10 mins each and allowed to incubate overnight with
primary antibodies for the protein of interest (Table 3.1) with slow shaking at 4°C.
GAPDH was used as an internal loading control and membranes were cut appropriately
to be able to detect GAPDH simultaneously along with the proteins of interest.
Table 3.1 Primary antibodies used in Western Blotting

Protein
RPA3

Detected
Size
14 kDa

RAD23B

58 kDa

XPC

125 kDa

GAPDH

37 kDa

Source

Type

Dilution

AbcamÒ
(Cat# ab97436_
Bio-RadÒ
(Cat# VPK00151)
Cell SignalingÒ
(Cat# 12701)
Cell SignalingÒ
(Cat# 5174)

Rabbit
polyclonal
Goat
polyclonal
Rabbit
polyclonal
Rabbit
monoclonal

1:1000 in
TBST
1:1000 in
TBST
1:1000 in
TBST
1:2000 in
TBST

Membranes were washed in TBST with vigorous shaking for an optimized
number of times based on protein of interest, after incubation with the primary
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antibodies, for 10 minutes per wash. This was followed by incubation with the secondary
antibody labelled with the detection molecule, which was goat anti-rabbit horseradish
peroxidase conjugated secondary antibody (Sigma-AldrichÒ) (Cat# A0545) for RPA3,
XPC and GAPDH, and rabbit anti-goat horseradish peroxidase conjugated secondary
antibody for RAD23B (Sigma-AldrichÒ) (Cat# A5420). Secondary antibody dilutions
and their respective solutions are as described in Table 3.3. These conditions were arrived
upon after optimization with controls. Incubation with secondary antibody solutions was
done for one hour, followed by vigorous washes for 10 minutes each with TBST for
optimized number of times (Table 3.2). Finally, membranes were washed once with TBS
and were then ready for detection.
Detection of bands for proteins of interest was performed by chemiluminescence.
SuperSignal West Femto Kit (Life TechnologiesÒ) (Cat# 34095), a high sensitivity
detection kit for low expressing proteins, was used to detect XPC, RPA3 and RAD23B
whereas SuperSignal West Pico kit (Life TechnologiesÒ) (Cat# 34095), a low sensitivity
kit that can be used to detect highly expressed proteins, was used to detect GAPDH. After
mixing peroxidase and luminol/enhancer solutions from the respective kits in a 1:1 ratio,
membranes were allowed to incubate with this solution for 4 mins in a light-proof box.
Band intensities detection was performed using the Azure C400 machine (Azure
BiosystemsÒ).

120
Table 3.2 Optimized concentrations of blocking solution, secondary antibody and
number of washes for each protein of interest
Protein of
Blocking
No. of
Secondary Secondary
No. of
Interest
solution
washes
Antibody
Antibody
washes
and time
with TBST used
solution
with TBST
before
concentration after
secondary
secondary
antibody
antibody
RPA3
5% non-fat 6
Goat anti1:2500 in
5
milk in
rabbit
TBST
TBST for 1
(HRP
hour
conjugated)
XPC
5% non-fat 6
Goat anti1:2500 in
5
milk in
rabbit
blocking
TBST for 1
(HRP
solution (2.5%
hour
conjugated) non-fat dry
milk in TBST)
RAD23B
5% non-fat 6
Rabbit
1:5000 in
5
milk in
anti-goat
blocking
TBST for 2
(HRP
solution (5%
hours
conjugated) non-fat dry
milk in TBST)
GAPDH
5% non-fat 3
Goat anti1:5000 in
3
milk in
rabbit
TBST
TBST for 1
(HRP
hour
conjugated)
3.2.12 Data analysis for western blotting
Images obtained from Azure C400 were imported into Image Studio Lite 5.2.5v
(Li-CorÒ) to measure band intensities. Background was calculated by measuring
intensities above and below the band of interest and this was subtracted from the band
intensity. Intensity values for GAPDH for each lane was used to normalize amounts
loaded for that particular lane, to correct for loading errors. Finally, student’s t-tests were
used to find differences in expression levels for proteins among the tumor and NTA lines
of the respective pairs (one-tailed for the High: Low pair and two-tailed for the Low:
Low pair), and the values of NTA were expressed relative to that of the tumor line.
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Expression of the respective protein in each cell line was also represented relative to that
of JL BRL-6, the normal non-diseased control line.
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3.3 Results
This study was begun with data generated by one of Dr. Latimer’s laboratory.
UDS assay was performed on primary cultures of tumor and NTA samples obtained from
Stage I sporadic breast cancer patients undergoing lumpectomy along with those of breast
reduction explant (BRE) samples obtained from women undergoing breast reduction
mammoplasty for non-disease related purposes at Magee Women’s Hospital of the
University of Pittsburgh Medical Center. Where the NER capacities of all Stage I tumors
were observed to be significantly lower than that of the average of breast reduction
epithelium (BRE) (Latimer et al., 2010), the NER capacities of the NTA samples were
spread out across a range spanning that of the tumor samples as well as the BREs (Figure
3.6A). The average of the NER capacities of the NTA samples was significantly higher
than that of the Stage I tumors (p = 0.01).
Upon closer examination, it was observed that the NTA samples could be divided
into 2 groups. Out of the 12 isogenically-matched tumor-NTA samples, 3 NTA samples
had NER capacities higher than the average of BRE, whereas their matched tumors had
lower NER capacity than the BRE average (Figure 3.6B). This group was called the
High: Low pairs group, denoting high repair capacity in the NTA and low in the matched
tumors. The remaining majority (9/12) of NTA samples had NER capacities lower than
that of the BREs, similar to those of their matched tumor samples. This group was
referred to as the Low: Low pairs denoting lower NER capacities than BRE average for
both NTA samples and their matched tumor samples.
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Figure 3.6A NER capacity of primary cultures obtained from UDS assay. Normal breast
epithelium (N = 22, star represents a high outlier), early (stage 1) breast tumors (N = 17),
and histologically normal breast epithelium (N = 13) adjacent to stage 1 tumors. The
orange circle represents a sample form the contralateral (unaffected) breast of a breast
cancer patient). The turquoise circles represent patients who chose not to have their lymph
nodes examined (and therefore possibly have higher stage tumors) (Latimer et al., 2013).

Figure 3.6B. NER capacities of NTA measured by the UDS assay reveals two groups
of tumor-NTA pairs. A) 3/12 NTA samples have NER capacity higher than the average
of BRE with their matched tumor samples still having low NER capacity. The difference
between the two sample groups of the High: Low pairs was significant at p = .036. B)
9/12 NTA samples showed NER capacities lower than the average of BRE, and similar
to those of their matched tumor samples. No significant difference was observed
between the NTA and tumor groups of the Low: Low pairs (p = .54) (Latimer et al.,
2013).
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3.3.1 Identification of High: Low and Low: Low groups
Not all of the early stage breast cancer primary cultures and their matched NTA
cultures surveyed previously were available as cell lines, as at that point in time Dr.
Latimer’s lab was unaware of their capability to develop cell lines from primary explants.
In order to proceed with the proposed study, it was a necessity to have cell lines for the
NTA tumor pairs representative of each of the two groups, High: Low and Low: Low
pairs, as cell lines are manipulable and essential to carry out in-depth mechanism-related
investigations. Initially, it was proposed to use 3 cell line pairs for each of the two
groups, however 3 cell lines per group were not available and we found that we could
proceed with detailed molecular analyses with 1cell line pair for each of the two groups
identified previously.
A cell line pair representing the Low: Low group from the previously assayed
pairs using the UDS assay was previously identified. The tumor line of this pair was JL
BTL-37 and was established from a patient having Stage I breast cancer who had
undergone lumpectomy for tumor removal. The matched NTA line of this tumor was JL
NTAL-37, and this cell line pair was one among the 9/12 pairs in Figure 4.2B.
Unfortunately, none of the pairs from Figure 4.2A representing the High: Low pairs had
been established as cell lines, i.e., the samples were not passaged. Therefore, in order to
find a representative cell line for the High: Low group, the UDS assay was run on
existing early stage breast cancer tumor cell lines and their matched NTA lines that were
not previously assayed for their NER capacity. One cell line pair was subsequently
identified where the early stage tumor line had low NER capacity but its matched NTA

125
line had a high NER capacity. This pair consisted of JL BTL-47, which was the tumor
line, and it’s matched NTA line JL NTAL-47. Therefore, 4 cell lines, namely JL BTL-37
- JL NTAL-37 and JL BTL-47 - JL NTAL-47 were used in the current study, the
characteristics of which are elaborated in Table 3.3.
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Table 3.3 Characteristics and NER capacity of the cell lines used in this study. * denotes values from experiments done previously by the lab.
$
From experiments performed for finding the High: Low pair of cell line, average of two individual counters
NER capacity
S-Phase Index
Group
Cell line
Cell line type Age and
Stage
Receptor
(%FF)
Ethnicity
status

Low: Low

High: Low

Control

JL BTL-37

Tumor

JL NTAL-37

NTA

JL BTL-47

Tumor

JL NTAL-47

NTA

JL BRL-6

Breast
reduction

44, Caucasian

I

ER+
PR++
-

13.75*

24%*

19.78*

24%*

28.75$

5%$

-

ER+
PR+
-

57.93$

14%$

-

-

26.63*

31%*

78, Caucasian

62, Caucasian

II
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3.3.2 Gene expression microarray results conform to the functional NER capacity in the
two cell line pairs
Gene expression microarray analyses were performed to see whether expression
of the 20 canonical NER genes conforms to that of functional NER capacity. For
example, where functional NER capacity was low, gene expression was hypothesized to
be low as well. First, we saw that both tumor lines (of the High: Low and the Low: Low
groups) that showed a low NER capacity than the normal breast reduction line JL BRL-6
also showed a lower gene expression signature as well. 11/20 genes were significantly
downregulated in both tumor lines JL BTL-37 and JL NTAL-47 relative to the nondiseased breast line JL BRL-6 (p <0.05) (Figure 3.7). An additional two genes were

2

* * *

*

*

* * *

*

* *

#

#

1.5
1

JL BRL-6
JL BTL-37

0.5
JL BTL-47
0
XP
C
RP
GT A 2
F2
H
ER 4
C
GT C 2
F2
H2
RP
A
ER 1
C
GT C 3
F2
H3
RP
A
ER 3
C
RA C 8
D2
3
ER B
CC
4
CD
K7
DD
B
ER 1
CC
ER 1
CC
5
DD
B2
XP
ER A
CC
6
CC
NH

Gene expression relative to
JL BRL-6

downregulated in the line JL BTL-47 (denoted by # in Figure 4.3, p <0.05).

Figure 3.7 Gene expression of early stage tumor lines JL BTL-37 and JL BTL-47 relative to
non-diseased breast line JL BRL-6. 3 biological replicates were assessed for each cell line. *
denotes gene expression significantly lower than JL BRL-6 for both tumor cell lines. # denotes
significant lowering of expression in just JL BTL-47 relative to JL BRL-6 (one-tailed student’s ttest. p<0.05)
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The tumor-NTA pairs where then compared for expression of the 20 canonical
NER genes conforms to their respective gene expressions. In the Low: Low pair, no
significant difference was observed for 15/20 genes, while there were 5 genes that still
showed a significant difference between JL BTL-37 and JL NTAL-37 (Figure 3.8A). In
contrast, in the High: Low pair, 13/20 genes were significantly higher in the NTA line JL
NTAL-47 than the tumor line JL BTL-47, indicating an overall down regulation of the
pathway in the High: Low pair (Figure 3.8B).
The differences in NER gene expression between the two types of NTAL lines
was also compared with that of the non-diseased line JL BRL-6 to see if there are
noticeable differences between the two types of NTA tissue. It was observed that the
gene expression of majority of NER genes in the NTA line of the High: Low pair, JL
NTAL-47, was not significantly different from that of JL BRL-6, with only 6/20 genes
significantly different in expression between JL NTAL-47 and JL BRL-6 (p<0.05, twotailed Student’s t-test) (Figure 3.9A). On the contrary, 9/20 genes showed significantly
reduced gene expression in the NTA line of the Low: Low pair, i.e., JL-NTAL 37,
compared to Jl-BRL6 using a one-tailed t-test (p<0.05) (Figure 3.9B).
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Gene expression relative to JL BTL-37
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Figure 3.8A Gene expression of the Low: Low cell line pair via expression microarray
showed no significant difference in the expression of majority of NER genes among the
tumor line and the NTA line. 3 biological replicates were assessed for each cell line. 15 out
of 20 genes did not show significant differences in expression between the tumor line JL BTL37 (open bars) and the NTA line JL NTAL-37 (solid bars). The significant genes were ERCC2
(p= .007), ERCC6 (p= .03), CDK7 (p= .01), GTF2H4 (p= .003), DDB2 (p= .004) and XPC (p
= .01) (Two-tailed Student’s t-test, p<0.05).

Figure 3.8B Gene expression of the High: Low cell line pair via expression microarray
showed significant difference in the expression of 13/20 of NER genes among the tumor
line and the NTA line. 3 biological replicates were assessed for each cell line. The
significant genes were RAD23B (p= .02), ERCC6 (p= .007), RPA1 (p= .0006), ERCC3 (p=
.01), ERCC4 (p= .01), CDK7 (p= .008), ERCC2 (p= .002), GTF2H3 (p= .04), GTF2H4 (p=
.01), XPC (p= .005), ERCC8 (p= .002), RPA3 (p= .04) and GTF2H2 (p= .01). * indicates
significant differences in expression between the tumor line JL BTL-47 (open bars) and the
NTA line JL NTAL-47 (solid bars) (one-tailed student’s t-test. p < 0.05).

130

JL BRL-6

1.6

*

JL NTAL-47
*

*

*

*

XP
C

1.4

GT
F2
H4
ER
CC
2
RP
A2
GT
F2
H3

Gene Expression relative to JL BRL-6

2
1.8

1.2

*

*

*

1
0.8
0.6
0.4
0.2

CD
K7
ER
CC
8
RP
A3
ER
CC
6

CC
NH

XP
A
ER
CC
5

ER
CC
4
GT
F2
H2
ER
CC
3
DD
B2

RP
A1
DD
B1
RA
D2
3B
ER
CC
1

0

Figure 3.9A Gene expression is not significantly different for majority NER genes in the
NTA line of the High: Low pair, JL NTAL-47, relative to non-diseased breast line JL BRL6. 3 biological replicates were assessed for each cell line. * denotes significantly different gene
expression in the NTA line (solid bars) compared to the non-diseased breast line (open bars).
Genes that were significantly different included GTF2H4 (p<.001), ERCC2 (p<.001 ), RPA2
(p=.001 ), GTF2H3 (p=.007 ), XPC (p= .044), RPA1 (p= .001), RPA3 (p= .03) and ERCC6 (p=
.008) (two-tailed Students t-test, p<0.05).
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Figure 3.9B Gene expression is significantly low for 9/20 NER genes of the NTA line of the
Low: Low pair, JL NTAL-37, relative to non-diseased breast line JL BRL-6. 3 biological
replicates were assessed for each cell line. * denotes significantly different gene expression in the
NTA line (solid bars) compared to the non-diseased breast line (open bars). Genes that were
significantly different included RPA2 (p< .001), ERCC2 (p< .001), GTF2H4 (p< .001), RPA1
(p< .001), GTF2H3 (p< .001), ERCC3 (p=.02), ERCC8 (p= .04), CDK7 (p= .02) and ERCC1 (p=
.01) (one-tailed Students t-test, p<0.05).
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3.3.3 RNA sequencing validates results from gene expression microarray in the High:
Low pair as well as Low: Low pair
RNA sequencing was performed to independently validate the gene expression
microarray assessment of NER gene expression. RNA sequencing is exempt from the
probe bias that is intrinsic to array technologies. The microarray analyses compared with
normalized read counts for the NER genes were generally consistent and conformed to
NER function.
Normalized read counts for NER genes in the two tumor lines, JL BTL-37 and JL
BTL-47 were expressed relative to JL BRL-6, and it was observed that both tumor lines
showed a low NER signature, but less significantly different genes due to variability in
JL BRL-6. 3 genes were significantly lower in the Low: Low pair tumor JL BTL-37,
whereas 8 genes were significantly lower in the High: Low pair tumor JL BTL-47, both
relative to JL BRL-6 (Figure 3.10).
Upon comparing the pairs within themselves, expression of NER genes by RNA
sequencing conforms to that seen in microarray results above. In the Low: Low pair, no
significant difference was seen in the NER gene expression signature of the tumor line JL
BTL-37 and the NTA line JL NTAL-37, and no genes stood out significantly different
among the two lines (Figure 3.11A). This compares with 5/20 genes that stood out
significantly different in the microarray analyses of this pair (Figure 3.8A). On the
contrary, in the High: Low pair, 16/20 genes were significantly downregulated in the
tumor line JL BTL-47 (and therefore higher in expression in the NTA line JL NTAL-47)
(Figure 3.11B). In summary, these data from RNA sequencing validate the different gene
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expression profiles of the two types of pairs seen in microarray analyses, and also
conforms to functional NER capacity in these lines.
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Figure 3.10 Expression of NER genes via RNA sequencing in early stage tumor lines JL
BTL-37 and JL NTAL-37 relative to the non-diseased breast line JL BRL-6. 3 biological
replicates were assessed for each cell line. * denotes genes significantly downregulated in JL
BTL-37, which are XPC (p = .01), GTF2H2 (p = .036) and RAD23B (p = .046). # denotes
genes significantly downregulated in JL BTL-47, which are XPC (p = .001), GTF2H3 (p =
0.008), ERCC2 (p = .029), ERCC4 (p = .008), ERCC8 (p = .013), GTF2H4 (p = .035),
RAD23B (p = .017) and DDB1 (p = .038) (One-tailed Student’s t-test, p<0.05)

The gene expression signature of both NTA lines were also compared with that of
JL BRL-6 line, which were consistent with the trends seen in the microarray. JL NTAL47, which is similar to JL BRL-6 in functional NER capacity and gene expression by
microarray analyses, showed a similar trend with RNA sequencing, with majority of the
genes showing no significant difference in NER gene expression signature between JL
NTAL-47 and JL BRL-6 except for two genes, ERCC5 and ERCC6 (Figure 3.12A).
However, 6/20 genes were significantly lower in the NTA line of the Low: Low pair (JL
BTL-37) compared to JL BRL-6 (Figure 3.12B). This is not surprising as the DNA repair
function was low for this NTA line.
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Figure 3.11A Gene expression by RNA sequencing showed no significant difference
among the tumor and NTA line in the Low: Low pair. 3 biological replicates were assessed
for each cell line. None of the genes stood out significantly different based on a two-tailed
Student’s t-test.
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Figure 3.11B Gene expression by RNA sequencing showed 16/20 genes significantly
different among the tumor and NTA line in the High: Low pair. 3 biological replicates
were assessed for each cell line. * denotes genes that are significantly higher in expression in
the NTA line JL NTAL-47 relative to the tumor line JL BTL-47. These genes were DDB1 (p =
.002), ERCC1 (p = .005), CCNH (p =.01 ), CDK7 (p = .005), ERCC3 (p = .004), ERCC6 (p =
.002), RAD23B (p = .002), ERCC2 (p = .0002), GTF2H2 (p = .02), GTF2H4 (p = .002),
ERCC4 (p = .009), RPA1 (p = .002), ERCC8 (p = .004), XPC (p = .00002), RPA3 (p = .01)
and GTF2H3 (p = .002) (One-tailed Student’s t-test, p<0.05).
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Figure 3.12A Gene expression in the NTA line of the High: Low pair relative to JL BRL-6
measured by RNA sequencing showed no significant difference in majority of the NER
genes. 3 biological replicates were assessed for each cell line. * denotes significantly different
genes, which were ERCC5 (p = .03) and ERCC6 (p = .004) (Two-tailed Student’s t-test,
p<0.05)

Figure 3.12B Gene expression in the NTA line of the Low: Low pair relative to JL BRL-6
measured by RNA sequencing showed significant difference in 6/20 of the NER genes. 3
biological replicates were assessed for each cell line. * denotes the significantly lower
expressions in genes, which were ERCC2 (p = .03), ERCC8 (p = .02), XPA (p = .049),
RAD23B (p = .04), XPC (p = .03) and DDB1 (p = .04) (One-tailed Student’s t-test, p<0.05)

135

3.3.4 Hierarchical clustering of samples based on expression of the 20 NER genes by
RNA sequencing
Hierarchical clustering of the cell line groups is shown in Figure 3.13. Clustering
via the horizontal distances between the groups denote their closeness to each other with
respect to their NER gene expression profile for the 20 genes. Foreskin fibroblast lines
(n=3) cluster by themselves on the extreme right showing a distinct gene expression
profile from the rest of the samples which are all breast-derived lines. JL NTAL-47
(NTA-II) and JL BRL-6 (normal breast) are all situated in the center and cluster close to
each other and closer to the foreskin fibroblast lines, denoting a normal-like gene
expression signature in these lines.
JL BTL-37 (Tumor-I), JL BTL-47 (Tumor-II) and JL NTAL-37 (NTA-I) all
cluster towards the far left and closer to each other than the other normal-like cell lines.
This shows that they have a similar NER gene expression profile to each other, which is
distinct from the other lines. An anomaly seen in the dendrogram in Figure 3.13 is one
replicate of JL BTL-37 (Tumor-I) clustering in the middle along with the JL BRL-6
(normal breast) and JL NTAL-47 (Tumor-II) lines. This is most likely due to technical
variation in the RNA sequencing experimental runs.
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Figure 3.13 Dendrogram depicting hierarchical clustering for the sample replicates belonging to each cell line using Euclidean algorithm
and average linkage. Each arm clustering the samples represents one replicate for a particular sample group (n=3 for each group). The
descriptions of sample groups shown on the top panel along with their color codes are as follows. Human foreskin fibroblasts (dark blue) represent
2 replicates of FF-F cell lines and one of FF-C cell line, each established from two samples of newborn foreskins. Normal Breast: JL BRL-6 (red);
Tumor-I: JL BTL-37 (purple); NTA-I: JL NTAL-37 (orange); Tumor-II: JL BTL-47 (blue) and NTA-II: JL NTAL-47 (green). For intensities of
gene expression, red indicates over expression and green indicates under expression.
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3.3.4 RNA sequencing on tissue pairs representing Low: Low and High: Low groups
We sequenced total RNA isolated from flash frozen tissue pairs (from our tissue
bank in the Latimer Lab), using same parameters as the samples used in the study, in an
attempt to increase our limited sample size. Analysis of gene expression for the 20
canonical NER genes in one Low: Low tissue pair (Sample ID: TP96-36; for which no
cell line was available) did show a similar pattern as the Low: Low cell line pair in this
study, where no significant difference was seen in the NER pathway as a whole between
the tumor tissue and NTA tissue, and 11/20 genes were not significantly different
between the tumor tissue and NTA tissue via a two-tailed Student’s t-test (Figure 3.14A).
However, we also analyzed a High: Low pair, where the tumor had an established
cell line (JL-BTL4) but no tissue for the same, and the matched NTA for the said tumor
line did not have a cell line established, but we had the flash-frozen tissue for the NTA
sample (Sample ID: TP95-159). This pair did not follow their trend of functional repair
capacity, nor did this pair follow the gene expression trend seen in the High: Low cell
line pair, as only 4 genes were found to be significantly higher in the NTA tissue sample
compared to its matched tumor (Figure 3.14B).
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Figure 3.14A NER gene expression in a Low: Low tissue pair as measured by RNA
sequencing. 3 biological replicates were assessed for each sample. The NER capacities of
these two tissue samples were 19.48% of FF for the tumor and 9.6% of FF for the NTA. 79/20
genes were significantly different in the NTA compared to the tumor, which were DDB2 (p =
.001), ERCC5 (p = .03), ERCC1 (p = .02), CCNH (p = .03), RPA2(p = .04), ERCC8 (p = .04),
ERCC2 (p = .004), GTF2H3 (p = .002) and RAD23B (p = .005).

Figure 3.14B NER gene expression in a High: Low pair where tumor was a cell line and
NTA was a tissue sample, as measured by RNA sequencing. 3 biological replicates were
assessed for each cell line. The NER capacities of these two tissue explants were 42.59% of FF
for the NTA and 7.46% of FF for the tumor, which defined them as a High: Low pair. Only 4/20
genes were significantly higher in the NTA compared to the tumor, which were GTF2H2 (p =
.00005), XPA (p = .02), CCNH (p = .01) RPA3 (p = .03 and GTF2H4 (p = .049).
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3.3.5 Western blotting for RPA3 protein expression conforms to its gene expression in the
Low: Low pair but not the High: Low pair
Western blots were performed on protein from 3 biological replicates of JL BTL37, JL NTAL-37, JL BTL-47, JL NTAL-47, along with the control, JL BRL-6. A serial
dilution series of protein sample isolated from normal foreskin fibroblasts was also run to
confirm that the western was capturing the dynamic range of expression of the respective
protein. It was observed that RPA3 expression was not significantly different in the Low:
Low pair lines, namely JL BTL-37 and JL NTAL-37 (Figure 3.15A). RPA3 protein
expression for each of the cell lines of the Low: Low pair was also not significantly
different from that of JL BRL-6, and these observations were consistent with the gene
expression of RPA3 using RNA sequencing.
However, in the High: Low pair, contrary to the expected difference from results
of gene expression studies, no significant difference was observed for RPA3 protein
expression between JL BTL-47 and JL NTAL-47 (One-tailed Student’s t-test). Moreover,
RPA3 protein expression was significantly higher in JL BTL-47 than JL BRL-6 (Onetailed t-test), and this was not seen in RPA3 gene expression as per RNA sequencing
results (Figure 3.10). Finally, for RPA3 protein expression, JL NTAL-47 was
significantly higher as compared to JL BRL-6, and this result is also seen in RPA3 gene
expression, although not significant (Two-tailed Student’s t-test) (Figure 3.15B).
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Figure 3.15A Fold change in RPA3 protein expression in the Low: Low pair JL BTL-37
and JL NTAL-37 relative to JL BRL-6. 3 biological replicates were assessed for each cell
line. No significant difference was observed in protein expression of RPA3 in between JL
BTL-37 and JL NTAL-37. Both these cell lines of the Low: Low pair were also not
significantly different in protein expression of RPA3 than JL BRL-6 (Student’s t-test, a = .05)
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Figure 3.15B Fold change in RPA3 protein expression in the High: Low pair JL BTL-47
and JL-BTAL47 relative to JL BRL-6. 3 biological replicates were assessed for each cell
line. No significant difference was observed in protein expression of RPA3 in between JL
BTL-47 and JL NTAL-47 (One-tailed Student’s t-test). Both these cell lines of the High: Low
pair were significantly higher in protein expression of RPA3 than JL BRL-6 (One-tailed and
two-tailed Student’s t-test, p = .005 for JL BTL-47, p = .04 for JL NTAL-47)
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3.3.5 XPC protein expression is consistent with its gene expression in the Low: Low pair
but not in the High: Low pair
XPC gene expression was higher in both NTA lines than the tumor lines, however
this difference was seen to be significant only in the High: Low pair. Therefore, we
wished to see if this held true for the protein expression of XPC as well. In the Low: Low
pair, XPC protein expression was not significantly different between JL BTL-37 and JL
NTAL-37, as calculated by a two-tailed Student’s t-test. XPC protein expression was also
not significantly different for both JL BTL-37 (One-tailed Student’s t-test based on gene
expression) and JL NTAL-37 (Two-tailed Student’s t-test based on gene expression) as
compared to JL BRL-6 (Figure 3.16A).
Interestingly, in the High: Low pair, an inverse relationship was observed
between XPC gene and protein expression among the tumor and NTA cell lines. XPC
protein expression was significantly higher by about 3-folds in JL BTL-47 compared to
JL NTAL-47 (One-tailed Student’s t-test). Expression of XPC protein in JL BTL-47 was
also significantly higher than that of JL BRL-6 (One-tailed t-test). Nevertheless, we did
not see any significant difference in the expression of XPC protein in JL NTAL-47
relative to JL BRL-6 (Figure 3.16B), and this result conforms with that of XPC gene
expression.
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Figure 3.16A XPC protein expression shows no significant difference between the cell
lines in the Low: Low pair as well as relative to JL BRL-6. 3 biological replicates were
assessed for each cell line. Student’s t-test at a = .05 revealed lower expression in JL BTL-37
compared to JL NTAL-37 and JL BRL-6 but not statistically significant.
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Figure 3.16B XPC protein expression in the High: Low pair was seen to be significantly
higher in JL BTL-47 compared to both JL-NTAL46 and JL BRL-6.
3 biological replicates were assessed for each cell line. * indicates significantly higher
expression compared to JL NTAL-47 (p = .04, One-tailed Student’s t-test). # indicates
significantly higher expression compared to JL BRL-6 (p = .03, One-tailed Student’s t-test).
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3.3.6 RAD23B protein expression is consistent with its gene expression in both High:
Low and Low: Low pairs, however the difference is not significant in the High: Low pair.
According to results of gene expression via RNA sequencing, RAD23B showed
no difference between the lines of the Low: Low pair and was significantly higher in JL
BTL-47 of the High: Low pair compared to JL NTAL-47. Also, where RAD23B gene
expression was significantly lower in both tumor lines relative to JL BRL-6, the NTA
line of the Low: Low pair was also significantly lower as compared to JL BRL-6, but not
the NTA line of the High: Low pair. We wished to see if RAD23B’s protein expression
conformed to this pattern as well.
In the Low: Low pair, RAD23B protein expression was significantly lower in the
tumor line JL BTL-37 relative to JL BRL-6, but not significantly different from JL
NTAL-37, as expected from gene expression results. However, JL NTAL-37 was not
significantly different from JL BRL-6 in RAD23B’s protein expression (Figure 3.17A),
whereas gene expression of RAD23B was significantly lower in JL NTAL37 than JL
BRL-6 (Figure 3.12B). This could be attributed to the variation in the replicates.
In the High: Low pair, RAD23B protein expression was lower in JL BTL-47 than
that of JL NTAL-47, but this difference was not significant. Future westerns will be
performed on this protein in these lines to verify these findings. RAD23B protein
expression was significantly lower in JL BTL-47 relative to JL BRL-6 (Figure 3.17B)
which is consistent with its gene expression (Figure 3.10). It was not significantly
different from JL BRL-6 in JL NTAL-47 (Figure 3.17B), as expected from gene
expression results (Figure 3.12A).
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Figure 3.17A RAD23B protein expression, although lower in Jl-BTL37 compared to JL
NTAL-37, is not significantly different between the Low: Low pair. 3 biological replicates
were assessed for each cell line. * indicates significantly lower expression in JL BTL-37
compared to JL BRL-6 (p = .04) (One-tailed Student’s t-test)
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Figure 3.17B RAD23B protein expression, although lower in Jl-BTL47 compared to JL
BRL-6, is not significantly different between the High: Low pair. The absence of
significance is probably due to high variation within replicates for JL NTAL-47 and this will
be repeated by future students in the lab. 3 biological replicates were assessed for each cell
line. * indicates significantly lower expression in JL BTL-47 compared to JL BRL-6 (p =
.02, One-tailed Student’s t-test)
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3.3.7 Summary of gene and protein expression results for RPA3, XPC and RAD23B
Table 3.4 below highlights the key findings based on RNA sequencing gene expression and protein expression by western
blotting for the three NER proteins, namely RPA3, XPC and RAD23B.
Table 3.4 Summary of gene and protein expression results for RPA3, XPC and RAD23B. Red: RAD23B western goes in the right
trend as that of gene expression and but the difference is not significant; will be repeated for verification of these findings.
Low: Low
High: Low
JL NTAL-37
JL NTAL-37
JL BTL-37
JL NTAL-47
JL NTAL-47
JL BTL-47
relative to JL
relative to JL
relative to JL
relative to JL
relative to JL
relative to JL
BTL-37
BRL6
BRL6
BTL-47
BRL6
BRL6
RPA3 Gene
No significant No significant
No significant
Significantly
No significant
No significant
Expression
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3.3.8 TP53 gene expression might explain the XPC gene and protein expression
We checked the expression of TP53 gene and compared it to that of XPC gene
expression to be able to explain the results of XPC protein expression, as XPC is
regulated by p53. Expression of TP53 was found to be significantly lower in both tumor
lines, JL BTL-37 and JL BTL-47, as compared to that of their respective matched NTA
lines. The gene expression of TP53 was significantly lower in both tumor lines compared
to that in JL BRL-6 as well in both pairs (Figure 3.18). This was similar to the trend of
XPC gene expression and these results have been elaborated on in the discussion.
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Figure 3.18 Expression pattern of TP53 in the cell lines of this study by RNA sequencing
and the concurrent expression pattern of XPC. 3 biological replicates were assessed for
each cell line. TP53 was significantly downregulated in both tumors, JL BTL-37 (p = .03) as
well as JL BTL-47 (p = .01) relative to JL BRL-6. XPC expression was also concurrently
lower in both tumors, JL BTL-37 (p = .02) and JL BTL-47 (p = .002) relative to JL BRL-6. No
difference was observed in both NTA lines for TP53 as well as XPC relative to JL BRL-6.
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3.4 Discussion
Breast cancer is currently affecting the lives of about 3.1 million women in the
United States, and this number includes women who have received treatment as well as
those currently undergoing treatment (American Cancer Society, 2017). The etiology of
sporadic breast cancer is still largely unknown, and we are the first group to our
knowledge that show breast cancer etiology in early stage breast cancer lines with respect
to NER.
Studies that involve comparisons of matched tumor and NTA samples are usually
performed on blood samples representing the matched normal from the same patient as
the tumor sample, which is unsuitable for a study like ours. This is because NER is tissue
specific as we have shown previously (Latimer et al., 2003). In cases where they use the
adjacent normal from the tissue of origin as the tumor, samples are analyzed directly after
obtaining them from patients as either fresh tissues, FFPE (Formalin-Fixed ParaffinEmbedded) samples or flash frozen tissue samples (Quiroz-Zárate et al., 2017). Studies
involving such samples, although having the advantage of a large sample size and higher
power of the study, present several challenges. Firstly, uncultured tissue samples are a
heterogenous mix of various cell types including stroma, blood vessels, immune cells and
lymphatic vessels. Tumor heterogeneity in cancer is a widely studied topic, as this
heterogeneity poses challenges in research for advanced discoveries towards cancer
treatment (Cyll et al., 2017; Martelotto, Ng, Piscuoglio, Weigelt, & Reis-Filho, 2014).
We also experienced the challenge posed by tissue heterogeneity. Our findings on
expression data on tissue pairs representative of the High: Low and Low: Low pairs in
terms of functional repair capacity further emphasize the importance of using cell lines as
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model systems for in-depth molecular analyses (Figure 3.14A and 3.14B). In these tissue
pairs, the expression of the 20 canonical NER genes was not consistent to that of
functional NER capacity. Therefore, although one of the major limitations of this study
was its limited sample size in terms of representative pairs, our unique cell line pairs used
in this study (representative of the two groups of High: Low and Low: Low) show classic
gene expression signatures that conform to their NER capacity, and this could be
considered as a strength of our study.
Secondly, tissue samples or FFPE samples are not experimentally manipulable.
Therefore, most studies on regulatory mechanisms in cancer are performed on
commercially available cell lines that are established from advanced-stage cancers, which
makes them poor representatives for studying early stage cancer etiology. In this study,
we had the unique advantage of exploring breast cancer etiology of sporadic cases of
breast cancer using our own cell lines established in the Latimer Lab, where both tumor
and NTA are obtained from the same patient and the tissue of origin of the neoplasm,
which in this case is the breast.
We determined protein expression of NER genes in the Low: Low as well as
High: Low cell line pairs to see if differences in their gene expression are consistent with
the encoded protein. This would also aid in our search for a master regulator of the NER
pathway in early stage breast cancer. RPA3 protein expression in the High: Low pair did
not follow its gene expression pattern, and we saw no significant difference in its protein
expression where its gene expression was starkly different within the pair. With regard to
XPC, the trend in protein expression was significant but in the opposite direction to that
of its gene expression. In spite of the logical assumption of gene expression being an
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indicator of downstream protein expression, this correlation does not always hold true, as
multiple studies have reported non-correlation of protein expression with its gene
expression (G. Chen et al., 2002; Q. Tian et al., 2004; Vogel et al., 2010). Translational
control has been reported to be a major indicator of downstream protein abundance in
cells (Schwanhäusser et al., 2011), and investigation of NER regulation at the
translational level is, though out of scope for this dissertation research, a future direction
for this work.
XPC protein expression being inversely related to its gene expression could be
related to its regulation by p53. p53 is a major tumor suppressor protein found to be
frequently mutated in tumors, and a wild-type p53 phenotype induces XPC expression in
response to UV and ionizing radiation (Adimoolam & Ford, 2002; Amundson, Patterson,
Do, & Fornace, 2002). Exon 1 of XPC has been shown by ChIP experiments to contain a
p53 response element (Hastak, Adimoolam, Trinklein, Myers, & Ford, 2012). The gene
expression TP53 followed the same trend as that of XPC (Figure 3.18). However, high
protein expression of XPC suggests its regulation at either the post-transcriptional level
or the translational level. Overexpression of XPC has been shown to mediate degradation
of p53 via MDM2 ubiquitin ligase , therefore delineating a novel role for XPC as part of
a negative feedback loop to regulate p53 expression apart from its function as an damage
recognition protein in NER (Krzeszinski et al., 2014). Further studies are necessary in
order to validate the occurrence of this in the tumor cell line of the High: Low pair, as it
is still unclear as to under what circumstances does XPC regulate p53.
RAD23B protein expression showed a consistent trend with that of its gene
expression, however the difference seen in the High: Low was not significant due to
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variation in the replicates for the respective lines. A replication of the western blots for
RAD23B might yield significant differences upon eliminating the source of variation in
the band intensities of XPC, even after normalization with respective GAPDH band
intensities.
Finally, our findings are clinically relevant. Upon further validation of these
results in a larger cohort of patient samples, early stage breast cancer patients could
possibly be screened for their NER capacity or NER gene expression in the nonpathologic adjacent breast tissue, and their risk of recurrence could be predicted based on
the same, with a possible increase in the duration of post-operative adjuvant radiation
treatment for patients that have a low NER capacity in their NTA breast. Moreover,
identification of a candidate gene based on further studies on regulation of this pathway
will pave the way for the use of this as a biomarker to predict recurrence in early stage
breast cancer patients undergoing lumpectomy with radiation therapy.
3.5 Conclusion/Summary
We identified 2 varieties of non-tumor adjacent breast based on their functional
NER capacities as well as the expression of NER genes. While the NER capacity of their
matched sporadic early stage breast tumors was low in both varieties, the NER capacity
of the NTA most likely depends on whether loss of NER was an early or a late event in
tumorigenesis. Loss of NER being an early event is most likely the case where the NER
capacity is shared between the tumor and the NTA. However, loss of NER occurred later
in the trajectory of carcinogenesis where the NTA had a higher NER capacity than the
tumor. This chapter, coupled with the next chapter on mechanism of NER regulation, will
help us lay the foundation of the events happening in a pathologically normal breast
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sample en route to carcinogenesis. However, replication and validation of this work is
needed in additional representative cell line pairs of early stage breast cancer tumors and
their matched NTA lines, which the lab plans to establish by acquiring tissue samples
after an IRB is in place with a local hospital. This will ultimately allow us to build our
own “Vogelsteinogram” delineating the complex genetic and/or epigenetic alterations in
breast tumorigenesis, therefore laying a foundation for the mechanism of sporadic
carcinogenesis in the breast. Our findings lay the groundwork for being able to use NER
capacity in the non-tumor adjacent breast tissue as a prognostic marker for recurrence of
breast cancer and its possible role in advancement of treatment regimens.
With our study, we hope to be able to establish a ‘Vogelsteinogram’ for
sporadic breast cancer from an NER perspective. This study is also clinically relevant as
we show the non-normalcy of the NTA breast, which raises questions on the margin
width during lumpectomy and the latter is already a topic of debate among clinicians
(Houssami et al., 2010). A recent presentation in the 2017 San Antonio Breast Cancer
Symposium by Dr. Chirag Shah regarding a meta-analysis of 33 studies on breast cancer
refuted the SSO-ASTRO guidelines of ‘no ink on tumor’ basis of deciding margin width
This analysis showed a lower risk of ipsilateral breast recurrence with margins wider than
2mm (Shah, Verma, Sayles, Recht, & Vicini, 2018). Our study also reinforces the
groundbreaking clinical trial by Fisher and his colleagues which showed that lumpectomy
with radiation has similar outcomes to that of a total mastectomy, and post-operative
adjuvant radiation significantly lowers mortality in treated patients, and the latter has
been shown in another clinical trial as well in 2017 (B. Fisher et al., 2002; Poleszczuk et
al., 2017).
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Chapter 4
Elucidation of the mechanism of regulation of nucleotide excision repair
genes in early stage sporadic breast cancer using isogenically matched
non-tumor adjacent breast cell lines
4.1 Introduction
The multistep nature of cancer involves mutations as well as certain epigenetic
alterations that lead to the ultimate tumor phenotype (Armitage, 1985; Hanahan &
Weinberg, 2000; Vogelstein & Kinzler, 1993). The formation of cancer in an organ
usually takes decades. The carcinogenesis process is sped up by the presence of inherited
germline mutations, which can be seen in BRCA1 and BRCA2 mutation carriers who
manifest breast cancer at an earlier age than sporadic breast cancer cases (Dagan,
Gershoni-Baruch, Kurolap, & Fried, 2017; Thompson et al., 2012). We hypothesized that
the downregulation of NER in early stage sporadic breast cancer cases, as well as in their
matched NTA samples in most of the cases, is epigenetic based on the downregulation
seen in multiple genes and in multiple patients (Latimer et al., 2010; Latimer et al., 2003).
Moreover, as the rate of occurrence of a somatic mutation is one per 30 million
nucleotides per genome (Xue et al., 2009), it is highly unlikely that a mutation in each of
these genes could cause the observed downregulation. Therefore, in this study, we wished
to explore an epigenetic mechanism of regulation.

156
4.1.1 Epigenetic regulation of gene expression
Epigenetic regulation refers to the phenomenon which induces a change in the
expression of genes without a change in the genetic code or sequence of the DNA
(Jaenisch & Bird, 2003). Out of the three major mechanisms of epigenetic transcriptional
regulation, which are DNA methylation, histone modifications and regulation by small or
long non-coding RNA molecules (Handy et al., 2011). Methylation of DNA at the
cytosine-guanine dinucleotide bases (CpG) is the most widely studied. Methylation of
DNA is a heritable trait, usually passed on to daughter cells, and from gametes to
subsequent generations by a mechanism known as imprinting (Reik, 2007). Promoter
regions of genes are found to be rich in CpG sites (a GC percent of more than 50%), and
this is what constitutes a CpG island (Illingworth & Bird, 2009). Methylation of CpG
islands or sites at the promoter region of genes generally suppresses gene expression by
mechanisms like interference of binding of enhancer proteins, active removal of
transcription factors like RNA polymerases from the transcription initiation sites, binding
of specific proteins called methyl-CpG binding domain (MBD) proteins, and rendering of
the configuration of chromatin unsuitable for transcription (Fuks et al., 2003; Kass,
Landsberger, & Wolffe, 1997; Plass & Soloway, 2002).
4.1.1.1 Methylation and Cancer
Specific oncogenes have been known to be hypomethylated in cancer (Van
Tongelen et al., 2017), while tumor suppressor genes are hypermethylated at their
promoter region, thereby silencing the expression of these genes and promoting
carcinogenesis (Baylin & Ohm, 2006; Robertson, 2005). Overall, DNA has been found to
be hypomethylated globally in cancer genomes, owing to the demethylation and thereby
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transcriptional activation of repetitive elements and viral genes inserted into the human
genome, thereby increasing genomic instability (Kisseljova & Kisseljov, 2005).
4.1.1.2 Methylation and DNA repair
There have been accounts of methylation of NER genes in cancers.
Hypermethylation of promoter region in XPC has been shown to regulate its gene
expression in lung cancer (Y. Wu et al., 2007) and downregulation of XPG due to
promoter methylation has been shown to be implicated in chemotherapy resistance in
mouse as well as human cell line models (Sabatino et al., 2010). However, methylation
status of NER genes with regard to breast cancer has not been studied to date.
4.1.2 Single nucleotide variants in NER genes
Defects in the NER pathway caused due to germline mutations in NER genes in
individuals manifests as a disease called Xeroderma Pigmentosum or XP, which
increases their sensitivity to UV light and increases their risk of getting cancer by about
2000-fold (Bradford et al., 2010). Seven complementation groups were discovered for the
major NER genes, and a mutation in each one of these genes affects the NER capacity in
different degrees, where mutation in one gene has a different contribution towards repair
capacity than that in the other (de Boer & Hoeijmakers, 2000; Friedberg et al., 2005).
Although we hypothesized that the downregulation of NER capacity in our early stage
sporadic breast cancer lines was due to an epigenetic regulatory mechanism, we wished
to rule out the possibility of a mutation in one of our 20 NER genes.
Detection of single nucleotide variants or SNVs is a popular approach used in
literature for data obtained from DNA and RNA sequencing to look for putative
mutations in coding regions of genes or transcripts (Quinn et al., 2013). Most of these
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variants are known single nucleotide polymorphisms or SNPs, which are viable variants
for a specific base position in the DNA and are deemed such if their occurrence is more
than 1% in a given population. The variants are a mutation if they occur in less than 1%
of the population. These definitions telling a SNP apart from a mutation are now
overlapping (Karki, Pandya, Elston, & Ferlini, 2015). Although SNPs are more of a
population characteristic, their presence has also been associated with disease risk, and
several SNPs have been identified conferring an increased (or at times decreased) risk of
breast cancer as well (Coughlin & Piper, 1999), along with other cancers.
Polymorphisms in NER genes have been associated with a variety of cancers
including, but not limited to, gastric cancer (J. Liu et al., 2016), laryngeal cancer (B. Lu
et al., 2014), melanoma (C. Li et al., 2006), bladder cancer (Qiao et al., 2011), prostate
cancer (M. Wang et al., 2017), esophageal adenocarcinoma (Tse et al., 2008), and breast
cancer. With regards to breast cancer, the polymorphisms conferring increased breast
cancer risk were the ones found in XPC (Pérez-Mayoral et al., 2013), XPG/ERCC5 (C.
Han et al., 2017), XPD/ERCC2 (Bernard-Gallon et al., 2008; Wonshik Han et al., 2012;
A. K. Mitra et al., 2009; Smolarz et al., 2014), XPA (W. Han et al., 2012) and RAD23B
(Pérez-Mayoral et al., 2013) whereas a variant in XPB/ERCC4 (Milne et al., 2006) and
XPD/ERCC2 (J. Li et al., 2008) was shown to decrease breast cancer risk and have a
protective effect.
Our ultimate objective is to understand the molecular progression of breast cancer
from an NER perspective. Chapter 3 of this dissertation showed that we were able to
identify two varieties of non-tumor adjacent (NTA) breast obtained as matched pairs
along with their respective tumors. NER capacity in one variety was lower than normal
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non-diseased breast and so was that of its isogenically matched tumor sample (Low: Low
pair of NTA-tumor). NER capacity in the other variety was similar to that of normal nondiseased breast and higher than its isogenically matched tumor sample (High: Low pair of
NTA-tumor). We performed gene expression microarray analyses, RNA sequencing as
well as western blotting on cell line pairs representing the Low: Low and the High: Low
groups, as elucidated in Chapter 3. The aim for this study was to assess if methylation of
CpG sites on one or more NER genes is the mechanism of downregulation of NER gene
expression observed in 3 of our cell line pairs, mostly in their promoter regions where
these genes have been known to be rich in CpG islands (Johnson, 2006). This study also
explored the presence of single nucleotide variants that could be indicative of a putative
mutation in the coding region of the 20 canonical NER genes via variant calling on RNA
sequencing data.
4.2 Methods
4.2.1 Establishment of cell lines from tumor/NTA pairs of tissues
Tissue samples were obtained from surgeries performed at Magee Women’s
Hospital (Institutional review board approval 0609002). Primary cultures were
established as described previously (Chapter 2) and passaged into cell lines (>13
passages) (Latimer et al., 2010; Latimer et al., 2003). JL BRL-6 was obtained from a
breast reduction surgery performed on a non-diseased patient. Two cell line pairs (4 cell
lines) were used in this study, each of which represent the two groups of NTA-Tumor
pairs – Low: Low and High: Low, which were obtained from patients with early stage
breast cancer undergoing lumpectomy. The NTA samples were confirmed to be
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histopathologically normal. Their characteristics, along with their respective NER
capacities as measured by the UDS assay, are as described in Table 3.1 of Chapter 3.
4.2.2 MethylationEPIC array
4.2.2.1 DNA isolation
DNA was isolated from all four cell lines of the two pairs as well as the control
lines JL-BRL6 and FF-F in triplicate using the DNeasy mini kit (QiagenÒ) (Cat# 69504)
according to manufacturer’s protocol. Briefly, cultured monolayer of cells per cell line
was trypsinized pelleted at 800 rpm for 5 mins after neutralizing with culture medium
(MWRI). Two flasks of 12.5cm2 area per replicate for each cell line were combined for
each spin column. The pellet was resuspended in 200µL of PBS in a 1.5 mL Eppendorf
tube. 20µL of proteinase K and 4µL RNAse A were added to the resuspended pellet,
mixed by vortexing and allowed to stand for 5 min at room temperature for protein and
RNA digestion respectively. Then, 200µL of buffer AL (without ethanol) was added to
this mixture and, after covering the tube with the lid closed tightly, the mixture was
vigorously shaken manually by inverting the tube for 15sec to ensure uniform mixing.
The sample mixtures were then incubated at 56°C for 10 mins, after which 200µL of
100% ethanol was added to it and the sample was mixed thoroughly by vortexing. This
mixture was then added to a fresh DNeasy Mini spin column provided with the kit with a
2mL collection tube (provided by the kit) and centrifuged at 8000 rpm for 1 min after
which the flow through liquid was discarded. The spin column was washed with 500µL
of buffer AW1 (adding this to the column, centrifuging at 8000 rpm for 1min and
discarding the flow through along with the collection tube). The column was then washed
with 500µL of buffer AW2 at 14,000rpm and the flow through was discarded along with
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the collection tube. Finally, DNA was eluted into a 1.5mL clean Eppendorfâ tube using
200µL of buffer AE by centrifugation at 8000rpm for 1 min, and this process was
repeated with the eluate to obtain maximum yield of DNA.
4.2.2.2 Methylation EPIC array procedure
Isolated DNA was aliquoted into 2D barcoded matrix tubes provided by the core
facility such that at least 250ng of DNA was sent per sample at a max volume of 45µL.
These aliquots were then shipped on dry ice to the Center for Genome Technology at the
Hussman Institute for Human Genomics, University of Miami to be run on Methylation
EPIC arrays (Illuminaâ) according to manufacturer’s protocol. Briefly, DNA was
subjected to bisulfite conversion which consisted of the unmethylated cytosine bases
being converted to uracil and the methylated cytosines remaining unchanged. Bisulfiteconversion treated DNA was then isothermally amplified overnight, fragmented and
precipitated to obtain fragmented DNA. These fragments, after resuspension in a
hybridization buffer, were then made to hybridize to the EPIC BeadChip by overnight
incubation in the Illumina hybridization oven. The beadchips are designed with attached
locus-specific oligonucleotides of about 50-base pairs which hybridize to the fragmented
DNA in this hybridization step. Two types of beads, one each for methylated and
unmethylated cytosines, enable detection of methylation status by single base extension
of the oligo using the annealed DNA fragment as template. The single base extension was
detected with the help of fluorescent labels on beadchips. Beadchips were then scanned
on the Illumina iScan to obtain raw methylation values in the form of IDAT files.

162
4.2.2.3 Data analysis
Data from the Methylation EPIC array runs, along with the annotation file for the
array, were received from the core facility in the form of IDAT files, two for each of the
samples analyzed (one file each for red and green channel). IDAT files were analyzed to
obtain differential methylation data using RnBeads package in Bioconductor/R (Assenov
et al., 2014). After running QA/QC on the samples, the data was filtered to remove
probes that contain single nucleotide polymorphisms (SNPs) and the probes that have
missing values. Data was normalized using the beta-mixture quantile normalization
(BMIQ) method (Teschendorff et al., 2012). Differential methylation analysis was
performed using the rnb.run.differential command. Region-level methylation results were
analyzed further for finding differentially methylated regions on three levels, namely
promoter level, gene level and CpG island level. Promoter regions were defined for each
gene in the analysis by RnBeads as the region 1.5 kbp upstream and 500 bp downstream
of the transcription start site (TSS). Regions for analyzing gene level and CpG island
levels were defined based on the manifest file for the assay from the manufacturer. While
the promoter level and gene level output were already annotated with gene symbols, CpG
island level output was not. Therefore, Partek Genomics Suite software (Partek Inc.) was
used to annotate the CpG island level data with gene symbols using human genome
reference build 37, also known as hg19, and then was filtered for the data exclusively on
the 20 canonical NER genes. The reference genome build used was hg19 instead of the
latest hg38, as the probes for the Illumina Methylation EPIC array are designed based on
hg19.
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RnBeads performed all pairwise comparisons for the groups included in the
analysis. The p value under the column comb.p.val was used to assess significance in the
differential methylation seen at the region level. This represented an aggregated p-value
for all the CpG sites in a given region based on a generalization of Fisher’s method
(Makambi, 2003; Müller et al., 2015). Multiple testing correction was not performed
(usually done via false discovery rate or FDR-based p-values), as we tested a set number
of predefined hypotheses for just our 20 NER genes. We did not test every possible
combination that could be done on the data we had, and this is the main reason FDR is
implemented (Perneger, 1998; Rothman, 1990).
Pearson’s correlation coefficients were also calculated in order to correlate log
expression values of the 20 NER genes to their methylation levels. Sample groups
constituted of 3 replicates each of JL-BRL6, JL-BTL37, JL-NTAL37, JL-BTL47 and JLNTAL47. The expected result was an inverse correlation between methylation and gene
expression and therefore the correlation coefficient was expected to be negative.
However, we also noted the instances where the correlation coefficient was positive and
higher than 0.7 denoting strong positive correlation. Where a correlation coefficient
below -0.7 (or above 0.7) was observed, simple linear regression was used to see if the
correlation was significant for that particular gene.
The Methylation module in Illumina’s Genome Studio software was used to
generate box whisker plots and heat maps for visualization of the global methylation
profile of our sample groups.
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4.2.3 Variant calling from RNA sequencing data
At this point in our work, we transitioned to RNA sequencing to assess gene
expression levels and validate previously performed expression microarray analyses.
RNA sequencing also reveals the presence of single nucleotide variants, which might be
indicative of the possibility of the presence of a mutation in the exonic regions of the 20
NER genes, to get to the root of the mechanism of differential NER gene expression as
well as function in our early stage sporadic breast cancer cell line pairs.
4.2.3.1 RNA isolation and RNA sequencing procedure
Total RNA was isolated using the miRNeasy mini kit for total RNA isolation
(QiagenÒ) (Cat#217004) according to manufacturer’s protocol (refer to Chapter 3 for
details). Quality and concentration check was performed using Agilent’s TapeStation
4200 system (Cat# G2991AA) according to the manufacturer’s instructions. 1 µg of
isolated total RNA sample per replicate for each cell line was sent to the Genomics core
facility at the Hussman Institute for Human Genomics for RNA sequencing, where
library preparation and sequencing of the samples was carried out, a brief description of
which can be found in Chapter 3 as well. Data was delivered by the core facility as
FASTA files which were analyzed further for variant identification.
4.2.3.2 Data analysis
Raw FASTA files were uploaded to Partek’s server using FTP with the help of
Filezillaâ and pre-alignment QA/QC was performed in Partek Flow (Partek Inc.). After
validating integrity of raw unaligned reads, alignment was performed to the human
reference genome build 38 (hg38) using 3 aligners, namely GSNAP, HISAT2 and BWAMEM (Kim et al., 2015; Heng Li, 2013; Heng Li & Durbin, 2009; T. D. Wu et al., 2016).
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Every aligner has a different alignment algorithm and hence, getting a consensus on
variants called on reads aligned using 3 aligners served as a variant validation strategy.
Post-alignment QA/QC was performed after alignment using each of the 3 aligners to
ensure optimum alignment. Aligned reads from each aligner were filtered to remove
duplicate reads in order to avoid redundant variant calling.
Variant calling, which means noting differences in base positions compared to the
reference genome, was performed on sequenced fragments called reads that were aligned
to the reference genome using all the aforementioned aligners. SAMtools was used for
this, which uses its mpileup algorithm to call for single nucleotide variants against the
reference genome, which in this case was the human genome reference build 38 (Heng
Li, 2011; Heng Li et al., 2009). Variants were filtered to include those only within our
regions of interest which, in the case of this research study, were the 20 NER genes. This
was done by importing a gene transfer format (GTF) file for the 20 NER genes, obtained
using the UCSC Table Browser (Karolchik et al., 2004), into Partek Flow. While
filtering, only those variants were included to which at least 3 reads mapped, which is a
validation strategy to weed out artifacts and wrong base detections during sequencing.
Also, mapping quality was used as a measure of high-quality variants, where this is a
measure of how well the reads higher than 30 to filter out artifacts. The filtered variants
were then annotated with Ensembl transcripts (release 88) as well as with known variants
from the dbSNP database (build 150) (Sherry et al., 2001). The filtered variants from
each aligner were then combined to include just the intersects, i.e., common variants
between all three aligners. The combined variants were downloaded as tab delimited text
files for each sample from the ‘View variants’ report that generates a variant table for
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each sample analyzed. These text files were further analyzed using Partek Genomics
Suite software.
Venn diagrams were constructed to find common variants, first between replicates
of the same line, for consensus and validation, and then between pairs. The aim was to
find shared variants between the tumor and NTA lines of the Low: Low pair, and the
variants only in the tumor line but not in the NTA line for the High: Low pair. This
would narrow down on the variants common to a low NER signature. While constructing
Venn diagrams in Partek Genomics Suite, a Unique ID column was generated by merging
columns ‘Chr’ and ‘Position’ for every variant row. The format of the Unique ID column
was ‘chr.position’, and this was used as the key column to find shared variants.
4.3 Results
4.3.1 MethylationEPIC array
4.3.1.1 Global Methylation for all sample groups
Upon using Illumina’s Genome Studio software to visualize global DNA
methylation distribution as Box-Whisker plots, we saw that the median methylation
levels (denoted by the red line for each sample group) decreased progressively from JLBRL6 group to the JL-BTL37 group. The median methylation for the JL-NTAL47 and
JL-BTL47 were next, followed by JL-NTAL37 and JL-BTL37. The median methylation
levels of both tumors are lower than that of their NTA lines, and both are also lower than
that of JL-BRL6 (Figure 4.1).
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Figure 4.1 Box whisker plot showing methylation value distribution for the 5 sample
groups assayed. Sample groups constituted of 3 biological replicates for each cell line. The red
line indicates the median methylation level of each group, which is seen to progressively
increase from the group having low NER capacity line to that having high NER capacity. The
numbers in blue for each sample group indicate total number of probes included in the group
and scale on the y-axis indicates the minimum to maximum values that a b-value can take, i.e.,
0 to 1 where 0 indicates an unmethylated site, 1 indicates a completely methylated site, and 0.5
would mean a hemi-methylated locus.

We also created heat maps and performed hierarchical clustering of sample
groups in Illumina’s Genome Studio software using Euclidian distance metrics of probe
intensities to look at methylation levels for all the probes across these groups and see how
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closely the sample groups related to each other. It was observed that JL-BTL37 clustered
by itself as a group that showed a distinct methylation profile compared to the other lines,
depicted by the right-most arm in Figure 4.2. The arm on the left showed JL-NTAL37
clustered by itself and showing a higher similarity to JL-BTL37 as expected (both
obtained from the same patient as well as both having low repair). The arms in the middle
show JL-BRL6 (high repair) cluster by itself and were closely related to JL-NTAL47
(high repair) and JL-BTL47 (low repair). The cell lines of the High: Low pair (JL NTAL47 and JL BTL-47) again clustered together showing a similar methylation profile, and
this was as expected as well, considering the pair has been derived from the same patient.

Figure 4.2 Hierarchical clustering of sample groups depicting their methylation profiles
using Euclidian distance. Sample groups constituted of 3 biological replicates for each cell
line. Red indicates maximum b-value and green indicates minimum b-value (see scale to the
right of image). This figure in itself does not depict all of the probes assessed but is however a
representation of the data to show the clusters generated. This figure is intended to give a
visual depiction of the closeness of the sample groups to one another in terms of their
methylation profiles.
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4.3.1.2 Promoter-level methylation for the High: Low pair revealed 2 differentially
methylated genes, DDB1 and ERCC5, but in the opposite direction to that expected.
Promoter regions were predefined by RnBeads for each gene to measure a
combined methylation level for all CpG sites in the region 1.5 kbp upstream and 500 bp
downstream of the transcription start site (TSS). The methylation differences were
expected to be most pronounced in the High: Low pair, owing to the starkly different
gene expression signatures in the NTA line compared to its matched tumor line Among
the promoter regions assessed for all the 20 NER genes for the cell lines in the High: Low
pair, JL-BTL47 and JL-NTAL47, the promoter region for DDB1 and ERCC5 stood out
significantly differentially methylated between the two groups, with their combined pvalues of 0.002 and 0.045 respectively (Table 4.1). For both these genes, mean
methylation was higher in the NTA than in the tumor.

170

Table 4.1 Differential methylation for promoter regions of NER genes in the High: Low pair

Gene
CCNH
CDK7
DDB1
DDB2
ERCC1
ERCC2
ERCC3
ERCC4
ERCC5
ERCC6
ERCC8
GTF2H2C
GTF2H3
GTF2H4
RAD23B
RPA1
RPA2
RPA3
XPA
XPC

Promoter Region Genomic Co-ordinates
mean.mean.diff*
Chromosome
Start
End
(NTAL47-BTL47) comb.p.val# num.sites@
chr5
86708337
86710336
-0.0451
0.1047
10
chr5
68529168
68531167
0.0007
0.6071
14
chr11
61109569
61111568
0.1762
0.0016
6
chr11
47234993
47236992
0.0191
0.1032
7
chr19
45981587
45983586
0.0022
0.4592
5
chr19
45873677
45875676
0.0019
0.5473
7
chr2
128051253
128053252
0.0032
0.2727
8
chr16
14012514
14014513
0.0104
0.2910
11
chr13
103495694
103497693
0.0388
0.0446
5
chr10
50747085
50749084
0.0109
0.1671
16
chr5
60240401
60242400
0.0013
0.2463
12
chr5
68854535
68856534
0.0374
0.1073
9
chr12
124116875
124118874
-0.0005
0.2933
16
chr6
30874461
30876460
0.0542
0.1202
9
chr9
110043918
110045917
-0.0105
0.1627
10
chr17
1731496
1733495
0.0403
0.0535
4
chr1
28240758
28242757
0.0097
0.0559
13
chr7
7757739
7759738
-0.0017
0.7984
2
chr9
100459140
100461139
0.0509
0.0689
5
chr3
14219784
14221783
-0.0213
0.2437
14

*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region
#
combination of p-values for all CpG sites assessed in the given region
@
number of CpG sites assessed for the given region
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4.3.1.3 Promoter-level methylation in the Low: Low pair revealed 3 significantly
differentially methylated genes between JL-BTL37 and JL-NTAL37, namely DDB1,
DDB2 and RPA2, in spite of no significant difference seen in their gene expression in this
pair
Based on gene expression results from RNA sequencing, there was no differential
methylation expected on the CpG sites within the promoter regions of our NER genes,
assuming methylation was the regulator mechanism for the gene expression patterns we
were seeing. However, significant differential methylation was still observed for
promoter regions of 3 NER genes, DDB1 (p = .003), DDB2 (p = .023) and RPA2 (p =
.005). The mean of means of b-values at CpG sites in the promoter region for DDB1 was
higher in JL-NTAL37 than JL-BTL37 for DDB1 (indicated by a positive mean.mean.diff
value), whereas it was lower in JL-NTAL37 for DDB2 and RPA2 than JL-BTL37
(indicated by a negative mean.mean.diff value) (Table 4.2).
4.3.1.4 Gene-level methylation for the High: Low pair showed 3 genes significantly
differentially methylated, namely DDB1, GTF2H4 and XPA
We also looked at gene-level methylation, the regions for which were defined by
RnBeads based on the reference human genome build 37. RnBeads gave a calculated
mean difference in b-values and a combined p-value of all the CpG sites assessed in the
given gene region for each of the 20 NER genes (the number of sites is shown in the
num.sites column in Table 4.3). It was seen that 3 genes were significantly differentially
methylated between JL-NTAL47 and JL-BTL47, which were DDB1 (p = .033), GTF2H4
(p = .039) and XPA (p = .048). The mean of the means for b-values on assessed CpG
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sites for JL-NTAL47 was higher than that of JL-BTL47 for all the three genes above
(indicated by a positive mean.mean.diff value) (Table 4.3).
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Promoter region genomic co-ordinates
mean.mean.diff*
Gene
Chromosome
Start
End
(NTAL37-BTL37)
comb.p.val#
CCNH
chr5
86708337
86710336
0.0437111
0.128505
CDK7
chr5
68529168
68531167
-0.00043
0.231331
DDB1
chr11
61109569
61111568
0.0882936
0.00335999
DDB2
chr11
47234993
47236992
-0.0422267
0.0227868
ERCC1
chr19
45981587
45983586
-0.0010492
0.614225
ERCC2
chr19
45873677
45875676
-0.0446693
0.110425
ERCC3
chr2
128051253
128053252
-0.004469
0.418972
ERCC4
chr16
14012514
14014513
-0.0771633
0.0769926
ERCC5
chr13
103495694
103497693
-0.0442703
0.175442
ERCC6
chr10
50747085
50749084
0.0435115
0.0936364
ERCC8
chr5
60240401
60242400
-0.0058256
0.405815
GTF2H2C
chr5
68854535
68856534
0.0567372
0.0960323
GTF2H3
chr12
124116875
124118874
-0.013184
0.230684
GTF2H4
chr6
30874461
30876460
0.057679
0.0722285
RAD23B
chr9
110043918
110045917
-0.004855
0.19057
RPA1
chr17
1731496
1733495
-0.0354298
0.0917978
RPA2
chr1
28240758
28242757
-0.0766177
0.00466714
RPA3
chr7
7757739
7759738
0.0380316
0.228663
XPA
chr9
100459140
100461139
-0.103974
0.0893749
XPC
chr3
14219784
14221783
-0.0396764
0.239385
Table 4.2 Differential methylation for promoter regions of NER genes in the Low: Low pair
*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region
#
combination of p-values for all CpG sites assessed in the given region
@
number of CpG sites assessed for the given region

num.sites@
10
14
6
7
5
7
8
11
5
16
12
9
16
9
10
4
13
2
5
14
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Table 4.3 Gene-level differential methylation of NER genes in the High: Low pair

Gene
CCNH
CDK7
DDB1
DDB2
ERCC1
ERCC2
ERCC3
ERCC4
ERCC5
ERCC6
ERCC8
GTF2H2C
GTF2H3
GTF2H4
RAD23B
RPA1
RPA2
RPA3
XPA
XPC

Gene region genomic co-ordinates
Chromosome
Start
End
chr5
86687311
86708836
chr5
68530668
68573250
chr11
61066923
61110068
chr11
47236493
47260767
chr19
45910591
45982086
chr19
45853095
45874176
chr2
128014866
128051752
chr16
14014014
14046202
chr13
103497194
103528345
chr10
50663414
50747584
chr5
60169658
60240900
chr5
68856035
68890550
chr12
124118375
124147153
chr6
30875961
30881883
chr9
110045418
110094475
chr17
1732996
1803376
chr1
28218035
28241257
chr7
7676149
7758238
chr9
100437191
100459639
chr3
14186647
14220283

mean.mean.diff*
(NTAL47-BTL47)
-0.0042224
0.00422781
0.00106784
0.0557286
0.00650957
-0.0083965
-0.0081726
-0.0028404
0.00800953
0.0019062
0.0243352
-0.0065665
-0.004625
0.0209659
0.00581346
0.0171036
0.0607131
-0.0030753
0.11686
-0.0153689

*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region
#
combination of p-values for all CpG sites assessed in the given region
@
number of CpG sites assessed for the given region

comb.p.val#
0.337844
0.126131
0.0328631
0.12335
0.0565207
0.259075
0.079543
0.118672
0.171167
0.0532732
0.0647655
0.287731
0.0577503
0.0388729
0.146832
0.0875882
0.171105
0.2402
0.0480386
0.11767

num.sites@
12
10
49
12
74
24
9
22
26
41
15
8
12
51
17
44
7
26
4
26
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4.3.1.5 Gene-level methylation for the Low: Low pair showed 10 genes to be significantly
differentially methylated among JL-NTAL37 and JL-BTL37
Gene-level methylation for the Low: Low pair showed some interesting results. A
total of 10 genes were found to be significantly differentially methylated between JLNTAL37 and JL-BTL37. Among the significant genes, DDB1 (p = .01), DDB2 (p = .03),
RAD23B (p = .047) and RPA1 (p = .02) had higher mean of mean methylation on
assessed CpG sites in JL-NTAL37 than JL-BTL37 (indicated by a positive
mean.mean.diff value in Table 4.4). However, for ERCC1 (p = .045), ERCC3 (p = .01),
ERCC4 (p = .02), ERCC6 (p = .035), GTF2H3 (p = .03), GTF2H4 (p = .001), mean of
mean methylation on assessed CpG sites in JL-NTAL37 was lower than that of JLBTL37 (indicated by a negative mean.mean.diff value in Table 4.4).
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Table 4.4 Gene-level differential methylation for of NER genes in the Low: Low pair

Gene
CCNH
CDK7
DDB1
DDB2
ERCC1
ERCC2
ERCC3
ERCC4
ERCC5
ERCC6
ERCC8
GTF2H2C
GTF2H3
GTF2H4
RAD23B
RPA1
RPA2
RPA3
XPA
XPC

Gene region genomic co-ordinates
Chromosome
Start
End
chr5
86687311
86708836
chr5
68530668
68573250
chr11
61066923
61110068
chr11
47236493
47260767
chr19
45910591
45982086
chr19
45853095
45874176
chr2
128014866
128051752
chr16
14014014
14046202
chr13
103497194
103528345
chr10
50663414
50747584
chr5
60169658
60240900
chr5
68856035
68890550
chr12
124118375
124147153
chr6
30875961
30881883
chr9
110045418
110094475
chr17
1732996
1803376
chr1
28218035
28241257
chr7
7676149
7758238
chr9
100437191
100459639
chr3
14186647
14220283

mean.mean.diff*
NTAL37-BTL37
-0.0293
0.0200
0.0041
0.0244
-0.0165
-0.0189
-0.0026
-0.0288
0.0106
-0.0261
0.0214
0.0090
-0.0583
-0.0351
0.0158
0.0043
0.0425
-0.0230
0.0019
-0.0542

*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region
#
combination of p-values for all CpG sites assessed in the given region
@
number of CpG sites assessed for the given region

comb.p.val#
0.0852
0.2729
0.0123
0.0307
0.0446
0.2044
0.0106
0.0206
0.2154
0.0346
0.2600
0.2034
0.0258
0.0016
0.0474
0.0224
0.1071
0.1341
0.7326
0.0572

num.sites@
12
10
49
12
74
24
9
22
26
41
15
8
12
51
17
44
7
26
4
26
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4.3.1.6 CpG Island-level methylation level showed none of the genes significantly
differentially methylated between the High: Low pair
Upon looking at CpG-island level methylation, none of the 20 NER genes stood
out significantly differentially methylated in the High: Low pair, JL NTAL-47 and JL
BTL-47 (Table 4.5).
4.3.1.7 CpG Island-level methylation level showed 3 genes significantly differentially
methylated in the Low: Low pair
CpG Island-level methylation was assessed for NER genes in both pairs using
RnBeads. However, in the Low: Low pair, 3 genes showed significant differential
methylation between JL-NTAL37 and JL-BTL37. DDB2 was significant at p = .04,
where the mean of mean methylation values of CpG sites assessed in the given region
was higher in JL-NTAL37 than in JL-BTL37. The other two genes, GTF2H4 and RPA2,
were significant each at p = .0007 and p = .03 respectively and the mean of mean
methylation values for CpG sites assessed in the region was lower for both genes in JLNTAL37 than in JL-BTL37 (Table 4.6)
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Table 4.5 Differential methylation at the CpG Island-level in the High: Low pair
Gene
CCNH
CDK7
DDB1
DDB2
ERCC1
ERCC1
ERCC2
ERCC2
ERCC3
ERCC4
ERCC5
ERCC6
ERCC8
GTF2H2C
GTF2H3
GTF2H4
GTF2H4
RAD23B
RPA1
RPA2
RPA3
XPA
XPC

CpG Island genomic co-ordinates
Chromosome
Start
End
chr5
86708297
86708878
chr5
68530598
68531001
chr11
61100074
61100972
chr11
47236405
47236933
chr19
45931688
45932295
chr19
45926662
45927191
chr19
45866931
45867362
chr19
45873340
45874033
chr2
128051348
128051857
chr16
14013752
14014295
chr13
103498101
103498763
chr10
50746635
50747329
chr5
60240780
60241490
chr5
68855810
68856161
chr12
124118098
124118479
chr6
30881534
30882296
chr6
30875643
30875957
chr9
110045113
110046303
chr17
1799542
1799756
chr1
28240585
28241535
chr7
7679841
7680679
chr9
100459097
100459775
chr3
14219716
14220408

id$
6834
6729
14389
14303
24107
24106
24098
24099
3354
19081
16786
13027
6700
6734
16159
7908
7907
12030
20154
744
9200
11975
4254

region id; *mean of the mean values of differences in b-values for all the CpG sites assessed in the given region;
combination of p-values for all CpG sites assessed in the given region; @number of CpG sites assessed for the given region

$
#

mean.mean.diff*
NTAL47-BTL47
-0.0008
0.0005
0.0002
-0.0020
-0.0078
0.0004
-0.0091
0.0031
0.0066
0.0054
0.0038
0.0019
0.0001
0.0024
0.0025
0.0193
0.0091
0.0044
-0.0104
-0.0262
0.0014
-0.0012
-0.0012

comb.p.val
0.3511
0.5706
0.5536
0.3735
0.1825
0.4399
0.2932
0.4013
0.2494
0.3769
0.6164
0.2792
0.4497
0.3574
0.3639
0.0751
0.3200
0.2330
0.0739
0.1108
0.4112
0.7527
0.3853

num.sites
5
8
9
3
3
8
4
7
5
6
6
8
8
7
11
24
3
9
3
11
9
1
11
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Table 4.6 Differential methylation at the CpG Island-level in the High: Low pair
Gene
CCNH
CDK7
DDB1
DDB2
ERCC1
ERCC1
ERCC2
ERCC2
ERCC3
ERCC4
ERCC5
ERCC6
ERCC8
GTF2H2C
GTF2H3
GTF2H4
GTF2H4
RAD23B
RPA1
RPA2
RPA3
XPA
XPC

CpG Island genomic co-ordinates
Chromosome
Start
End
chr5
86708297
86708878
chr5
68530598
68531001
chr11
61100074
61100972
chr11
47236405
47236933
chr19
45931688
45932295
chr19
45926662
45927191
chr19
45866931
45867362
chr19
45873340
45874033
chr2
128051348
128051857
chr16
14013752
14014295
chr13
103498101
103498763
chr10
50746635
50747329
chr5
60240780
60241490
chr5
68855810
68856161
chr12
124118098
124118479
chr6
30881534
30882296
chr6
30875643
30875957
chr9
110045113
110046303
chr17
1799542
1799756
chr1
28240585
28241535
chr7
7679841
7680679
chr9
100459097
100459775
chr3
14219716
14220408

id

$

6834
6729
14389
14303
24107
24106
24098
24099
3354
19081
16786
13027
6700
6734
16159
7908
7907
12030
20154
744
9200
11975
4254

region id; *mean of the mean values of differences in b-values for all the CpG sites assessed in the given region;
combination of p-values for all CpG sites assessed in the given region; @number of CpG sites assessed for the given region

$
#

mean.mean.diff*
NTAL37-BTL37
-0.0001
0.0023
0.0004
0.0855
-0.0090
-0.0014
-0.0169
-0.0006
-0.0053
0.0013
0.0017
-0.0014
-0.0057
-0.0001
-0.0021
-0.1488
-0.0094
-0.0049
-0.0184
-0.0018
-0.0043
0.0033
-0.0003

comb.p.val#
0.2629
0.3060
0.3330
0.0395
0.1610
0.5920
0.1876
0.3069
0.3372
0.3308
0.3801
0.5462
0.4389
0.3713
0.3059
0.0007
0.1418
0.1731
0.0722
0.0289
0.4911
0.3537
0.4203

num.sites@
5
8
9
3
3
8
4
7
5
6
6
8
8
7
11
24
3
9
3
11
9
1
11
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4.3.1.8 Correlation between log gene expression and methylation values at the promoter
level showed a strong correlation for CDK7, GTF2H2 and XPC, but this correlation was
not significant.
In order to ascertain if methylation was the reason we were seeing gene
expression patterns of our 20 NER in the two pairs assessed and the normal breast line as
well, correlation coefficients (R2) were calculated using Microsoft Excel’s ‘CORREL’
function for log gene expression values obtained via RNA sequencing and the averages
of b-values for methylation via the Methylation EPIC array for all the lines assessed. R2
values range from -1 to 1, where 0 means no correlation between the two parameters
being studied, 1 means perfect positive correlation and -1 means perfect inverse
correlation among the parameters being studied (gene expression and methylation in our
case). The ideal expected outcome, if methylation was indeed the mechanism of
regulation of expression of the 20 NER genes in our cell lines, would be an inverse
correlation. This would mean higher methylation indicates a lower gene expression and
vice versa. A value above 0.7 for direct correlation, or below 0.7 for inverse correlation is
used as a threshold in literature.
Correlation of gene expression with methylation at the promoter level showed 2
genes with an R2 value above 0.7 (for direct correlation), namely CDK7 (R2 = 0.72) and
GTF2H2 (R2 = 0.85). Only one gene showed an R2 below -0.7 (meaning inverse
correlation), which was XPC with an R2 = -0.83 (Table 4.7). For the 3 genes above that
showed high correlation among its gene expression and methylation at the promoter
level, we calculated significance of this correlation by running linear regression for the
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two variables. It was found that none of the correlations for either CDK7 (p = .17),
GTF2H2 (p = .07) or XPC (p = .08) were significant.
4.3.1.9 Correlation between log gene expression and methylation values at the gene level
showed a strong correlation for ERCC8, but this correlation was not significant.
When correlation coefficients were calculated to see if methylation at the gene
level for the 20 NER genes correlated with log gene expression, we found one gene,
ERCC8, that had a R2 of 0.76 (Table 4.8). However, upon checking for significance of
this correlation coefficient using linear regression, it was not found to be significantly
correlated (p = .14).
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Table 4.7 Correlation between Log gene expression values and b-values for
methylation for promoter regions of the 20 NER genes for all groups. Groups
consisted of replicates of all cell lines assessed. Positive values indicate a positive
correlation between gene expression and methylation. Negative values indicate an inverse
correlation between gene expression and methylation. Rows highlighted in read indicate a
correlation above 0.7 or below -0.7. None of the correlation coefficients in red were
significant a=0.05 based on logistic regression run for those genes, namely CDK7,
GTF2H3 and XPC.

CCNH

R2
(Log Gene expression vs Promoterlevel methylation)
-0.63

CDK7

0.72

DDB1

0.02

DDB2

-0.32

ERCC1

0.65

ERCC2

0.48

ERCC3

0.19

ERCC4

-0.23

ERCC5

0.23

ERCC6

0.03

ERCC8

0.40

GTF2H2

0.85

GTF2H3

0.00

GTF2H4

0.32

RAD23B

0.31

RPA1

0.39

RPA2

0.13

RPA3

0.44

XPA

0.51

XPC

-0.83

Gene
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Table 4.8 Correlation between log gene expression values and b-values for gene-level
methylation for the 20 NER genes for all groups. Groups consisted of replicates of all
cell lines assessed. Positive values indicate a positive correlation between gene
expression and methylation. Negative values indicate an inverse correlation between gene
expression and methylation. Rows highlighted in read indicate a correlation above 0.7 or
below -0.7. The correlation coefficient in red for ERCC8 was not significant based on
logistic regression at a=0.05.
Gene

R2
(Log Gene expression vs Gene level
methylation)

CCNH

0.14

CDK7

-0.33

DDB1

0.16

DDB2

0.25

ERCC1

0.49

ERCC2

0.32

ERCC3

0.02

ERCC4

-0.11

ERCC5

-0.14

ERCC6

0.42

ERCC8

0.76

GTF2H2

-0.08

GTF2H3

0.21

GTF2H4

-0.28

RAD23B

-0.22

RPA1

0.53

RPA2

-0.29

RPA3

-0.06

XPA

-0.02

XPC

-0.34
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4.3.1.10 Correlation between log gene expression and methylation values at the CpG
island level showed a strong correlation for XPC, but this correlation was not significant.
Lastly, we also ran correlations between log gene expression values and
methylation values at the CpG-island level for the 20 NER genes. We found that XPC
had a correlation coefficient below -0.7, indicating a good inverse correlation, as would
be expected between gene expression and methylation (Table 4.9). However, in spite of
an R2 of -0.74, this correlation for XPC was not found to be significant via linear
regression (p = .15).
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Table 4.9 Correlation between log gene expression values and b-values for CpG
island-level methylation for the 20 NER genes for all groups. Groups consisted of
replicates of all cell lines assessed. Groups consisted of replicates of all cell lines
assessed. Positive values indicate a positive correlation between gene expression and
methylation. Negative values indicate an inverse correlation between gene expression and
methylation. Rows highlighted in read indicate a correlation above 0.7 or below -0.7. The
correlation coefficient in red for XPC was not significant based on logistic regression at
a=0.05.

Gene
CCNH

R2
(Log Gene expression vs CpG Island-level
methylation)
-0.30

CDK7

0.19

DDB1

0.17

DDB2

0.53

ERCC1

0.20

ERCC2

0.60

ERCC3

0.46

ERCC4

0.68

ERCC5

-0.58

ERCC6

0.54

ERCC8

0.01

GTF2H2

0.62

GTF2H3

0.65

GTF2H4

-0.25

RAD23B

0.44

RPA1

-0.13

RPA2

0.24

RPA3

0.25

XPA

-0.69

XPC

-0.74
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4.3.2 Variant calling using SAMtools on RNA sequencing data
4.3.2.1 Number of variants detected in all lines
We first looked at consensus on single nucleotide variants from the 3 aligners,
GSNAP, HISAT and BWA-MEM, we chose, and then also looked at consensus for the
variants among replicates of each line that was run using RNA sequencing. These data
are summarized in Table 4.10. A number of NER genes showed single nucleotide
variants in all the 6 lines assessed, including the normal breast line and the foreskin
fibroblast lines. The total number of single nucleotide variants detected in the NER genes
for each line did not seem to follow any particular pattern. Therefore, we explored the
variants in our High: Low and Low: Low pairs further to focus on shared variants, and to
the variants coinciding with a low NER signature.
Table 4.10 Total number of single nucleotide variants per sample group in NER
genes
Cell line

No. of
variants
detected

Genes Involved

JL-BTL37

30

RPA2, ERCC6, GTF2H3, ERCC5, ERCC4,
RPA1, ERCC2, ERCC1, XPC, RAD23B

JL-NTAL37

32

ERCC1, ERCC2, ERCC3, ERCC4, ERCC5,
ERCC6, GTF2H3, XPC, RAD23B

JL-BTL47

19

RPA2, ERCC6, GTF2H3, ERCC5, RPA1,
ERCC2, ERCC1, RAD23B

JL-NTAL47

34

ERCC1, ERCC2, ERCC3, ERCC4, ERCC5,
ERCC6, ERCC8, DDB1, DDB2, CDK7,
RAD23B, XPC, RPA1

JL-BRL6

24

ERCC1, ERCC4, ERCC5, ERCC6, ERCC8,
XPC, GTF2H3

FF

25

RPA2, ERCC6, GTF2H3, ERCC5, ERCC4,
RPA1, ERCC1, XPC
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4.3.2.2 Variant calling and Venn diagram construction for single nucleotide variants in
cell lines of the Low: Low pair revealed 24 shared variants
To address our major hypothesis of finding shared alterations between the cell
line pairs where the NER capacity was shared, we explored shared single nucleotide
variants between the tumor and the NTA line of our Low: Low pair, JL-BTL37 and JLNTAL37. The Low: Low pair showed 24 shared single nucleotide variants (Figure 4.3).
Upon taking a look at the variants that were shared, except for 3 variants that represented
intron indels, all the others were also found as known single nucleotide polymorphisms in
the dbSNP database. The genes that these variants were found, along with their
association to clinical conditions/response to treatment with certain therapeutic agents are
listed in Table 4.11.
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Figure 4.3 Venn diagram for variants shared between JL-BTL37 and JL-NTAL37, the
Low: Low pair. The area of interest in this Venn diagram is the olive-green section in the
center of the diagram that represents shared variants between JL-NTAL37 and JL-BTL37 (24).
The light green section shows number of variants that are unique to JL-NTAL37 (8), whereas
the pick section shows number of variants unique to JL-BTL37 (6).
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Gene

No. of
variants

No. of
known
variants

Variants
Zygosity of the
Clinical
causing variants causing
association of
AA change
AA change
variants with AA
change

ERCC6

3

3

1
(rs4253072)

Homozygous

-

ERCC5

5

4

2
(rs9514066;
rs9514067)

Both homozygous
(BIVM-ERCC5
fusion protein)

-

ERCC4

1

1

0

-

RPA1

5

5

1
(rs5030755)

Heterozygous

rs5030740-altered
pre-menopausal
breast cancer risk (J.
Han et al., 2009)

ERCC2

5

4

1
(rs13181)

Homozygous
(rs13181)

rs13181- XP, NSC
lung cancer, triple
negative breast
cancer,
osteosarcoma

Other

rs1047768 – platinum-based chemo response
(Landrum et al., 2017; NCBI, 2016a)

rs4781563-alters miR-2355-3p binding (Mi et
al., 2014)

rs1052555-platinum-based chemo response;
rs238406-XP increased toxicity with
platinum-based chemo in NSC lung cancer;
increased bladder cancer risk; predisposition
to head/neck & breast cancer
(Landrum et al., 2017; Malats, 2008; Amit
Kumar Mitra et al., 2009; NCBI, 2016b,
2016d, 2016h; Smolarz et al., 2014; W. Wu et
al., 2009)
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ERCC1

2

1

0

-

rs3212986-platinum-based chemo response
(Landrum et al., 2017; NCBI, 2016g)

XPC

2

2

0

-

rs2228001-platinum-based chemo response,
cardiomyopathy, XP
(Landrum et al., 2017; NCBI, 2016e)

RAD23B

1

1

0

-

-

Table 4.11 Characteristics of the shared single nucleotide variants between the Low: Low pair of cell lines and their association with
disease or clinical outcome studied in literature.
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Most of these variants, identified in the dbSNP database as known single
nucleotide polymorphisms, were associated with an altered response to platinum-based
chemotherapeutic agents like cisplatin (variants in ERCC1, ERCC2, ERCC5 and XPC)
(Landrum et al., 2017). One known variant in RPA1, rs5030740, has been shown to have
altered risk of breast cancer in pre-menopausal women (J. Han et al., 2009). Also, the
variant in ERCC4 (rs4781563) has been implicated to alter the binding of a microRNA,
miR-2355-3p (Mi et al., 2014).
Among the 24 variants found, 3 variants were unknown, and were a result of an
insertion/deletion or indel in the sequence of the particular gene. One of those indels was
in a gene BIVM-ERCC5 readthrough, that codes for a fusion protein which has sequence
similarity to proteins coded by both genes individually (NCBI(Gene), 2018). The second
indel was in the 3p-UTR region of ERCC2, which also lies in the exon for another gene
KLC3. The third indel was in the 3p-UTR of ERCC1 but was also in the exon of a gene
CD3EAP.
We also looked at the variants that were not shared within the Low: Low pair of
cell lines. 6 variants were seen exclusively in the tumor line JL BTL-37, out of which 5
were known from the dbSNP database. However, only one of these six variants (in
GTF2H3) was predicted to produce an amino acid change and had a heterozygous
genotype (Table 4.12). The one unknown variant was seen GTF2H3 which was a single
nucleotide change from A to G with a heterozygous genotype, but with no amino acid
change predicted. However, this unknown variant checked for its location in the
consensus coding sequence (CCDS) database via the UCSC Genome browser and was
found in the 3’ UTR region of GTF2H3.
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There were 8 variants exclusively in JL NTAL-37 that were not shared with JL
BTL-37, and all of them were known through the dbSNP database. Out of those, one
variant in ERCC2 showed an amino acid change and has been shown to have
implications in XP, response to platinum-based chemotherapy and susceptibility to
certain cancers (Table 4.13).
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Table 4.12 Characteristics of the single nucleotide variants the tumor line of the Low: Low pair, JL BTL-37, that are not
shared with the NTA line, JL NTAL-37, and their association with disease or clinical outcome studied in literature.
Gene

No. of
variants

No. of
known
variants

Variants
causing AA
change

Zygosity of the variants
causing AA change

Other

-

Clinical
association of
variants with
AA change
-

ERCC4

1

1

-

ERCC5

1

1

-

-

-

1

-

-

-

1
1

1 (rs1051793)
-

Heterozygous
-

-

rs2296147: XP; altered response
to platinum-based chemotherapy
in gastric cancer and lung
cancer; colorectal cancer; XP
(Landrum et al., 2017)
rs147228327: Cockayne
Syndrome; Macular
Degeneration; Cerebro-oculofacio-skeletal
Syndrome(Landrum et al., 2017)
-

ERCC6

1

GTF2H3
RPA2

2
1

rs3743538: XP
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Table 4.13 Characteristics of the single nucleotide variants the NTA line of the Low: Low pair, JL NTAL-37, that are not shared with the
tumor line, JL BTL-37, and their association with disease or clinical outcome studied in literature.
Gene

No. of
variants

No. of
known
variants

Variants
causing AA
change

ERCC1

1

1

-

Zygosity of the
variants
causing AA
change
-

ERCC2

1

1

1 (rs1799793)

Homozygous

ERCC3

1

1

-

ERCC4

2

2

-

Clinical association of
variants with AA change

Other

-

-

-

XP; certain alleles alter
response to platinum based
chemotherapy in TNBC
and NSCLC; increased
susceptibility to glioma in
Asian population; high risk
of breast cancer for certain
alleles; increased risk of
prostate cancer (Agalliu et
al., 2010; B. H. Fu et al.,
2017; Hardi et al., 2018; C.
Li et al., 2006; J. Lu et al.,
2015; Qian, Zhang, Qian,
He, & Li, 2017)
-

-

-

rs2276464:XP; rs1799801:
XP, increased toxicity to
platinum based
chemotherapy; reduced
cancer risk in a Caucasian
population study (T.-Y.

-
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GTF2H3

1

1

-

-

-

XPC

2

2

-

-

-

Shi et al., 2012; Y. Zheng
et al., 2017) (Landrum et
al., 2017)
rs1126549: XP;
Cardiomyopathy
(Landrum et al., 2017)
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4.3.2.3 Variant calling and Venn diagram construction for single nucleotide variants in
cell lines of the High: Low pair revealed 11 shared variants
Variant calling on the High: Low pair and subsequent Venn diagrams revealed the
presence of 11 shared variants overlapping the 20 NER genes (Figure 4.4), the
characteristics of which are described in Table 4.14. Among these, 10 were known
variants from the dbSNP database. Among the 10 known variants, 4 variants were
predicted to have a downstream amino acid change, and these were found in ERCC1,
ERCC5 (2) and ERCC6. The two variants in ERCC5 and one in ERCC6 were both
homozygous and the one in ERCC1 had a heterozygous genotype.
Our High: Low pair showed the case where NER capacity was not shared
between the tumor line and the NTA line. Therefore, we were interested in looking at
variants that are exclusive to JL-BTL47, and not present in JL-NTAL47. A total of 8
variants were discovered in some of the NER genes, as show in Figure 4.4 and listed in
Table 4.11. Among the 8 variants that were found, only 1 was an unknown variant
resulting from an indel in the 3’-UTR region of RPA1 but was not predicted to cause a
downstream amino acid change. Out of the remaining 7 known variants, none were
predicted to cause a downstream amino acid change. The variants in XPG/ERCC5
showed evidence in literature for an altered response to platinum-based chemotherapy
and were also implicated in numerous studies for lung cancer, colorectal cancer and
gastric/esophageal cancer. One variant in XPD/ERCC2 was also implicated in an altered
response to, and increase in toxicity after, platinum-based chemotherapy administration
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in lung cancer and colorectal cancer and has been associated with an increased bladder
cancer risk (Table 4.11).
We also looked at the variants exclusively in JL NTAL-47 that are not shared in
JL BTL-47. A total of 23 variants were seen only in JL NTAL-47, that were not shared
with JL BTL-47. Out of these, 5 variants showed an amino acid (AA) change, and these
were the variants in ERCC2, ERCC5 (2), CDK7 and RAD23B. 4 out of 5 of these
variants had a heterozygous genotype and one in ERCC5 had a homozygous genotype,
which was associated with an increased risk for a number of cancer types. (Table 4.12)
It is notable that among the variants listed in Table 4.11 and 4.15, two variants
stood out common to a low NER signature. They were rs1047768 in XPG/ERCC5 and
rs238406 in XPD/ERCC2.
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Figure 4.4 Venn diagram showing variant distribution in the High: Low pair of cell lines,
JL-NTAL47 and JL-BTL47. The area of interest in this diagram is the red section, which
denotes variants unique to JL-BTL47 and not shared with JL-NTAL47, possibly characterizing
a low NER phenotype (8). The light green section denotes variants unique to JL-NTAL47 (23)
and the yellow section in the middle denotes variants shared between JL-BTL47 and JLNTAL47 (11).
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Table 4.14 Characteristics of the shared single nucleotide variants between the High: Low pair of cell lines, JL NTAL-47 and
JL BTL-47 and their association with disease or clinical outcome studied in literature.
Gene

No. of
variants

No. of
known
variants

Variants
causing AA
change

Clinical association of
variants with AA change

Other

-

Zygosity of
the variants
causing AA
change
-

ERCC2

1

1

-

-

ERCC5

3

3

2 (rs9514066;
rs9514067)

Both
homozygous

4

4

1 (rs4253072) Homozygous

rs9514067: XP (NCBI,
2016f; Shiomi et al., 2004);
rs1047768 – platinum-based
chemo response (Landrum et
al., 2017; NCBI, 2016a)
-

ERCC6

ERCC1

2

1

1 (rs3212986) Heterozygous

GTF2H3

1

1

-

-

rs32129686: higher
nephrotoxicity with
platinum-based
chemotherapy for certain
amino acid substitutions at
this locus (Khrunin,
Moisseev, Gorbunova, &
Limborska, 2010)
-

rs2228524: XP,
macular degeneration,
Cerebro-oculo-facioskeletal Syndrome
(Landrum et al., 2017;
NCBI, 2016c)
-

-
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Table 4.15 Characteristics of the single nucleotide variants the tumor line of the High: Low pair, JL BTL-47, but not in the
NTA line, JL NTAL-47, and their association with disease or clinical outcome studied in literature.

No. of
variants

No. of
known
variants

ERCC6

1

1

-

-

ERCC5

2

2

-

-

RPA1

2

1

-

-

rs12727- altered pre-menopausal breast cancer risk
(J. Han et al., 2009)

RPA2

1

1

-

-

rs7356- rectal cancer
(Naccarati et al., 2012)

ERCC2

1

1

-

-

rs238406 – XP; increased toxicity with platinum-based chemo
in NSC lung cancer and colorectal cancer; increased bladder
cancer risk (Kweekel et al., 2009; Malats, 2008; NCBI, 2016i;
W. Wu et al., 2009)

RAD23B

1

1

-

-

-

Gene

Variants
causing AA
change

Clinical association
of variants with AA
change

Other

rs1047768 – platinum-based chemo response
rs2296147 – altered response to platinum-based chemotherapy
in gastric cancer and lung cancer; colorectal cancer; XP
(Landrum et al., 2017; NCBI, 2016a, 2016j)

Table 4. 16 Characteristics of the single nucleotide variants the NTA line of the High: Low pair, JL NTAL-47, but not in the
tumor line, JL BTL-47, and their association with disease or clinical outcome studied in literature.

201

Gene

No. of
variants

Variants
causing AA
change
1 (rs13181)

Zygosity of the
variants causing
AA change
Heterozygous

Clinical association
of variants with AA
change
rs13181- XP, NSC
lung cancer, triple
negative breast
cancer,
osteosarcoma

Other

2

No. of
known
variants
2

ERCC2

ERCC3

2

2

-

-

-

-

ERCC4

1

1

-

-

-

ERCC5

3

3

2
(rs144208043;
rs17655)

rs144208043:
Heterozygous;
rs17655:
Homozygous

ERCC6

2

2

-

-

rs144208043: XP
(Bodian et al.,
2014); rs17655:
increased risk of
gastric, lung,
colorectal and
cervical cancer (Joo
et al., 2016; Y.
Liang, Deng, Xiong,
Wang, & Xiong,
2014; Yong Zeng,
Wei, Wang, & Liu,
2015; J. Zhao et al.,
2018)
-

rs1799801: XP; increased
toxicity to platinum based
chemotherapy; reduced cancer
risk in a Caucasian population
study (T.-Y. Shi et al., 2012;
Y. Zheng et al., 2017)
-

rs1052555: poor overall
survival and progression freesurvival with a specific allele
in non-small cell lung cancer
(Tan et al., 2017)

rs147228327: Cockayne
Syndrome; Macular
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Gene

No. of
variants

No. of
known
variants

Variants
causing AA
change

Zygosity of the
variants causing
AA change

ERCC8

1

1

-

-

Clinical association Other
of variants with AA
change
Degeneration; Cerebro-oculofacio-skeletal Syndrome
(Landrum et al., 2017)
rs3117: Cockayne Syndrome

DDB1

1

1

-

-

-

-

DDB2

2

2

-

-

-

rs4647760: XP

RPA1

4

4

-

-

-

CDK7

1

1

Heterozygous

-

RAD23B

2

2

1
(rs34584424)
1 (rs1805329)

rs5030740: altered premenopausal breast cancer risk
(J. Han et al., 2009)
-

Heterozygous

-

XPC

1

1

-

-

rs1895329:
significantly
associated with
breast cancer risk in
Puerto Rican women
(Pérez-Mayoral et
al., 2013)
-

GTF2H3

1

-

-

-

-

-

-
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4.4 Discussion
There is a general consensus in literature that genomes of tumor cells are found to
be globally hypomethylated, which is mostly due to the demethylation of repeated
elements and retro transposons that form almost half of the human genome (Deng et al.,
2006; M Ehrlich, 2006; Melanie Ehrlich, 2009; Feinberg & Vogelstein, 1983; Gaudet et
al., 2003). We also distinctly saw this observation in our methylation distributions in the
box whisker plot in Figure 4.3, thus making our observations consistent with those seen
in cancer. Overall, most NER genes showed no correlation between gene expression and
methylation. The ones that showed strong correlations were not correlated significantly
(Table 4.7, 4.8 and 4.9). For differential methylation between the cell lines of each pair,
we saw differential methylation for 3 genes on the promoter level (Table 4.2) and10
genes on the gene-level (Table 4.4) between JL BTL-37 and JL NTAL-37 of the Low:
Low pair, whereas there was no difference in their gene expression by RNA sequencing.
Also, differential methylation for the High: Low pair at the promoter level showed 2
differentially expressed genes, DDB1 and ERCC5. However, gene expression for ERCC5
showed no difference between JL BTL-47 and JL NTAL-47 of the High: Low pair.
DDB1 stood out as differentially methylated in both promoter level and gene level
methylation for Low: Low as well as High: Low pair. Taking into consideration the
paradigm of promoter methylation leading to gene silencing, we were seeing the opposite
effect, where methylation was relatively higher in the NTA line of the High: Low pair,
JL-NTAL47, than the tumor line JL-BTL47. This finding does not conform to its
expression levels, where DDB1 expression is lower in JL-BTL47 than in JL-NTAL 47
(Figure 3.11B). We therefore believe the effect we observed might be the result of the
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methylation of a repressor binding site on the promoter region of DDB1. Repressors are
transcription factor proteins that bind to specific regions on DNA called silencers and
negatively regulate gene expression (Maston, Evans, & Green, 2006). Methylation of
these binding sites can inhibit the binding of these repressors, wherein an increase in
transcription of the gene would be the result (Medvedeva et al., 2014). We did a brief
survey on possible transcription factors binding to the DDB1 promoter region using the
UCSC Genome browser, where we used the ENCODE regulation track to look for
chromatin immunoprecipitation or ChIP-seq-validated binding sites for transcription
factors, and this is shown in Figure 4.5. The transcription start site for DDB1 is at the coordinate chr11:61109938-61109939, as obtained from the UCSC Table browser’s
SwitchGear TSS track under ‘Regulation’ for the human genome assembly hg19.
Among the transcription factors indicated by the red arrow in Figure 4.5, there
were 18 factors found to bind the promoter of DDB1 that are known repressors. These are
ZNF274 (O'Leary et al., 2015; Yano et al., 2000), CBX3 (UniProt_Consortium, 2018),
RCOR1 which is a repressor for neuron-specific genes in non-neuronal cells
(UniProt_Consortium, 2018), IRF1 (Nguyen, Teskey, Lin, & Hiscott, 1999;
UniProt_Consortium, 2018; Xie et al., 2003), BCLAF1 (Kasof, Goyal, & White, 1999),
EP300 (Snowden, Anderson, Webster, & Perkins, 2000), TRIM28, also known as KAP-1
(Friedman et al., 1996), MAZ (Bossone, Asselin, Patel, & Marcu, 1992), SP1 (though
mostly an activator, has also been identified as a repressor) (Zaid, Hodny, Li, & Nelson,
2001), HDAC2-a major transcriptional repressor protein via histone deacetylation (Kong,
Fang, Li, Fang, & Xu, 2009; R. Liu et al., 2009), PML (N. Martin et al., 2012; Mu, Chin,
Liu, Lozano, & Chang, 1994; W.-S. Wu et al., 2001), ATF3 (B. Chen, Liang, Whelan, &
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Hai, 1994), REST (Chong et al., 1995; Lunyak et al., 2002; Mulligan et al., 2008), MAX
(Comino-Méndez et al., 2015; Hurlin et al., 1995), NR2F2 (K. Chu & Zingg, 1997),
ZBTB7A (C.-j. Liu et al., 2004), E2F-6 (Trimarchi et al., 1998) and CEBPB (Narayanan
et al., 2004; S.-H. Park et al., 2010). This suggests that the promoter region of DDB1 is a
highly regulated region having binding sites for multiple repressor proteins. This is an
interesting future direction that could be pursued, where repressor binding to NER genes
and the possible inhibition of their DNA binding ability due to methylation could be
studied further to explore the mechanisms of downregulation of the NER gene
expression.
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Figure 4.5 Map for the region assessed for promoter-level methylation of DDB1, based on the definition by RnBeads, obtained from the
UCSC Genome Browser. The pink arrow denotes the direction of transcription of DDB1. Grey and black horizontal bars under the track
‘Transcriptional Factor ChIP-seq from ENCODE with Factor Motifs’ denote the putative binding site for the respective DNA binding
transcription factor indicated on the left of each bar. Green spots on these gray/black horizontal bars indicate the sites with the highest score for
binding of that factor.
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The map for ERCC5, on the contrary, for the region that came up differentially
methylated among the High: Low pair, only one factor binding to the region. Moreover,
this region seemed to be rather an intronic segment for a fusion gene BIVM-ERCC1, that
codes for a fusion protein which retains structural similarity to proteins coded by both
these individual genes. It would be an interesting question as to why this region was
defined as the promoter region for ERCC5 by RnBeads, as we could not find a
transcription start site at this region using SwitchGear TSS track of the UCSC Genome
browser. The only transcription factor binding to this region, CTCF, is a zinc-finger
protein and also a known repressor of transcription (Figure 4.6).
CpG sites on genes are considered ‘mutation hotspots’ and this is due to the
cytosines and methylated cytosines being prone to spontaneous deamination, which leads
to uracil in case of cytosines, and thymine in case of methyl cytosines (Walsh & Xu,
2006). Now, presence of thymine is harder to detect as thymine is a usual component of
DNA. However, uracil is not found in DNA, and therefore is a major mutagenic event
which is repaired by the base excision repair pathway (Pearl, 2000; Wood, Mitchell,
Sgouros, & Lindahl, 2001). A good example of this is TP53, a gene frequently mutated in
tumors, as 49% of germline mutations and 24% of somatic mutations commonly known
in this gene are a G:C to A:T transition (Walsh & Xu, 2006). Also, gene-level
methylation showed differential methylation for 10 out of 20 NER genes in the Low:
Low pair, while only 3 were found to be differentially methylated between the High: Low
pair. A hypothesis that a low repair signature might be a methylation enabler could be
tested for in future studies. DNA repair has been shown to have a role in methylation
control, which might affect the changes in methylation patterns seen with the
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development of malignancy (Schär & Fritsch, 2011). It is possible that a low functional
repair capacity is unable to correct the aberrant methylation occurring in tumors, similar
to what we see in our Low: Low pair where we see a higher number of genes
differentially methylated than the High: Low pair. A normal repair capacity in the NTA
of the High: Low pair might help in maintaining the fidelity of methylation patterns, until
the DNA repair capacity is lost in its tumor. This interesting hypothesis could be tested
for in future studies.
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Figure 4.6 Map for the region assessed for promoter-level methylation of DDB1, based on the definition by RnBeads, obtained from the
UCSC Genome Browser. Grey horizontal bars under the track ‘Transcriptional Factor ChIP-seq from ENCODE with Factor Motifs’ denote the
putative binding site for the respective DNA binding transcription factor indicated on the left of each bar.
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Variant calling results on the pairs showed that there are more shared variants in
the Low: Low pair (24) than in the High: Low pair (11). This is consistent with our
expected observations and the known fact that a low repair capacity enables the
accumulation of mutations (Hanahan & Weinberg, 2000). The two variants in the NER
genes, which are also known SNP’s, that were common to a low NER capacity signature
(which means present in the Low: Low pair and in the tumor of the High: Low) were
seen in XPD/ERCC2 (rs238406) and in XPG/ERCC5 (rs1047768) (Table 4.11 and 4.15).
Both these variants have been studied in literature for having an association with an
altered response to platinum-based chemotherapeutic agents like cisplatin. However, no
change in amino acid was predicted to occur in the downstream protein composition of
XPD or XPG in any of these three lines that manifested a low DNA repair capacity, and
therefore is unlikely that these two variants might be behind the downregulation of the
NER pathway. An interesting observation in the Low: Low pair was the presence of one
variant, also a known SNP rs13181, in XPD/ERCC2 that has a homozygous genotype as
well as caused a downstream amino acid change in the XPD protein. This SNP has been
implicated in XP as well in associations with the risk of a number of cancer types,
including breast cancer (Table 4.11). It is possible that the low NER capacity in the Low:
Low pair (for this particular patient) could be a result of this variant if this were a true
XPD mutation. However, this is a known SNP with a minor allele frequency ranging
from 23.66% to 33.08% and therefore, a chance of this SNP being a mutation and causing
the observed low repair in the Low: Low pair is unlikely (dbSNP, 2017; Sherry et al.,
2001).
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Associations of SNPs with disease risks have shown conflicting results in the
literature, as these associations might just be statistical artifacts and their true biological
impact needs to be verified. For example, the aforementioned SNP in ERCC2 (rs13181),
which we have seen in our Low: Low pair, has been shown to reduce breast cancer risk
whereas patients the mutant genotype for this SNP have been associated with a lower
likelihood of hormone receptor positivity (J. Li et al., 2008). Another large study found
no association of 3 SNPs in ERCC2 with breast cancer risk (Kuschel et al., 2005).
Finally, yet another study on 321 patients and their age-matched controls did not show
any significant association of polymorphisms in XPC, XPD, XPG and XPF genes
(Jorgensen et al., 2007). Therefore, caution needs to be exercised while making decisions
to study these SNPs in terms of disease risk and its prediction.
4.5 Conclusion and Summary
Our study calls for further evaluation of mechanism of transcriptional regulation
of the NER pathway, as methylation or single nucleotide variation do not seem to
completely explain the downregulation seen in multiple NER genes along with a low
functional NER capacity. DDB1 was found to be a putative study subject for methylation
of its promoter region in our pairs, and the activity of repressors binding to this region
might explain the differential methylation we observed in our pairs. Treating these pairs
with 5-azacytidine and then measuring restoration of gene expression will help
understand if methylation is, in fact, the regulator at the promoter site of genes found
differentially methylated among our cell line pairs. Alternatively, future studies will
include the investigation of the role of small inhibitory non-coding RNA molecules,
called miRNAs, in the transcriptional regulation of NER. Previous studies in our group
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showed a putative miRNA candidate that regulates some of the genes in the NER
pathway using late stage cell lines and also showed a change in functional NER capacity
(As Sobeai, 2017). Future studies will involve miRNA profiling in these cell line pairs
and molecular studies to observe their effect on the regulation of transcription and
downstream function of the NER pathway in early stage lines and their matched NTA
lines.
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Chapter 5
Mutations in breast cancer and the construction of person-specific maps
of genetic alterations for breast tumorigenesis
5.1 Introduction
The somatic evolution of cancer is now well established, and numerous models
have been proposed explaining the progression of cancer. The earliest theories came from
rodent models which proposed only two stages of tumor development, initiation and
promotion (Berenblum & Shubik, 1947; Fujiki et al., 2013; Mottram, 1944). It was later
shown that cancer follows three major stages, tumor initiation, promotion and
progression. The specific events or mutations that lead to phenotypic transformation of
the cells from normal to malignant are deemed as driver events, and they mainly aim at
altering genomic stability. Loss of genomic stability is a hallmark of most cancers
(Hanahan & Weinberg, 2000). This in turn allows the accumulation of further somatic
mutations, known as passenger mutations or events, thus leading to the formation of a
full-blown tumor (Vogelstein et al., 2013).
Certain genetic models for carcinogenesis have laid the framework for delineating
the steps that the cells of a normal tissue undergo at the genetic level towards their
transformation to neoplasia. The earliest multistep model was established for colorectal
cancer by Vogelstein and colleagues in 1953 (Vogelstein & Kinzler, 1993). Similar
models were established for Barrett’s esophagus, a pre-malignant condition for
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esophageal carcinoma, and for breast cancer as well (Bieche & Lidereau, 1995; Gregson
et al., 2016). These models show the loss of function or altered function of important
tumor suppressor genes like TP53 and APC (Figure 2.13 and 2.14). Breast cancer, being
a heterogenous disease, does not always follow the linearity of steps mentioned in this
model. Moreover, the driver events are tumor- and individual- specific and therefore it is
difficult to have one conclusive model for mammary carcinogenesis.
The field cancerization theory showed the importance of studying the
histopathologically normal tissue adjacent to the tumor to find the changes that the tissue
undergoes during transformation (Heaphy et al., 2009; Rivenbark & Coleman, 2012;
Stern et al., 2002; Trujillo et al., 2011). Here, we chose to study possible mutations in the
coding regions of a list of genes known to play important roles in tumorigenesis,
especially of the breast, using RNA sequencing performed on our Low: Low and High:
Low pairs of early stage tumor lines and their matched non-tumor adjacent lines. Most of
the genes in their list were chosen as they have been shown (by ChIP-seq experiments) to
bind to the promoter regions of the 20 canonical NER genes based on Factorbook Motif’s
161 transcription factor binding sites database from the ENCODE Consortium. These
include E1F1, GABPA, E2F1, E2F4, E2F6, BRCA1, ELF1, YY1, MAX, USF1, SP1,
SP4, EGR1, RUNX3, MYC, PHF8, FOXA1, TEAD4, JUND, STAT1 and ZNF143. The
remainder of the genes in our list are important genes with respect to cancer, especially of
the breast. These genes, along with their functions are listed in Table 5.1. We therefore
aimed to establish a temporal scheme of alterations or our own “Vogelsteinogram” in
breast cancer.
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Table 5.1 List and functions of genes with their protein products evaluated for the presence of mutations by variant calling on
RNA sequencing data in the High: Low and the Low: Low pairs. * indicates the NER genes the respective protein has been found
to interact with as a transcription factor. This was based on the maps of 5’ ends for the NER genes obtained from the UCSC Genome
browser with ENCODE Factorbook Motif track denoting transcription factor binding sites based on validation from ChIP-seq
experiments. The gene and protein functions have been obtained from GeneCards, an online database (Safran et al., 2010), the entries
in which are based on the reference column.
Protein Name

Gene
Name

Function and role in cancer

HER2

ERBB2

p53

TP53

BRCA1

BRCA1

c-FOS

FOS

JUND

JUND

CHK1

CHEK1

CHK2

CHEK2

Belongs to Epidermal growth factor (EGF) family of
receptor tyrosine kinases. Found overexpressed in
20-30% of breast cancers, and mutations in this are
involved in breast tumorigenesis
Tumor suppressor protein frequently mutated in
cancers including breast cancer
Involved in double strand break repair, mutation
causes increase in breast cancer and ovarian cancer
risk
Nuclear phosphoprotein that forms a complex with
the JUN/AP-1 transcription factor complex.
Important in cell growth and differentiation; also, a
proto-oncogene
Component of the AP-1 transcription factor
complex; also, a proto-oncogene
Belongs to the Serine/Threonine protein kinase
family. Plays an important role in cell cycle arrest
for DNA damage repair. Found overexpressed in
breast cancer
Belongs to the Serine/Threonine protein kinase
family. Plays an important role in cell cycle arrest
for DNA damage repair. Found overexpressed in
breast cancer; mutations predispose to breast cancer

NER genes this protein
interacts with as a
transcription factor*
-

Reference

-

(Walerych, Napoli,
Collavin, & Del Sal, 2012)
(Antoniou et al., 2003;
Petrucelli, Daly, &
Feldman, 2010)
(Pandey, Liu, Cooper, &
Mulder, 2012)

CCNH, XPC
-

(Herter-Sprie, Greulich, &
Wong, 2013)

DDB1, RPA3, ERCC1,
RAD23B, ERCC1
-

(Caffarel et al., 2008)

-

(Z. Fan et al., 2018; Luo et
al., 2018)

(Al-Kaabi et al., 2015;
Albiges et al., 2014)
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Protein Name

Gene
Name

Function and role in cancer

p21; CDN1A

CDKN1A

EGR1

EGR1

p16; CDN2A

CDKN2A

RAD21

RAD21

PALB2;
FANCN

PALB2

RAD51C

RAD51C

ER ALPHA

ESR1

E2F1

E2F1

Inhibitor of cyclin dependent kinases; regulate cell
cycle and cell proliferation in response to DNA
damage. Mutations implicated in bladder cancer
Nuclear protein belonging to the C2H2 zinc finger
protein family of early growth receptors. Has a
tumor suppressor role and is a transcriptional
regulator
Inhibitor of cyclin dependent kinases CDK4 and
CDK6. Mutations are implicated in melanoma,
pancreatic cancer and breast cancer susceptibility
Nuclear phosphor-protein involved in double strand
break repair. Mutation in this gene causes Cornelia
de Lange syndrome
Partner and localizer of BRCA2; protein involved in
double strand break. Associated with Pancreatic
cancer and Fanconi Anemia
Involved in homologous recombination repair
pathway. Mutations have been associated with breast
and ovarian cancer, Fanconi Anemia
Proteins forming the estrogen receptor. Mutations
causes resistance to estrogen, thereby causing female
developmental abnormalities like delay in puberty,
osteoporosis and unfused epiphyses
Codes for the retinoblastoma-associated protein.
E2F family of transcription factors; important in cell
cycle regulation and the activity of tumor
suppressors. Mutation associated with
mesothelioma, colorectal cancer, diabetes mellitus
and Sjogren’s syndrome

NER genes this protein
interacts with as a
transcription factor*
-

Reference

DDB2, GTF2H3, ERCC6,
DDB1, GTF2H4, CCNH,
ERCC3, ERCC8,
RAD23B, ERCC1
-

(C. Liu, Rangnekar,
Adamson, & Mercola,
1998; Wei, Wu, Gong, &
Pei, 2017)
(Borg et al., 2000;
Dębniak et al., 2005)

-

(Deardorff et al., 2012)

-

(Jones et al., 2009)

-

(Meindl et al., 2010; J.-Y.
Park et al., 2014;
Thompson et al., 2012)
(Bernard et al., 2016;
Quaynor et al., 2013)

-

GTF2H3, DDB2,
GTF2H4, XPA, ERCC8,
CCNH, RAD23B

(Yang Liu &
Kwiatkowski, 2015)

(Lopes-Ramos et al.,
2017; Salam et al., 2004;
W. Yu et al., 2011)
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Protein Name

Gene
Name

Function and role in cancer

TERT

TERT

MYC

MYC

MAX

MAX

MAZ

MAZ

ELK1

ELK1

ELF1

ELF1

RUNX3

RUNX3

Codes for the reverse transcriptase component of
telomerase enzyme which maintains telomere
length. Mutations haven been implicated in aplastic
anemia, melanoma, dyskeratosis congenita and
pulmonary fibrosis
Nuclear phosphoprotein playing an important role in
cell cycle progression, apoptosis and transformation.
A proto-oncogene binding to the VEGF promoter
thereby promoting angiogenesis. Mutation
associated with Burkitt lymphoma
Myc-associated factor X-member of the leucine
zipper family of transcription factors. Acts as an
activator by complexing with MYC, whereas a
complex of MAX with MAZ is a transcriptional
repressor. Mutation associated with
pheochromocytoma
Myc-associated zinc finger protein with dual roles in
transcription initiation and termination. Functions as
a transcriptional activator as well as repressor
Belongs to the ETS family of transcription factors;
binds to the serum response elements on the
promoter of proto-oncogenes like FOS;
transcriptional activator
Belongs to the ETS family of transcription factor;
encodes for a E26 transformation related
transcription factor; acts as a transcriptional
activator
Member of the runt domain containing family of
transcription factors; transcriptional activator or

NER genes this protein
interacts with as a
transcription factor*
-

Reference

ERCC6, GTF2H3, RPA3,
GTF2H4, ERCC3,
ERCC8, RAD23B

(K. Bhatia et al., 1993)

DDB2, ERCC6, GTF2H3,
DDB1, RPA3,, ERCC4,
GTF2H4, ERCC8,
RAD23B

(Comino-Méndez et al.,
2011)

DDB1, GTF2H4, CCNH,
ERCC3, RAD23B

(Bossone et al., 1992)

-

(Pastorcic & Das, 2003)

ERCC6, GTF2H2,
ERCC4, CCNH, ERCC3

(J.-Y. Cho et al., 2004; H.
Song et al., 2009)

GTF2H3, RPA3,
RAD23B ERCC1

(Mabuchi et al., 2010)

(Armanios et al., 2005;
Horn et al., 2013; J. Liang
et al., 2006; Tsakiri et al.,
2007)
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Protein Name

Gene
Name

TEAD4

TEAD4

YY1

YY1

RAD21

RAD21

USF1

USF1

FOXA1

FOXA1

ZNF 143

ZNF143

SP1

SP1

Function and role in cancer
repressor; functions as a tumor suppressor in
conjunction with ATBF1
Member of the transcription enhancer factor family
of transcription factors; belongs to the Hippo
signaling pathway that is involved in tumor
suppression functions
Transcription factor belonging to the GLI-Kruppel
family of zinc finger proteins; transcriptional
repressor as well as activator; shown to have a role
in homologous recombination
Cleavable component of the cohesion complex,
involved in cohesion of sister chromatids during cell
cycle, DNA double strand break repair and apoptosis
Ubiquitous upstream stimulatory factor 1;
transcription factor that is a member of the leucine
zipper family proteins; mainly functions as a
transcriptional activator
Belongs to the forkhead family of DNA binding
proteins; transcriptional activators for liver-specific
proteins; involved in cell cycle regulation by
activation of CDKN1B along with BRCA1;
associated with ER+ breast cancers
Zinc finger protein 143, functions as a
transcriptional activator of the gene for
selenocysteine tRNA
Zinc finger protein that binds to GC-rich regions on
promoters of genes; regulates cell growth and
differentiation, proliferation, chromatin remodeling,
DNA damage response and apoptosis. Mutations
cause Huntington’s disease

NER genes this protein
interacts with as a
transcription factor*

Reference

DDB1, ERCC3, RAD23B,
ERCC1

(W. Wu et al., 2009; H.
Zhang et al., 2009)

DDB2, GTF2H3, ERCC4,
XPA, ERCC8, RAD23B,
XPC, CDK7, RPA1

(Y. Shi, Seto, Chang, &
Shenk, 1991; Siednienko
et al., 2011; S. Wu et al.,
2007)
(McKay et al., 1996)

DDB2, ERCC6, DDB1

(Gregor, Sawadogo, &
Roeder, 1990; Z. Ma,
Jhun, Jung, & Oh, 2008)

ERCC6, ERCC8

(Laganière et al., 2005;
Williamson et al., 2006)

ERCC1, XPC

(Kubota, Yokota, Yanagi,
& Yura, 2000)

GTF2H3, ERCC2, DDB2,
GTF2H4, CCNH, ERRC8,
RAD23B

(M.-C. Hsu, Chang, &
Hung, 2006; Olofsson,
Kelly, Kim, Hornsby, &
Azizkhan-Clifford, 2007)

219

Protein Name

Gene
Name

Function and role in cancer

SP4

SP4

Transcription factor that binds to GC regions on
promoters of genes; a probable transcriptional
activator

STAT1

STAT1

ATM

ATM

ATR

ATR

FANCD2

FANCD2

E2F4

E2F4

E2F6

E2F6

Signal transducer and activator of transcription 1;
transcription activators that modulate cellular
responses to interferons, cytokines and growth
factors; has tumor suppressive functions
ATM serine threonine kinase that activates cell cycle
checkpoints and is a DNA damage sensor.
Phosphorylates important proteins involved in DNA
damage signaling and repair like BRCA1, p53,
RAD21, CHEK2, etc. Mutations cause Ataxia
Telangiectasia
ATR Serine/threonine kinase that activates cell cycle
checkpoints and is a DNA damage sensor.
Phosphorylates important proteins involved in DNA
repair like BRCA1, p53, RAD21, CHEK1, MCM2
etc.
Fanconi Anemia Complementation Group D2;
Maintains chromosomal stability and promotes
accurate pairing of homologs during meiosis,
involved in double strand break repair and
associated with the disease Fanconi Anemia
E2F transcription factor 4; controls cell cycle
regulation and the DNA replication. Associated with
Retinoblastoma disease
E2F transcription factor-6; involved in cell cycle
regulation, has a transcriptional suppressing role via
the recruitment of a chromatin remodeling complex

NER genes this protein
interacts with as a
transcription factor*
DDB2, GTF2H3,
GTF2H4, XPA, CCNH,
RAD23B, ERCC2
DDB2, RAD23B, ERCC1

Reference
(Davis Jr, Chen, Ile, &
Tew, 2003; Hagen,
Dennig, Preiß, Beato, &
Suske, 1995)
(Chapat et al., 2013; K.
Chen et al., 2017)

-

(Canman et al., 1998;
Herbig, Jobling, Chen,
Chen, & Sedivy, 2004)

-

(Cimprich, Shin, Keith, &
Schreiber, 1996; Haahr et
al., 2016; Tibbetts et al.,
1999)

-

(Jin et al., 2003; Taniguchi
et al., 2002)

DDB2, GTF2H3,
GTF2H4, ERCC3

(Beijersbergen et al.,
1994; Rubin, Gall, Zheng,
& Pavletich, 2005)
(Trimarchi et al., 1998)

ERCC6, DDB2, ERCC4,
RAD23B
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Protein Name

Gene
Name

Function and role in cancer

GABPA

GABPA

PHF8

PHF8

GA binding transcription factor protein subunit
alpha; binds to purine (GA) rich DNA regions and
important for the transcription of the adenovirus E4
gene
PHD finger protein 8; an X-linked gene coding for a
histone demethylase that has important functions in
cell cycle progression, rDNA transcription and brain
development

NER genes this protein
interacts with as a
transcription factor*
ERCC6, GTF2H3,
GTF2H2, ERCC4,
GTF2H4, XPA, CCNH,
ERCC3
ERCC6, ERCC2, ERCC4,
XPA, CCNH, ERCC3,
ERCC8, RAD23B

Reference
(Reiff et al., 2014)

(Jihui Qiu et al., 2010;
Zhu et al., 2010)
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5.2 Methods
Total RNA isolation was performed using Qiagen’s miRNeasy mini kit according
to manufacturer’s protocol (as described in Chapter 3). RNA sequencing was performed
on the cell line pairs in triplicate for each cell line at the Hussman Institute for Human
Genomics at the University of Miami (as described in Chapter 3) and data analysis of the
sequencing output was performed as described in Chapter 4. Alignment of reads was
performed using 3 aligners, GSNAP, HISAT and BWA to gain consensus on the called
variants and to eliminate artifacts. Variant calling was performed using SAMTools in
Partek Flowâ, as described in Chapter 4. The GTF file for the gene list in Table 5.1 was
obtained from the UCSC Table browser (hg38). This was used to filter and include only
the variants overlapping our genes of interest. Venn Diagrams were constructed using
Partek Genomics Suiteâ to find variants shared and not shared between the Low: Low
pair of cell lines, JL NTAL-37 and JL BTL-37, as well as the High: Low pair of cell
lines, JL NTAL-47 and JL BTL-47.
5.3 Results
5.3.1 Variants in the Low: Low pair of cell lines
Upon performing variant calling and getting consensus variants using 3 aligners
as well as a consensus between 3 replicates for each cell line, a total of 55 variants were
discovered in JL-NTAL-37 and 48 in JL BTL-37. Venn diagrams constructed for the
variants in this pair showed 44 shared variants among JL NTAL-37 and JL BTL-37
(Figure 5.1). The characteristics of the variants and the genes they were found in are
listed in Table 5.2. Shared missense mutations were found in CHECK1, ELF1, TP53 and
ATR where they showed a homozygous mutant genotype. A missense mutation was also
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found in ERBB2 with a heterozygous mutant phenotype (Table 5.2). There were 5
unknown variants found that were shared in the Low: Low pair which were the results of
indels seen in SP1 (2), ELF1, YY1 and RAD21. No amino acid change was predicted for
these indels.
Among variants not shared in between the Low: Low pair of cell lines, 11 variants
were seen only in JL NTAL-37. One of these variants was the result of a missense
mutation in BRCA1 gene with a heterozygous mutant genotype (Table 5.3). In JL BTL37, 4 variants were found that were not shared with JL NTAL-37. One unknown variant
resulting from an indel was also found in ELF1 in the line JL BTL-37. However, none of
the variants exclusive to JL BTL-37 resulted into an amino acid change (Table 5.4).
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JL NTAL-37 (55)

JL BTL-37 (48)

Figure 5.1 Venn diagram showing number of variants in the list of genes in the Low: Low
pair of cell lines, JL NTAL-37 (= 3) and JL BTL-37 (n = 3). The gray shaded area in the
middle of the Venn diagram indicates number of variants shared between JL NTAL-37 and JL
BTL-37 (44). The pink area denotes number of variants just in JL BTL-37 (4) and the green area
indicates variants only in JL NTAL-37 (11)
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Table 5.2 Characteristics of shared variants between JL NTAL-37 and JL BTL-37, the Low: Low pair. The rows in red indicate variants that
have a homozygous genotype and showed an amino acid (AA) change.

Gene
USF1

No. Of
Variants
1

No. of known
variants
1

No. of variants that showed
AA change
-

Zygosity of variants causing the
AA change
-

ATM

2

2

-

-

CHEK1

1

1

1 (rs506504)

Homozygous

SP1

3

1

-

-

ELF1

4

3

2 (rs1056820; rs7799)

Both homozygous

YY1

4

3

-

-

MAX

8

8

-

-

MAZ

2

2

-

-

ERBB2

1

1

1 (rs1058808)

Heterozygous

TP53

1

1

1 (rs1042522)

Homozygous

JUND

1

1

-

-

STAT1

1

1

-

-

ATR

2

2

1 (rs2227928)

Homozygous

ESR1

1

1

-

-

CDKN1A

7

7

-

-

CDKN2A

1

1

-

-

RAD21

3

2

-

-
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Table 5.3 Variants present only in the NTA line of the Low: Low pair, JL NTAL-37, and not shared with JL BTL-37. The orange variant is
also present in the NTA of the High: Low pair, JL NTAL-47

Gene
ATM

No. Of
Variants
2

No. of known
variants
2

No. of variants that showed
AA change
-

Zygosity of variants causing the
AA change
-

ELF1

1

1

-

-

YY1

1

1

-

-

BRCA1

1

1

1 (rs1799966)

Heterozygous

E2F1

1

1

-

-

ATR

2

2

-

-

SP4

2

2

-

-

Table 5.4 Variants present only in the tumor line of the Low: Low pair, JL BTL-37, and not shared with JL NTAL-37
Gene
ELF1

No. Of
Variants
1

No. of known
variants
-

No. of variants that showed
AA change
-

Zygosity of variants causing the
AA change
-

SP1

1

1

-

-

CDKN1A

1

1

-

-

CDKN2A

1

1

-

-

226

5.3.2 Variants in the High: Low pair of cell lines
A total of 44 variants were discovered each in JL-NTAL-47 and in JL BTL-47.
Venn diagrams constructed for the variants in this pair showed 25 shared variants among
JL NTAL-47 and JL BTL-47 (Figure 5.2). The characteristics of the variants and the
genes they were found in are listed in Table 5.5. Shared missense mutations were found
in ELF1, ERBB2 and TP53 and all three showed a heterozygous mutant genotype.
Among variants not shared in between the High: Low pair of cell lines, 19
variants were seen only in JL NTAL-47. Among the 19 variants, two had amino acid
changes. One of these variants was the result of a missense mutation in BRCA1 gene
with a heterozygous mutant genotype, where the other missense mutation was seen in the
E2F1 gene, and the variant showed a heterozygous phenotype as well (Table 5.6). There
were 19 variants found exclusively in JL BTL-47 as well, that were not shared with JL
NTAL-47. Among these, two were the results of missense mutations each in the genes
SP1 and ATR. The variant in ATR had a homozygous mutant genotype, whereas the one
in SP1 had a heterozygous mutant genotype.
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JL NTAL-47 (44)

JL BTL-47 (44)

Figure 5.2 Venn diagram showing number of variants in the list of genes in the Low: Low
pair of cell lines, JL NTAL-47 (n = 3) and JL BTL-47 (n = 3). The gray shaded area in the
middle of the Venn diagram indicates number of variants shared between JL NTAL-47 and JL
BTL-47 (25). The pink area denotes number of variants just in JL BTL-47 (19) and the green area
indicates variants only in JL NTAL-47 (19).
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Table 5.5 Characteristics of shared variants between JL NTAL-47 and JL BTL-47, the Low: Low pair.
Gene
ELF1

No. Of
Variants
3

No. of known
variants
3

No. of variants that showed
AA change
2 (rs1056820; rs7799)

Zygosity of variants causing the
AA change
Both heterozygous mutants

YY1

3

3

-

MAX

5

5

-

MAZ

1

1

-

ERBB2

1

1

1 (rs1058808)

Heterozygous

TP53

1

1

1 (rs1042522)

Heterozygous

JUND

1

1

-

ATR

3

3

-

ESR1

1

1

-

CDKN1A

2

2

-

CDKN2A

1

1

-

RAD21

2

1

-

-
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Table 5.6 Variants present only in the NTA line of the High: Low pair, JL NTAL-47, and not shared with JL BTL-47. The orange variant is
also present in the NTA of the Low: Low pair, JL NTAL-37

Gene

No. Of
Variants

No. of known
variants

No. of variants that showed
AA change

Zygosity of variants causing
the AA change

USF1

1

1

-

-

SP1

1

-

-

-

ELF1

1

1

-

-

MAX

1

1

-

-

MAZ

2

2

-

-

BRCA1

2

2

1 (rs1799966)

Heterozygous

JUND

1

-

-

-

E2F6

1

1

-

-

STAT1

5

4

-

-

E2F1

1

1

1 (rs3213176)

Heterozygous

ATR

1

1

-

-

SP4

1

1

-

-

RAD21

1

1

-

-
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Table 5.7 Variants present only in the tumor line of the High: Low pair, JL BTL-47, and not shared with JL NTAL-47. The rows in red
indicate variants that have a homozygous genotype and showed an amino acid (AA) change.

Gene

No. Of
Variants

No. of known
variants

No. of variants that showed
AA change

Zygosity of variants causing the
AA change

SP1

3

2

1 (rs200394677)

Heterozygous

ELF1

1

1

-

-

YY1

3

3

-

-

MAZ

1

1

-

-

ERBB2

1

-

-

-

STAT1

3

3

-

-

ATR

1

1

1 (rs2227928)

Homozygous

CDKN1A

6

6

-

-
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5.4 Discussion
Variant calling on the list of important genes in breast cancer revealed some
interesting findings. First, the Low: Low pair of cell lines had more shared variants (44)
compared to those between the High: Low pair (25). This suggests that the low DNA
repair of the NTA for that pair is a mutation enabler. This theory goes with the fact that
loss in DNA repair mechanisms enables the accumulation of mutations and is a major
hallmark of cancer (Hanahan & Weinberg, 2000).
Among the shared mutations in the Low: Low pair of cell lines, CHEK1, ELF1,
TP53 and ATR showed a homozygous mutant phenotype resulting from missense
mutations in those genes and ERBB2 showed a heterogenous mutant phenotype, also
resulting from a missense mutation in the gene. All these genes have important
implications in cancer. Mutations in CHEK1, TP53 and ERBB2 have all been associated
with breast cancer (Table 5.1). ATR activates CHK1 and p53 proteins by
phosphorylation, thereby also playing an important role in maintenance of genomic
stability. ATR and CHK1 are being explored as therapeutic targets for cancer, and
inhibitors for these proteins are being tested (Z. Qiu, Oleinick, & Zhang, 2017).
An interesting finding was missense mutations in BRCA1 in both NTA lines, but
not the tumor lines of the Low: Low as well as the High: Low pairs (Table 5.4 and 5.7).
Both these NTA lines derived from histopathologically normal tissue adjacent to the
tumor from two different patients containing the same missense mutation in BRCA1
indicates that both these women might be carriers for a germline BRCA1 mutation, but
somehow clonal selection led to the disappearance of this mutation. This is a common
occurrence in cancer, where favorable mutations thrive and are selected for while
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unfavorable mutations disappear in clonal evolution of cells, and this process is also
called negative selection of mutations (Goyal et al., 2012; Martincorena et al., 2017).
Another interesting finding was the presence of a specific ATR missense mutation
in all the cell lines with a low repair signature, i.e., JL BTL-37, JL NTAL-37 and JL
BTL-47. This resulted in a specific known variant in the ATR transcripts, which hasn’t
been widely studied in literature. However, ATR has been known to promote NER, and is
required for global genomic repair in cells (Auclair, Rouget, Affar, & Drobetsky, 2008;
Musich, Li, & Zou, 2017; Shell et al., 2009). Therefore, ATR could be investigated in
future studies as the master regulator of NER in our early stage breast tumor cell lines
and also in their matched NTA lines where the repair capacity is low as well.
We therefore propose our own multistep model for breast carcinogenesis,
explaining the clonal expansion of cells harboring abnormal alterations. This model
emphasizes the field cancerization theories that have been put forth for a number of
cancer types. Starting from the first mutation that a cell sustains on its path to
tumorigenesis, there is subsequent proliferation of these cells. This leads to accumulation
of further step-wise mutations and accumulation of these in populations of cells that are
now spread out throughout the tissue of origin but are still morphologically and
histopathologically normal. The final morphology-altering mutation then leads to the
formation of the first tumor cell, and its clonal expansion leads to the formation of the
tumor mass (Figure5.3). Based on the mutations found in this chapter as well as the
methylation analysis and variant calling on NER genes, person specific maps of the
mutations occurring from the NTA tissue to the tumor were also created that might
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explain the drivers or master regulators as well as passenger events in breast
tumorigenesis for these patients (Chapter 6, Figures 6.4 and 6.5).
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Figure 5.3 The Latimer multistep model for breast tumorigenesis. The green cell in the first panel is the first to sustain an abnormal mutation
(or mutation like event) which clonally expands to generate a population of these cells. One of these gets another mutation (orange cell) and
subsequent proliferation and accumulation of mutations takes place until the final mutation alters the phenotype of the cell making it neoplastic
(blue cell with the large nucleus). This cell clonally expands to generate the tumor mass, thereby leaving behind multiple clonally selected
populations of preneoplastic cells harboring mutations or mutation like events
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Chapter 6
Summary and Conclusions
In the present thesis, we have identified and studied cell line pairs representing 2
varieties of non-tumor adjacent breast with their matched early stage breast tumor in
terms of their ability to perform Nucleotide Excision Repair. Previous studies identified
Low: Low and the High: Low groups of matched NTA-tumor pairs. The NER capacity
for tumors was lower than that of breast reduction explants for all early stage tumors and
that of the NTA was similar to the tumors for the Low: Low pairs. However, NER
capacity was higher than breast reduction for the High: Low pairs while that of the
tumors were lower than breast reduction explants. We were able to identify representative
cell line pairs for each of these groups, where JL NTAL-37 and JL BTL-37 represented
the Low: Low pair of NTA-tumor lines, and JL NTAL-47 and JL BTL-47 represented
High: Low pair of cell lines. We performed in-depth molecular analyses on these cell line
pairs to be able to understand the mechanism of regulation of the NER pathway in these
specific cell line pairs, with an ultimate aim of establishing a temporal scheme of breast
cancer with respect to NER.
In chapter 3 I show gene expression analyses by microarray and its validation by
RNA sequencing showed that the expression profiles of the 20 canonical NER genes
were consistent with their functional repair capacity as measured by the UDS assay. In
the Low: Low pair, most of the 20 NER genes via microarray analyses (15/20) and none
of these genes via RNA sequencing showed significant differences in their expression.
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However, in the High: Low pair, most of the 20 NER genes via microarray (13/20) as
well as RNA sequencing (16/20) showed a significantly higher expression in the NTA
line compared to the tumor line. Therefore, the functional NER capacity of these cell line
pairs was seen to be consistent with their NER gene expression pattern and these lines
were deemed to be excellent representatives to study the mechanism of transcriptional
regulation of the NER pathway. Protein expression consistent with gene expression in the
NER pathway was not completed for these 2 pairs of cell lines but will be ongoing in the
laboratory.
Differential expression of multiple genes in the pathway indicated an epigenetic
mechanism of regulation in this pathway. My work in the present study (Chapter 5)
confirmed the absence of frameshift or nonsense mutations (truncating mutations) in the
NER genes in these 4 cell lines. The previous work of Dr. As Sobeai in our laboratory
confirmed that key NER proteins were expressed at the RNA and protein levels similarly,
in other breast cancer cell lines, so that transcriptional regulation or pre-translational
regulation seemed to be the most likely possibilities. Finally, the consistent low
expression of NER genes in the 19 different stage I tumors (As Sobeai, 2017; Johnson,
2006; Latimer et al., 2010) was also indicative of an epigenetic regulation of the NER
genes in breast cancer.
In Chapter 4, we therefore explored the mechanism of DNA methylation as a
transcriptional regulator of the NER pathway. DNA methylation was our choice of a
possible mechanism because previous work in the laboratory showed the 20 NER genes
to be rich in CpG islands in their promoter regions and also that the expression of 3 genes
was restored upon treatment of the DNA-demethylating agent 5-azacytidine (Johnson,
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2006). We performed methylation profiling on our High: Low and Low: Low call line
pairs using the MethylationEPIC array and did not see any significant correlations among
gene expression and methylation for our cell line pairs and the control breast reduction
line JL BRL-6.
However, upon looking at promoter-level methylation, DDB1 stood out
significantly differentially methylated among both pairs of cell lines, with the NTA line
having a higher methylation level than the tumor line of both pairs for DDB1. This is
exactly the inverse of the expected trend of methylation on DDB1 in the High: Low pair,
as the expression of DDB1 is higher in the NTA line than the tumor line. In the Low:
Low pair, DDB1 shows no difference in expression but a significant difference in its
promoter methylation. The inverse trend of methylation of DDB1 in the High: Low pair
suggests a possible role of the inhibition of transcriptional repressor binding to the
promoter region of DDB1. This calls for confirmation of the promoter methylation of
DDB1and its role in transcriptional regulation in future studies. ERCC5 in the High: Low
pair and DDB2 and RPA2 in the Low: Low pair showed differential methylation,
whereas there was no difference in expression of these genes in these pair of cell lines.
Future studies with a larger sample size could be performed in order to validate these
findings although confirmation with the proteins encoded by these genes must first be
performed. If the proteins do not reflect the gene expression in these early stage breast
cancer lines and matching NTAL cell lines, there is little point in going any further with
studies of methylation because the foundation of this work is based on NER function.
Some protein expression correlation with RNA expression was seen preliminarily with
RAD23B in Chapter 3.
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One possible explanation for the lack of correlation between any of the NER
genes and the methylation patterns (analyzed at the promoter level, gene level and CpG
island level) is that methylation is not the mechanism by which NER gene and protein
expression is regulated. It is also possible based on the data generated in As Sobeai, 2017
that the regulation is not at the transcriptional level but rather pre-translational due to
elements like microRNAs. It is also possible that some NER genes are regulated by
methylation while others are regulated post transcriptionally and pre-translationally but
these data (Chapter 4) show no agreement with previous Azacytidine experiments that
did not point to DDB1 or ERCC5.
In addition to the methylation analyses on whole genes, promoter regions and
individual CpG sites in the NER genes, we looked for known binding sites of
transcriptional factors, common to 2 or more NER genes, that might be differentially
methylated. The promoter regions for these genes as a whole, that contained these
binding sites, were not differentially methylated, but a more exhaustive examination is
needed (see appendix for the maps of these promoter regions for all 20 NER genes).
These binding sites were surveyed in the promoter regions (1500 bp upstream and 500 bp
downstream of the transcriptional start site).
RNA sequencing, primarily performed for validation of gene expression results,
also allowed us to look for known and unknown single nucleotide variants which might
be related to putative mutations, within the exons of our 20 canonical NER genes in
Chapter 4. Although SNP analysis is designed to be performed on large populations, we
used this analysis to correlate to a known NER phenotype. A future goal is to add more
SNP data from our own collection of NTA and tumor (unmatched samples and future

239
matched samples) to these analyses to utilize SNP variant analysis in a more conventional
way. This study done in great molecular detail on 2 cases of breast cancer, did however
identify several important markers such as an ATR variant (shared among only the Low
repairing samples) that will be followed up in future work.
In Chapter 5 we examined the transcription factors that were shown to have
binding sites and were common among at least 3 of the 20 NER genes. Only the most
stringent evidence of binding was used as a criterion to select that transcription factor.
Some of these transcription factors were oncogene or tumor suppressor gene related. In
addition to these factors, a selection of other important oncogenes and tumor suppressor
genes (with no known direct connection to NER) that have been shown to play a role in
breast cancer were also examined. The presence of single nucleotide variants within
these genes was explored with an aim to find possible associations with mutations. The
variants were also annotated to see if they were already known as single nucleotide
polymorphisms (SNPs) in the dbSNP database.
The words “mutations” and “SNPs” are often used interchangeably in the 2nd
generation sequencing literature and it is often difficult to distinguish one from the other
from a small-scale study, as SNPs are more of a population characteristic that represent a
viable change in the DNA sequence and mutations are defined based on their rarity in a
given population and are sometimes associated with a phenotype. We therefore confined
our study to the definition of variants, where we variants that were known as well as
unknown in literature, and some of these known variants caused downstream changes in
the amino acid sequence coded by the gene segment containing the variant (missense
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variants). These are summarized in Chapter 5, and the most important ones are
summarized in Table 6.1.
One of the most notable variants discovered in this study was the ATR gene,
which is a nodal gene that regulates DNA damage signaling and repair. This particular
variant was seen in all the cell lines that had a low functional NER capacity, namely JL
BTL-37, JL NTAL-37 and JL BTL-47, but not in JL NTAL-47 that had NER capacity
higher than the tumors and similar to the normal breast reduction line. This variant might
be specific to a low repair signature, thus emphasizing the possible importance of the
ATR gene in the regulation of NER. ATR phosphorylates important tumor suppressor
proteins like CHK1 and CHK2, and we also saw a missense variant in CHEK1 gene. This
variant was shared in the Low: Low pair of cell lines (Table 6.1) (Figure 6.2). Therefore,
ATR is a putative candidate that can be studied further as a master regulator of the NER
pathway in our samples.
Another interesting finding in our variant calling results on the cell line pairs was
a missense variant in BRCA1 that had a heterozygous genotype (Table 6.1). This variant
was found in both the NTA lines, JL NTAL-37 as well as JL NTAL-47, but not in the
tumor lines. A possible explanation would be loss of heterozygosity at the specific locus
of the variant found in BRCA1. Loss of heterozygosity in the BRCA1 and 2 genes has
been known as one of the driver events in cancer and has also been shown to be a
frequent occurrence in breast cancer (Locke et al., 2006; Maxwell et al., 2017). Future
studies will include confirmation of this possibility via DNA sequencing and copy
number variation analysis.
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Missense variants in ERCC2, ERCC5 and ERCC6 were found frequently, shared
between both the Low: Low and the High: Low pair of cell lines. All these known
variants have been associated with risks of cancer, with the cancer prone disease XP, as
well as with Cockayne Syndrome (Table 6.1). SNP association studies with disease and a
phenotype are generally done with large sample sizes and hence, future studies will
involve the investigation of the presence of these particular variants in breast tumors and
their adjacent normal tissues from The Cancer Genome Atlas database.

Figure 6.1 The ATM and ATR pathway of DNA damage signaling and response. ATM
(Ataxia Telangiectasia mutated) and ATR (ATM and RAD3 related) proteins are damage sensors
that activate CHK1 and CHK2, which are both serine/threonine kinases. This initiates a DNA
damage response and cessation of replication upon sensing helix distortion, and single and double
strand breaks. These proteins function as cell-cycle checkpoints, the loss of which is a hallmark

242
of cancer. Mutations in ATM, ATR, Chk1 and Chk2 are therefore drivers of carcinogenesis in
many cancers, including the breast. Reprinted with permission (Ashwell & Zabludoff, 2008).

Finally, taking into consideration our findings in chapter 4 and 5, we constructed
person-specific maps delineating the alterations that were shared between the paired cell
lines, and also the ones that were found exclusively in the tumor or NTA line. The map
for the Low: Low pair is shown in Figure 6.4 and that for the High: Low pair is shown in
Figure 6.5. Future studies with a higher sample size will help validate these findings and
enable us to select the most important alterations to find the etiology of early stage breast
cancer.
We are the first group to investigate the role of NER in early stage breast cancer
and its involvement in tumorigenesis by studying the matched non-tumor adjacent breast
by measuring direct functional NER capacity and the expression of the canonical NER
genes. Candidate genes identified in our study will be focused on in future studies in
order to find marker genes and proteins that could give an insight into the regulation of
the NER pathway in breast cancer.
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LOW
JL NTAL-37

ATR
ELF1
TP53
ERBB2
CHEK1
ERCC5
ERCC6
ERCC2
Differential
promoter
methylation
for DDB1,
DDB2,
RPA2

LOW
JL BTL-37

HIGH
JL NTAL-47

ELF1
TP53
ERBB2
ERCC5
ERCC6
Differential
promoter
methylation for
DDB1, ERCC5

LOW
JL BTL-47

Figure 6.2 Summary Venn diagrams for visualization of the genes involved in shared alterations between the pair of cell lines used in this
dissertation. Panel A consists of genes involved in the shared changes in the Low: Low pair (JL NTAL-37 and JL BTL-37) and Panel B is for the
genes involved in shared changes in the High: Low pair (JL NTAL-47 and JL BTL-47). The details on these shared changes are delineated in
Table 6.1.
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A

LOW
JL NTAL-37

B

BRCA1
ERCC2

HIGH
JL NTAL-47

LOW
JL BTL-37

ATR

LOW
JL BTL-47

Figure 6.3 Summary Venn diagrams for visualization of the genes involved in shared alterations between cell lines used in this dissertation.
Panel A consists of genes involved in the shared changes in the NTA lines (JL NTAL-37 and JL NTAL-47) and Panel B is for the genes involved
in shared changes in the tumor lines (JL BTL-37 and JL BTL-47). The details on these shared changes are delineated in Table 6.1
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LOW
JL BTL-37

LOW
JL NTAL-37

ATR

LOW
JL BTL-47

Figure 6.4 Summary Venn diagrams for visualization of the genes involved in shared alterations between cell lines used in this dissertation.
The shaded area in the middle consists of genes involved in the shared changes in all the lines that showed low functional NER capacity (JL
NTAL-37 and JL BTL-37 and JL BTL-47). The details on these shared changes are delineated in Table 6.1
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Table 6.1 Summary of important shared changes between the cell line pairs belonging to the Low: Low and High: Low groups
respectively. This table shows that certain variants are shared between each pair are also present in the other cell line pair and might
indicate universality, which could be verified by future studies on a larger sample size. The variants in bold lettering indicate
candidates for further studies that are of priority. Blue indicates either the cell line in which the alteration was seen or clinical
association or a specific notation of the alteration seen with regards to the particular gene.
Low: Low
JL NTAL-37
Low: Low

JL NTAL-37 ERCC2 (rs1799793)-  BC,
Pros. Can., Platinum tox; XP

JL BTL-37

ATR (rs2227928),
ELF1 (rs1056820; rs7799),
TP53 (rs1042522),
ERBB2 (rs1058808),
CHEK1 (rs506504),
ERCC5 (rs9514066;
rs9514067) - XP,  Platinum
tox

High: Low
JL BTL-37

ATR (rs2227928)
ELF1 (rs1056820; rs7799)
TP53 (rs1042522)
ERBB2 (rs1058808)
CHEK1 (rs506504)
ERCC5 (rs9514066;
rs9514067)- XP,  Platinum
tox
ERCC6 (rs4253072)
ERCC2 (rs13181) - BC,
NSCLC, Osteosarc.; XP
Differential promoter
methylation for DDB1 (JL
NTAL-37 )
DDB2 (JL BTL-37  )and
RPA2 (JL BTL-37 )
GTF2H3 (rs1051793)

JL NTAL-47

JL BTL-47

BRCA1 (rs1799966)
ERCC2 (rs13181)-
BC, NSCLC,
Osteosarc.; XP

ATR (rs2227928)

ERCC5 (rs9514066;
rs9514067) - XP, 
Platinum tox
ERCC6 (rs4253072)
ERCC2 (rs13181) -
BC, NSCLC,
Osteosarc.; XP

ATR (rs2227928)

ERCC5 (rs9514066;
rs9514067) - XP, 
Platinum tox
ERCC6 (rs4253072)
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Low: Low
JL NTAL-37

High: Low

ERCC6 (rs4253072), ERCC2
(rs13181) - BC, NSCLC,
Osteosarc.; XP, Differential
promoter methylation for
DDB1 (JL NTAL-37 ),
DDB2 (JL BTL-37  )and
RPA2 (JL BTL-37 )
JL NTAL-47 BRCA1 (rs1799966)
ERCC2 (rs13181) - BC,
NSCLC, Osteosarc.; XP

JL BTL-47

ATR (rs2227928)

High: Low
JL BTL-37

JL NTAL-47

JL BTL-47

ERCC5 (rs9514066;
rs9514067) – XP, 
Platinum tox
ERCC6 (rs4253072)

ERCC5 (rs144208043;
rs17655)- XP, 
gastric, lung, colorectal,
cervical cancer
RAD23B (rs1805329)  BC

ELF1 (rs1056820;
rs7799)
TP53 (rs1042522)
ERBB2 (rs1058808)
ERCC5 (rs9514066;
rs9514067) - XP, 
Platinum tox
ERCC6 (rs4253072)
Differential promoter
methylation for DDB1
and ERCC5 (JL
NTAL-37 )

ATR (rs2227928)

ELF1 (rs1056820;
rs7799)
TP53 (rs1042522)
ERBB2 (rs1058808)
ERCC5 (rs9514066;
rs9514067) - XP, 
Platinum tox
ERCC6 (rs4253072)

NA
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Low: Low
JL NTAL-37

High: Low
JL BTL-37

JL NTAL-47
Differential promoter
methylation for DDB1
and ERCC5 (JL NTAL37 )

JL BTL-47
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Shared Alterations in
the Low: Low pair

Alterations only in
NTA line
JL NTAL-37

Missense variants in
TP53 ELF1 ERBB2
ERCC5 ERCC6
(Same as in JL BTL-47
and JL NTAL-47)

Missense variants
in BRCA1 and
ERCC2

CHEK1 ATR
ERCC2 RPA2

Non-Tumor Adjacent
LOW Repair

Alterations only in Tumor line
JL BTL-37
Missense variant in GTF2H3
Need further evidence with more
sample pairs for:
Loss of heterozygosity for
BRCA1
Loss of promoter methylation
for DDB1, gain of promoter
methylation for DDB2 and RPA2

Tumor

Non-Tumor Adjacent

LOW Repair

Figure 6.5 Map of genetic changes for the patient from which the Low: Low pair of cell lines were derived. The red oval shapes denote
places from where our tumor and NTA tissues were theoretically sampled. Missense variants found in this chapter in important cancer genes along
with those found in chapter 4 in the NER genes are included in this person-specific map. Important promoter methylation differences found with
the help of methylation arrays are also included in this map to make it comprehensive. This map differs from the map of changes for the High:
Low pair, with the exception of a few commonalities, like a missense variant in ATR, loss of promoter methylation in DDB1, and missense
variants in TP53, ELF1, ERBB2 that are shared and one in BRCA that is lost en route to the tumor.
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Alterations only in NTA
line
JL NTAL-47

Shared Alterations in the
High: Low pair

Missense variant in
BRCA1

Missense variants in
TP53 ELF1 ERBB2
ERCC5 ERCC6

ERCC2

ERCC1

ESP1
ERCC5 RAD23B
CDK7

Alterations only in Tumor line
JL BTL-37
Missense variant in ATR
Need further evidence with more
sample pairs for:
Loss of heterozygosity in BRCA1
Loss of promoter methylation for
DDB1
Loss of promoter methylation for
ERCC5

Non-Tumor Adjacent
High Repair

Tumor

Non-Tumor Adjacent

Low Repair

Figure 6.6 Map of genetic changes for the patient from which the High: Low pair of cell lines were derived. The red oval shapes denote
places from where our tumor and NTA tissues were theoretically sampled. Mutations found in this chapter in important cancer genes along with
those found in chapter 4 in the NER genes are included in this person-specific map. Important promoter methylation differences found with the
help of methylation arrays are also included in this map to make it comprehensive. This map differs from the map of changes for the Low: Low
pair, with the exception of a few commonalities, like mutations in ATR, loss of promoter methylation in DDB1, and missense mutations in TP53,
ELF1, ERBB2 that are shared and one in BRCA that is lost en route to the tumor.
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Appendix
Appendix A: R code used for analysis of data from the MethylationEPIC arrays
using RnBeads
library(RnBeads)
data.dir <- "~/Desktop/Manasi/All IDAT files/Analysis excluding
BRL2"
idat.dir <- file.path(data.dir)
sample.annotation <- file.path(data.dir,
"Sample_Sheet_NoBRL2.csv")
analysis.dir <- "~/Desktop/Manasi/All IDAT files/Analysis
excluding BRL2"
report.dir <- file.path(analysis.dir, "RnBeadsreport_Feb192018")
rnb.options(identifiers.column="Sample_Name")
data.source <- c(idat.dir, sample.annotation)
result <- rnb.run.import(data.source=data.source,
data.type="infinium.idat.dir", dir.reports=report.dir)
rnb.set <- result$rnb.set
rnb.run.qc(rnb.set, report.dir)
any.bad.p.val <- apply(dpval(rnb.set)>0.01, 1, any)
rnb.set3 <- remove.sites(rnb.set, any.bad.p.val)
rnb.set3_p_cont <- rnb.execute.context.removal(rnb.set3)$dataset
rnb.set3_p_cont_SNP <- rnb.execute.snp.removal(rnb.set3_p_cont,
snp="any")$dataset
rnb.set4_greedy <rnb.execute.greedycut((rnb.set3_p_cont_SNP))$dataset
rnb.set5_NAbvalues <rnb.execute.na.removal(rnb.set3_p_cont_SNP)$dataset
rnb.set6_var <rnb.execute.variability.removal(rnb.set5_NAbvalues)$dataset
rnb.set.norm <- rnb.execute.normalization(rnb.set6_var,
method="bmiq")
rnb.get.annotation("genes", assembly = "hg19")
rnb.get.annotation("promoters", assembly = "hg19")
rnb.get.annotation("cpgislands", assembly = "hg19")
rnb.options(exploratory.columns="Sample_Group")
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Ner_genes <- c("XPA", "ERCC3", "XPC", "ERCC2", "DDB2", "ERCC4",
"ERCC1", "ERCC5", "ERCC6", "ERCC8", "RPA1", "RPA2", "RPA3",
"GTF2H2C", "GTF2H3", "GTF2H4", "DDB1", "CCNH", "CDK7", "RAD23B")
rnb.options(exploratory.gene.symbols=Ner_genes)
rnb.options(exploratory.clustering="top")
rnb.options(exploratory.clustering.top.sites=1000)
rnb.options(export.to.csv=TRUE)
rnb.run.exploratory(rnb.set.norm, report.dir)
rnb.options(differential.comparison.columns.all.pairwise =
c("Sample_Group"))
rnb.options(differential.site.test.method="ttest")
rnb.options(differential.enrichment.go =TRUE)
rnb.run.differential(rnb.set.norm, report.dir)
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Appendix B: Maps for promoter regions for the 20 NER genes using UCSC Genome browser (defined in the analysis of data
from the MethylationEPIC array)
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